



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **On the origin of proteins in human drusen : The meet, greet and stick hypothesis**

Bergen, A. A., Arya, S., Koster, C., Pilgrim, M. G., Wiatrek-Moumoulidis, D., van der Spek, P., Hauck, S. M., Boon, C. J. F., Emri, E., Stewart, A. J., & Lengyel, I. (2018). On the origin of proteins in human drusen : The meet, greet and stick hypothesis. *Progress in Retinal and Eye Research*.  
<https://doi.org/10.1016/j.preteyeres.2018.12.003>

**Published in:**  
Progress in Retinal and Eye Research

**Document Version:**  
Peer reviewed version

**Queen's University Belfast - Research Portal:**  
[Link to publication record in Queen's University Belfast Research Portal](#)

### **General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

## On the Origin of Proteins in Human Drusen: The Meet, Greet and Stick Hypothesis

Arthur A. Bergen<sup>a,b,c,\*</sup>, Swati Arya<sup>d</sup>, Céline Koster<sup>a</sup>, Matthew G. Pilgrim<sup>e</sup>, Dagmara Wiatrek-Moumoulidis<sup>d</sup>, Peter van der Spek<sup>f</sup>, Stefanie M. Hauck<sup>g</sup>, Camiel J. F. Boon<sup>b,h</sup>, Eszter Emri<sup>i</sup>, Alan J. Stewart<sup>d</sup> and Imre Lengyel<sup>e,i</sup>

### Affiliations:

Departments of <sup>a</sup>. Clinical Genetics and <sup>b</sup>. Ophthalmology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands (NL).

<sup>c</sup>. Netherlands Institute for Neuroscience (NIN-KNAW), Amsterdam, NL.

<sup>d</sup>. School of Medicine, University of St Andrews, St Andrews, United Kingdom (UK).

<sup>e</sup>. UCL Institute of Ophthalmology, University College London, London, UK. Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, UCL, London, UK.

<sup>f</sup>. Dept. of Pathology, division Clinical Bioinformatics, Erasmus MC, Rotterdam, NL.

<sup>g</sup>. Research Unit Protein Science, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.

<sup>h</sup>. Department of Ophthalmology, Leiden University Medical Center, Leiden, NL.

<sup>i</sup>. Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, Northern Ireland, UK

\*Corresponding author:

Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

Email address: [aabergen@amc.uva.nl](mailto:aabergen@amc.uva.nl) (A.A. Bergen).

**Key words:** Drusen proteins, Retinal Pigment Epithelium (RPE), Bruch's membrane, Blood, Age-related Macular Degeneration (AMD), Alzheimer's disease.

### Acknowledgments:

This research was part-supported by de Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), de Stichting Blinden-Penning, de Gelderse Blinden Stichting, de Landelijke Stichting voor Blinden en Slechthzienden (LSBS), Stichting Oogfonds Nederland, Stichting MD Fonds and Stichting Retina Nederland Fonds (represented by Uitzicht, grants 2011-6 and 2014-7 to A.A.B.), de Rotterdamse Stichting Blindenbelangen (RSB), de Haagse Stichting Blindenhulp, Stichting Lijf en Leven, Stichting Ooglijders (to A.A.B.); ZonMW grant nr 446001002 (to A.A.B. and C.K.) ; the Bill Brown Charitable Trust, Moorfields Eye Hospital Special Trustees, Mercer Fund from Fight for Sight, the Eye-Risk project funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 634479 (I.L. and E.E.), Fight for Sight project grant (I.L. and A.S.), the Bright Focus Foundation grant nr M2015370 (to SMH). The authors thank Dr J Booij for partly unpublished data and the reviewers for their invaluable comments to improve the manuscript.

### Conflict of interest statement:

The authors do not have any competing financial interest to declare.



1 **Title:** On the Origin of Proteins in Human Drusen: The Meet, Greet and Stick Hypothesis

2  
3 **Abstract:** Retinal drusen formation is not only a clinical hallmark for the development of  
4 age-related macular degeneration (AMD) but also for other disorders, such as  
5 Alzheimer's disease and renal diseases. The initiation and growth of drusen is poorly  
6 understood. Attention has focused on lipids and minerals, but relatively little is known  
7 about the origin of drusen-associated proteins and how they are retained in the space  
8 between the basal lamina of the retinal pigment epithelium and the inner collagenous  
9 layer space (sub-RPE-BL space). While some authors suggested that drusen proteins are  
10 mainly derived from cellular debris from processed photoreceptor outer segments and  
11 the RPE, others suggest a choroidal cell or blood origin.

12 Here, we reviewed and supplement the existing literature on the molecular composition  
13 of the retina/choroid complex, to gain a more complete understanding of the sources of  
14 proteins in drusen. These "drusenomics" studies showed that a considerable proportion  
15 of currently identified drusen proteins is uniquely originating from the blood. A smaller,  
16 but still large fraction of drusen proteins comes from both blood and/or RPE. Only a  
17 small proportion of drusen proteins is uniquely derived from the photoreceptors or  
18 choroid. We next evaluated how drusen components may "meet, greet and stick" to each  
19 other and/or to structures like hydroxyapatite spherules to form macroscopic deposits  
20 in the sub-RPE-BL space. Finally, we discuss implications of our findings with respect to  
21 the previously proposed homology between drusenogenesis in AMD and plaque  
22 formation in atherosclerosis.

23	<b>Table of Contents</b>
24	
25	<b>1. Drusen.</b>
26	
27	<b>2. Functional annotation of drusen proteins.</b>
28	2.1. Biological or disease motifs and canonical pathways.
29	2.2. Molecular networks.
30	2.2.1. Network 1.1, 1.2, 1.3: Complement, collagens and crystallins.
31	2.2.2. Network 2.4: development, genetics ophthalmic disorders.
32	2.2.3. Network 3.5: Immunological response.
33	2.2.4. Network 4.6: Cell-to-cell signaling and systemic involvement, lipid
34	metabolism.
35	
36	<b>3. Drusenomics, part I: Where do drusen proteins come from: <i>the literature</i>.</b>
37	3.1. The neural side of drusen.
38	3.1.1. Histopathological, retinal imaging observations.
39	3.1.2. Proteomic level observations.
40	3.2. The systemic side of drusen.
41	3.2.1. Bruch's membrane.
42	3.2.2. Choroidal capillaries.
43	3.2.3. Contribution of blood proteins.
44	
45	<b>4. Selection of transcriptomic and proteomic datasets to determine the origin of drusen</b>
46	<b>proteins.</b>
47	4.1. Selection criteria and considerations.
48	4.2. Description of expression datasets used for drusenomics.
49	4.3. Functional annotation of the photoreceptor (cPR-ET) and choroidal (cChor-
50	ET) datasets.
51	<b>5. Drusenomics, part II: Qualitative analysis.</b>
52	5.1. Comparative study design considerations.
53	5.2. Where do proteins in drusen come from? A qualitative comparison.
54	5.2.1. Network 1.1: The complement gene cluster.
55	5.2.2. Network 1.2: The collagen cluster.
56	5.2.3. Network 1.3: The crystallin cluster.
57	5.2.4. Network 2.4: Genetic and developmental ophthalmic disorders.
58	5.2.5. Network 3. 5: Injury, inflammation and dermatological disease.
59	5.2.6. Network 4.6: Cell to cell signaling; systemic involvement.
60	
61	<b>6. Drusenomics, part III: A quantitative approach.</b>
62	6.1. Quantitative analysis and curation of datasets.
63	6.1.1. Ten out of 89 drusen proteins originate uniquely from the PR/RPE.
64	6.1.2. Twenty-three of 89 drusen proteins originate from both the "neural

65 and systemic side” of drusen.  
66 6.2. Nineteen drusen proteins out of 89 were not assigned.  
67 6.3. Blood proteins are an important source of drusen proteins.  
68  
69 **7. Drusen and hydroxyapatite.**  
70  
71 **8. Drusen and plaques: age-related macular degeneration and atherosclerosis.**  
72 8.1. Clinical and epidemiological studies.  
73 8.2. Histological and pathobiological similarities.  
74 8.3. Genetics and molecular biology.  
75  
76 **9. Future directions and conclusions.**

## 1. Drusen.

Drusen are extracellular deposits of bio-materials underneath the retinal pigment epithelium (RPE) in the eye (Farkas et al., 1971b; Sarks, 1976). They are considered clinical hallmarks for a number of diseases, including age-related macular degeneration (AMD) (Hogan, 1965; Sarks, 1976; Hageman et al., 2001; Khan et al., 2016), Alzheimer disease (AD) (Csincsik et al., 2018) and dense deposit disease (DDD) (Duvall-Young et al., 1989; Mullins et al., 2000; Boon et al., 2009). AMD is the leading cause of severe visual impairment, affecting 4% of the population over 60 years old (de Jong, 2006). AD is the biggest cause of dementia, affecting millions of people in the western world. DDD is a relatively rare juvenile disease characterized by kidney malfunction (Ito et al., 2017; Wang et al., 2017; Cunningham and Kotagiri, 2018). Despite the potential relevance for diseases, little is known about the composition of drusen and how and why biomaterials accumulate these deposits.

Drusen are heterogeneous in terms of size, shape, color on retinal imaging, retinal location and molecular content (Sarks, 1976; Sarks et al., 1980; Sarks et al., 1999; Crabb et al., 2002; Khan et al., 2016). In the clinic, drusen can be identified as yellow spots on funduscopy and color fundus images or dome shaped objects of different sizes under the RPE on Optical Coherence Tomography (OCT) (Marshall et al., 1992; Bird et al., 1995; Loeffler and Lee, 1998; Khan et al., 2016). Histopathological examination of drusen showed that are located between the basal lamina of the RPE cells and the Inner collagenous layer of the Bruch's membrane, a space that had been termed recently as sub-RPE-BL space (Balaratnasingam et al., 2016; Li et al., 2018). Clinical definition of drusen depends on size, color, auto fluorescence, and retinal location (Sarks, 1976; Bird et al., 1995) (Figure 1). Drusen may appear in the macula, peri-macular area or in the mid-and/or far periphery (Lengyel et al., 2015; Domalpally et al., 2017; Csincsik et al., 2018). A particular druse can be termed as "hard", when it's appearance is small, round and well demarcated, with a size of  $<63\text{ }\mu\text{m}$ . "Intermediate" drusen have a size of approximately  $63\text{-}125\text{ }\mu\text{m}$ , while "soft" drusen are  $>125\text{ }\mu\text{m}$  in size, and frequently have more ill-defined edges (Bird et al., 1995). A few ( $<5$ ) small hard (sub-clinical) drusen in the macula does not raise alarm bells, but when numbers of hard drusen increase, or the size of drusen increases such that they become "intermediate" and/or- "soft" drusen, the likelihood to progression to AMD is increased significantly (Bird et al., 1995). Drusen

110 should be distinguished from reticular pseudodrusen (or subretinal drusenoid deposits)  
111 that occur between the RPE and photoreceptor (PR) in the subretinal space (Zweifel et  
112 al., 2010; Spaide et al., 2018). Relatively little is known about pseudo-drusen and as  
113 such, they are excluded from this review. Drusen are formed in the sub-RPE-BL space,  
114 between the basement membrane of the RPE and the inner collagenous layer of Bruch's  
115 membrane (BrM).

116 The RPE is a multifunctional single neuro-epithelial cell-layer that act as a metabolic  
117 interface between the choroid and the neurosensory retina (Strauss, 2005). The RPE  
118 cells are connected by intercellular tight junctions, together forming the outer blood-  
119 retina barrier. On the apical side, the photoreceptor cells line the RPE. On the basal side  
120 the interposing BrM separates the basement membrane of the RPE from the choroidal  
121 micro-vasculature (choriocapillaris). The choroidal capillaries are fenestrated, and not  
122 surrounded by pericytes or smooth muscle cells. The BrM consists of three interleaved  
123 layers: the inner and outer collagenous layers with an elastic layer in between them  
124 (Booij et al., 2010a). Often, the basement membranes of the endothelium and the  
125 epithelium are classified as part of the BrM but we will refer here to the BrM structure  
126 as tri-laminar (rather than as penta-laminar). Embedded in the BrM are macromolecules  
127 such as proteins and proteoglycans to help remodeling the extra cellular matrix (with  
128 age)(Guo et al., 1999; Guymer et al., 1999; Del Priore et al., 2006; Beattie et al., 2010;  
129 Booij et al., 2010a; Hussain et al., 2011). The diffuse thickening of BrM is also a  
130 characteristic age-related feature (Hogan, 1965; Sarks et al., 1999). This is largely due to  
131 the entrapment of proteins and lipids within the ECM (Curcio et al., 2011; Curcio and  
132 Johnson, 2012). The diffuse build-up of extracellular bio-materials between the  
133 basement membrane of the RPE and the inner collagenous layer of the BrM is called  
134 basal linear deposits while the deposit formation between the basement membrane and  
135 the cell membrane of the RPE are called basal laminar deposits (Sarks, 1976; Sarks et al.,  
136 1980; van der Schaft et al., 1993; Abdelsalam et al., 1999; Curcio and Millican, 1999;  
137 Spraul et al., 1999). Due to the lack of information of the composition of these deposits,  
138 these specific classifications are excluded from our analysis. The deposits in BrM result  
139 in a decline in the conductivity of the membrane creating in a diffusion barrier that  
140 further enhances the accumulation of biomaterials (Green and Enger, 1993; Moore et al.,  
141 1995; Starita et al., 1997; Curcio and Millican, 1999; Curcio et al., 2011; Curcio, 2018b).

This phenomenon may be a general “passive” pathophysiological process that resembles plaque formation in disorders such as AD or atherosclerosis.

Even more detailed insights into sub-RPE-BL space deposits originated from molecular and histochemical studies on isolated drusen material. Recent investigations have shown that drusen contain lipids, trace elements, including zinc, iron and calcium, as well as a wide array of different proteins (Crabb et al., 2002; Curcio et al., 2011; Thompson et al., 2015; van Leeuwen et al., 2018). The distribution of these components is not uniform, neither within nor between drusen, further emphasizing the heterogeneous nature of the deposits (Thompson et al., 2015).

Oxidative modification of lipids and proteins may result in the cross-linking of these molecules and may contribute to deposit formation and drusenogenesis. Subsequently, local cellular damage at the very early onset of AMD, via the complement cascade attack on drusen compounds and the NLRP3 inflammasome (Edwards and Malek, 2007; Yuan et al., 2010; Doyle et al., 2012), can lead to retinal damage and more advanced AMD.

Relatively few studies addressed the origin of proteins in the initiation and progression of drusen (Mullins et al., 2000; Nordgaard et al., 2006; Cryan and O'Brien, 2008; Wang et al., 2010; Crabb, 2014). A number of studies (Johnson et al., 2011; Kunchithapautham et al., 2014) have yielded conflicting data as to where drusen proteins originate from, and whether the accumulation of this apparent deposition of biomaterials in BrM is a passive or an active process. Several questions remain, which include: to what extent do proteins in drusen originate from photoreceptors, RPE, choroidal endothelium or even the circulating blood? How do drusen form and how are drusen components recruited and deposited in the sub-RPE-BL space? What is the extent of the (molecular) heterogeneity that exists within and between drusen? Here, we will review and combine data from the existing literature, and supplement these with our own (new and recently published) data from subretinal transcriptomic, proteomic and immunohistochemical staining experiments. To enable this, we have functionally annotated a compiled list of drusen proteins and compared these proteins with those identified in specific transcriptomic and proteomic datasets derived from cells and tissues of the various relevant compartments. These include both subretinal and choroidal tissues, as well as the plasma proteome. Collectively, these analyses increase our understanding of drusenogenesis, which may provide clues for the prevention of drusen formation and, ultimately, for the prevention of drusen associated disorders (Khan et al., 2016)

## 2. Functional annotation of drusen proteins.

One of the key aims of this study is to identify the most likely original sources of drusen proteins. More specifically, do drusen proteins only come from the neural tissues (photoreceptors and RPE) or is there also a choroidal or systemic component? In the next chapters, we try to answer this question through a literature search and by using a variety of qualitative and quantitative transcriptomics and proteomics meta-analyses of the relevant genes and proteins involved.

We did not distinguish between various drusen types, sizes and/or drusen locations, since little -omics data are available for each drusen subtype. Essentially, we followed the (sub-clinical) drusen type description used by Crabb and coworkers (Crabb et al., 2002) who defined drusen to appear as opaque, 0 to 250  $\mu\text{m}$  spherical to irregular deposits that remained attached to BrM after removing the RPE from human donor globes, both in the macular and the retinal periphery.

Based on relevant studies in the literature (Mullins et al., 2000; Crabb et al., 2002; Wang et al., 2010), we curated a list of 89 drusen proteins (Table 1). This was achieved by combining the published datasets and removing incomplete, duplicate or ambiguous entries. Several entries did not correspond to a single full-length cDNA annotated in the knowledge database Ingenuity ([www.ingenuity.com](http://www.ingenuity.com)) and were left out. Since the complement gene pathway is likely the best and most extensively studied pathway (compared to other pathways) we only added a few complement proteins to the list, to avoid bias toward one pathway and the “winner’s curse”. In addition, we also searched the literature for confirmatory immunohistochemistry (IHC) studies and manually added proteins from such smaller-scale studies. We realize this list may not be complete. For example, individual entries like the locally produced vitronectin (Hageman et al., 1999; Wasmuth et al., 2009) present in drusen is missing in Table 1 and an entry like elastin may be present as contamination of the BrM rather than a “specific” drusen protein. The problem with selecting these proteins lies with the heterogeneity of drusen (one protein may be present in one drusen but not in the other), lack of uniform criteria “what is drusen-specific (?)”, lack of uniformity in healthy or diseased stage of examined samples and overall, how much evidence is needed to assign proteins to drusen (see also discussion section). Nonetheless, we believe that, for the purposes of this study, our

selection of 89 proteins, largely based on the proteomic study of Crabb and colleagues (Crabb et al., 2002) provides us with a sufficient representative drusen protein dataset for the purpose of this study.

We used the 89 drusen protein data set first to investigate the molecular aggregation and the functional annotation of drusen proteins. A similar study was previously carried out by Crabb and coworkers (Crabb et al., 2002; Crabb, 2014). However, here we used a slightly different list of drusen proteins and subjected this to additional, advanced bioinformatics analysis. Consequently, we ran an Ingenuity knowledge database core analysis using our list of drusen components (Table 1) which yielded biological motifs, canonical pathways and molecular structural or functional networks. A summary of the results of this analysis is shown in Table 2.

### *2.1. Biological or disease motifs and canonical pathways.*

The functional annotation of the 89 drusen proteins (Table 2), revealed that these proteins (motifs or aggregates) can be associated with a number of functional or disease entities, such as “hereditary disorders”, “ophthalmic disease”, “organismal injury or abnormalities” and “metabolic disease and developmental disorders”. Although these annotation categories are broad and not very specific, they do point to a wide range of potential sources of drusen components from both local and systemic origin.

Ingenuity analysis also yielded a number of canonical pathways. A canonical pathway is the simplest linear representation of an established chain of biochemically related molecules in a given system or cellular environment. The software recognizes enriched canonical pathways specific for “acute phase response signaling”, the “retinoid- and farnesoid X receptors (LXR/RXR and FXR/RXR) response”, “atherosclerosis signaling” and “IL-12 signaling in macrophages” in the drusen dataset.

“The acute phase response” is a fast-systemic inflammatory response triggered by infection, tissue injury and/or immunological disease (Serhan et al., 2015). The response is mediated by the hypothalamus and several acute phase plasma proteins. These proteins have a broad-working spectrum: they kill micro-organisms and modulate complement activation, enzyme activity and the immune response. How and why these proteins potentially end up in drusen is not clear (Johnson et al., 2000). Although not undisputed, Despriet and coworkers found independently, that AMD is associated with



acute phase plasma protein levels and with genetic variation in C-reactive protein (CRP), one of the principal acute phase proteins (Despriet et al., 2006). Chirco and Potempa showed that CRP protein acts as a mediator of complement activation and inflammatory signaling in AMD (Chirco and Potempa, 2018). It is generally assumed that acute phase proteins are present in the blood; suggesting that some drusen proteins can originate from this pathway and have a systemic origin. While choroidal CRP apparently correlate to serum levels (Chirco et al., 2018), it cannot be said with certainty that these proteins are not (transiently and/or locally) produced by the choroid as well in cases of (nearby) low-grade inflammation.

“The retinoid X receptors (RXRs)” are nuclear retinoid receptors that regulate, via the ligand LXR, lipid and cholesterol metabolism as well as inflammation (Hiebl et al., 2018). Cholesterol metabolism is essential for many retinal functions (Pikuleva and Curcio, 2014), while ocular (para-) inflammation is crucial for maintaining retinal homeostasis (Xu et al., 2009). In the eye, retinoid X receptor activation contributes to retinal photoreceptor differentiation, survival, and disease (Forrest and Swaroop, 2012), and more specifically, for docosahexaenoic acid-mediated protection of photoreceptors (German et al., 2013). The presence of this protein signature in drusen points toward a local cellular origin of this protein. LXR can form heterodimers with “the farnesoid X receptor (FXR)” which is also a nuclear receptor, and is an important regulator of a variety of bile acid, glucose and lipid-related metabolic pathways, including the removal of cholesterol (Tu et al., 2000; Hiebl et al., 2018). FXR protein was detected in a variety of tissues, including heart, ovary, thymus and eye. Both LXR and FXR may be involved in cholesterol homeostasis in RPE and retina (Zheng et al., 2015). The presence of these receptor proteins in drusen points toward a local cellular origin.

“Atherosclerosis signaling”: Atherosclerosis is a low grade chronic inflammatory disorder characterized by local plaque deposition in the vessel wall, formed by a local accumulation of modified plasma lipoproteins and macrophage activation. The major cause of coronary events is rupture and thrombosis. Interestingly, clinical, epidemiological, pathobiological and molecular evidence suggest that an overlap exists between drusen in AMD and plaque formation in atherosclerosis. Indeed, like AMD, atherosclerosis is now considered as a low-grade chronic inflammatory process resulting from interaction (in) between plasma lipoproteins and the vascular wall (Mullins et al., 2000). In AMD, not only plasma lipoproteins, but also local lipoproteins

are involved. In section 8 of this manuscript, we describe the potential molecular and pathobiological overlap between drusen/AMD and vascular plaques in detail. Taken together, the homology between drusen and atherosclerotic plaques points toward a systemic origin of some drusen proteins.

“IL-12 Signaling and Production in Macrophages”: The production of the cytokine IL-12 by activated (incoming) macrophages in damaged or diseased retinal tissue, is well known (Zamiri et al., 2006; Chen et al., 2013). However, IL-12 exerts an autocrine effect since macrophages and dendritic cells also respond to IL-12 by producing interferons that stimulates T-helper cell differentiation. The RPE is apparently able to suppress inflammation by modulating IL-12 production (Zamiri et al., 2006). Cao and coworkers showed that cultured RPE cell *in vitro* secrete several cytokines, including IL-12, under conditions of oxidative stress and replicative senescence (Cao et al., 2013). Therefore, the molecules identified in this category (IL-12 signaling) can originate from both the circulation as well as from the local cellular environment.

## 2.2. Molecular networks.

Molecular networks in Ingenuity are built up from a myriad of relevant literature connections and they are formed on the basis of most likely physical or functional interactions between (input) genes and/or proteins. For example, see molecular network 1 in Figure 2a. Based on millions of experimentally verified and curated data points, these networks represent the most likely functional associations between components of the “biological soup” in the context of the input molecules. Structural, functional and mixed molecular networks exist. Structural networks contain primarily networks of structurally and physically interacting entries. Functional networks are dominated by functional relationship between participating molecules. A third, “mixed” network, contains both structural and functional associations. The molecular network analysis of drusen proteins yielded 4 significant networks, with 6 distinct functional clusters. Note that the networks are not *a priori* built through their possible relationship with drusen or AMD *per se*.

### 2.2.1. Network 1.1, 1.2 and 1.3: Complement, collagens and crystallins.

The most significant network formed in the data-driven Ingenuity drusen analysis, is presented in Figure 2a. This network consists of three functionally more or less specific molecular clusters: the complement protein cluster, the collagen protein cluster and the

crystallin heat shock protein cluster (Table 3). The presence of complement proteins in drusen (and the choriocapillaris) was previously shown in older and AMD affected eyes through immunohistochemistry, long before the genetic involvement of CFH and other complement factors in drusen formation and AMD became genetically apparent (Johnson et al., 2000; Hageman et al., 2001; Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005). Analyzing the drusen proteome, we confirmed the involvement of the terminal complement protein complex by identifying the complement factors C7, C8A, C8B, C8G, and the membrane attack complex (MAC) in drusen. Of note, the MAC was initially identified in drusen from unspecified retinal locations, but was later shown not to be present in macular drusen (Johnson et al., 2000; Mullins et al., 2014). The MAC is the final downstream event of the complement cascade. It results from the binding of C5b to blood plasma complement proteins C6, C7, C8, and C9, forming transmembrane pores that leads to cell lysis and death. In the same cluster, we found the Prolyl endopeptidase-like protein (PRELP), a small leucine-rich proteoglycan (SLRP) (Hultgardh-Nilsson et al., 2015), which among others, is involved in the inhibition of complement activation (Warwick et al., 2014). The main complement cascade regulator CFH is another member of the complement cascade that is present in the drusen proteome. Genetic variation in CFH may regulate complement activation on RPE cells (Radu et al., 2014). Of note, is that a certain degree of low-grade complement activation and para-inflammation is always present in healthy aging eyes, to maintain local health (Xu et al., 2009). In a recent review, Warwick et al. concluded that complement deposition in the retina could be of local and/or systemic origin (Warwick et al., 2014). The majority of complement genes are expressed in the liver, resulting in an abundance of complement proteins in the blood. However, the RPE expresses several key complement genes which may modulate the complement attack on RPE and drusen (Chen et al., 2007; Kim et al., 2009; Pao et al., 2018). Interestingly, locally produced CFH is, at least in cultured RPE cells, secreted apically, and not basally (Kim et al., 2009; Pao et al., 2018). Consequently, the potential regulating role of locally produced CFH *in vivo*, and other complement factors, potentially involved in the complement attack on drusen, needs to be further investigated. A diversity of collagen proteins, such as COLA1, A2, 6A1, 6A2 and 8A1 were previously consistently identified in basal laminar deposits and basal linear deposits, and, occasionally, in drusen (Newsome et al., 1987; Booij et al., 2010a; Curcio and Johnson, 2012). Newsome and coworkers (1987) noted that the

involvement of extracellular matrix components in drusen is variable but these findings have not been confirmed in other studies. These molecules may primarily present as a remnant from the (ab)normal turnover of BrM components (Newsome et al., 1987). Alternatively, they may be secreted by the RPE in response to challenges presented by drusen or by the conditions that lead to drusen formation. Interestingly, collagen IV is not present in our curated drusen dataset, despite the fact that collagen IV accumulations are found in autosomal dominant radiant drusen in Doyne Honeycomb Retinal Dystrophy caused by EFEMP1 (EGF-containing fibulin extracellular matrix protein 1) mutations (Sohn et al., 2015). In fact, in the absence of detailed electron microscopic examination it is not clear whether these are drusen or basal laminal deposits.

The presence of crystallin proteins in drusen had been shown by Crabb and co-workers (Crabb et al., 2002) and functionally studied by Nakata et al. (Nakata et al., 2005). These authors found that BrM, drusen and part of the choroidal connective tissue, when affected by AMD, showed higher immunoreactivity for  $\alpha$ - and  $\beta$ -crystallins than healthy control tissues. Retinal crystallins are also up-regulated in a variety of other retinal pathologies, including diabetic retinopathy, ischemia, mechanical injury and uveitis. The  $\alpha$ -crystallin family plays a crucial role in neuroprotection and inflammation (Fort and Lampi, 2011), while the  $\beta$ - and  $\gamma$ -crystallins are small proteins with a possible ganglion cell protective role in glaucoma (Anders et al., 2017) and a role in retinal tissue remodeling and repair (Thanos et al., 2014). Consequently, the presence of these proteins in drusen points to a local cellular origin.

#### *2.2.2. Network 2.4 development, genetics of ophthalmic disorders.*

The fourth cluster in our drusen protein analysis is actually similar to the entire network 2 which is functionally annotated as “network of genetic and developmental disorders”. The components of this cluster are functionally presented in detail in Figure 2b; Table 3. This network contains annexin A2 (ANXA2), a relatively small calcium and phospholipid-binding protein involved in multiple intra-cellular transport functions. The RPE secretion data set, called RPE-IVS (Table 3; STable 1) reveals that this protein is indeed secreted basally by the RPE (Pao et al., 2018). The protein was initially assigned to drusen (Crabb et al., 2002). However, the same authors showed, using IHC in a

number of human donor eyes, that ANXA2 is not associated with the interior of drusen, but with the basal lamina of the RPE close to the drusen surface.

### *2.2.3. Network 3.5: Immunological response.*

The fifth functional cluster in our drusen protein analysis represents network three: “Injury and inflammatory response; dermatological disease” (Figure 2c). The components are given in Table 3. This network contains, among others, annexin A1 (ANXA1). ANXA1 antibodies intensely stained whole drusen, but also the BrM and choroid (Rayborn et al., 2006). Given its positive staining in entire drusen, we consider it here as a drusen protein. Apolipoprotein E (APOE) is also present in this group. APOE is classically thought of as a cholesterol carrier. Risk alleles of the APOE gene were associated with a variety of diseases including AMD, AD and atherosclerosis (Klaver et al., 1998; Ashford, 2004; Song et al., 2004; Tikellis et al., 2007). Its presence in laminar deposits and drusen was initially established by Klaver and colleagues (Klaver et al., 1998) and later confirmed by Anderson and Malek (Anderson et al., 2001; Malek et al., 2003). Interestingly, in an RPE cell culture model that mimics drusen formation, Pao (2018) and coworkers found that APOE is secreted basally by these cells. Subsequent exposure of these cultures to human serum led to heterogeneous sub-RPE-BL space deposits, some of which were rich in serum-derived proteins such as vimentin, clusterin and amyloid P (Pao et al., 2018). In addition to ANXA1 and APOE, the serum amyloid proteins S100A7, S100A8 and S100A9 are part of this functional cluster and the drusen proteome. S100 proteins are a family of small calcium-binding proteins, produced in the nucleus and cytoplasm of a wide variety of cells (Gross et al., 2014; Narumi et al., 2015; Cunden et al., 2017).

### *2.2.4. Network 4.6 Cell-to-cell signaling and systemic involvement, lipid metabolism.*

The sixth cluster “cell-to cell signaling and systemic involvements” (Figure 2d; Table 3) points to proteins which come from an extracellular environment. For example, The APOA1, APOA4 and SAA1 lipoproteins and S, and the protein-groups related to the LDL, HDL, VLDL metabolism (that have been added by Ingenuity to construct a meaningful network) are most likely derived from the blood, and not from the retina. However, cautious interpretation of these general data is warranted, since the RPE is also capable of secreting a number of lipoproteins, such as APOB (Li et al., 2005b). The mechanisms

398 of biogenesis of lipid-laden soft drusen has been recently reviewed elsewhere (Curcio,  
399 2018a, b) as has the role of lipids in AMD (van Leeuwen et al., 2018).  
400 In at least two blood proteomics datasets (Table 3) the ORM1 (acute phase plasma  
401 protein of unknown function; [www.genecards.org](http://www.genecards.org)) and the SERPINA1 (serine protease  
402 inhibitor; [www.genecards.org](http://www.genecards.org)) proteins occur, which point also at a systemic origin of  
403 these drusen proteins. Furthermore, in this cluster we see the drusen protein clusterin  
404 (CLU), which is expressed in many cell types, including photoreceptors or RPE, and is  
405 also present in blood (Garcia-Aranda et al., 2018). The presence of annexin 6 (ANXA6) in  
406 drusen (and BrM) was previously confirmed using immunohistochemistry (Rayborn et  
407 al., 2006). Finally, we observe also the presence of the (systemic) HRG protein, which is  
408 extensively discussed in section 7 of this manuscript.

### 3. Drusenomics, part I: Where do drusen proteins come from: *the literature*.

Multiple epidemiological, genetic, biochemical and pathophysiological studies in the literature address the origin of drusen. While many studies address the origins of metal ions or lipids in drusen, here we focus on the likely source of proteins. Drusen proteins could originate from either the neural side of drusen (Photoreceptors, RPE), the systemic side (BrM, choroid complex, blood) BrM, or both (Penfold et al., 2001; Curcio and Johnson, 2012).

#### *3.1. The neural side of drusen.*

Theories on drusen accumulation from the neural side vary: proteins may either come from dying PR and RPE cells, or from (basal) secretion of proteins generated by the normal functions of the RPE (Crabb et al., 2002; Kinnunen et al., 2012). Respectively, cellular debris or secreted proteins may get trapped in BrM or drusen. Evidence for these origins was gathered from histopathological investigation, retinal imaging, and proteomics studies.

##### *3.1.1. Histopathological and retinal imaging observations.*

Drusen formation goes hand in hand with hypo- or hyperpigmentation (Curcio et al., 1998) of the RPE, especially in the early stages of AMD. Indeed, retinal cells overlying drusen exhibit numerous irregular structural and molecular abnormalities which are confined to areas directly internal to drusen (Farkas et al., 1971b; Hogan, 1972; Burns and Feeney-Burns, 1980; The Eye Disease Case-Control Study, 1992; Johnson et al., 2003). Deflection and shortening of rod inner and outer segments of rod photoreceptors have been postulated to contribute to sub-RPE deposit formation (Farkas et al., 1971a). Drusen have been also associated with more indirect changes, such as alterations in the synaptic terminals of photoreceptor cells and an increase in vimentin and glial fibrillary acidic (GFAP) protein within Müller cells (Johnson et al., 2003). Other retinal cells, such as bipolar, horizontal, amacrine and ganglion cells are most likely unaffected by drusenogenesis (Johnson et al., 2003).

Using immunohistochemical, molecular biological and biochemical approaches, Hageman and coworkers found that RPE cell loss is correlated with increasing drusen density (Hageman et al., 2001). More recent OCT studies, focusing on the integrity of the RPE layer directly internal to drusen showed that 41.3% of all drusen coincided with an

intact overlying RPE, and that in 28.1% of cases, the RPE was irregular but continuous (Schlanitz et al., 2018). In 30.6% of cases, the RPE layer adjacent to drusen was discontinuous. Larger drusen were associated with higher probability of RPE loss (Schlanitz et al., 2018). Taken together, these results suggest that RPE or PR cell death is associated with drusenogenesis. However, it is not clear whether the observed cellular damage is a cause or consequence of sub-RPE deposit formation.

The presence of cytoplasmic (Burns and Feeney-Burns, 1980), fibrous and membranous/lipoid material (Fine, 1981; Young, 1987; Green and Enger, 1993; Loeffler and Lee, 1998; Curcio and Millican, 1999) in drusen suggest that deposits are formed after cellular degeneration. According to Coats, small colloid bodies derived from degenerated RPE cells, develop into larger drusen due to uptake of biomolecules through a defective BrM (Coats, 1905) and clinical support was provided for the existence of these bodies (Pauleikhoff et al., 1990). Later, necrotic RPE cells were presumed to be incorporated into existing drusen (Young, 1987). However, these findings also did not distinguish between cause or consequence of deposit formation. To complicate matters further, there are a number of reports in the literature describing drusen regression; in an experimental study after laser photocoagulation and in clinical studies using fluorescein angiograms (FAs) fundus photography (Bressler et al., 1995) and OCT (Yehoshua et al., 2011). A similar observation were done in rhesus monkeys (Duvall and Tso, 1985) in APOE mice with thickened BrM as well as AMD patients (Jobling et al., 2015). This intriguing phenomenon may be linked to transiently increasing the RPE-mediated release of active MMP enzymes that alter the turnover of BrM (Zhang et al., 2012).

### *3.1.2 Proteomic level observations.*

Proteomics studies into drusenogenesis can be divided into studies on (archived) human post-mortem eyes, *in vitro* RPE culture, and proteomic studies on retinas of animal models. A variety of techniques, such as 2D gels and LC-MS/MS analysis have been used. To date, up to over 500 healthy and AMD-affected post-mortem human eye tissue specimens (numerous contributions of Sarks, Hageman, Mullins, Luty, Bergen, Lengyel, and Curcio) have been examined by light, confocal, or electron microscopy, in conjunction with proteomics and with antibodies to specific drusen-associated proteins (Curcio et al., 2017). These studies emphasize the heterogeneity of drusen, a concept



initially developed by Sarks and coworkers (Sarks et al., 1980; Sarks et al., 1994; Sarks et al., 1999) and strongly suggest that chronic local inflammation at the level of BrM is an important contributor to drusenogenesis.

*In vitro*, the transcriptome and proteome of RPE cells, such as cultured primary retinal cells (fetal or from postmortem human donor eyes) (Alge et al., 2003; Oshikawa et al., 2011; Pao et al., 2018) has been determined. Stable isotope labeling of amino acids showed that these cells secrete a variety of extracellular matrix proteins, complement factors, and protease inhibitors, that have also been reported to be major constituents of drusen (An et al., 2006). In addition, abnormal protein secretion by human primary RPE cultures derived from AMD patients has been observed compared to age-matched controls (An et al., 2006). However, the fact that major components of drusen can be reproduced by RPE cells without the need for PR outer segments, supports a crucial role of RPE in drusen formation (Pilgrim et al., 2017). At the same time, it suggests that PRs may contribute but are not essential for drusenogenesis. Off note, it is important to emphasize that cells in culture were treated with heat-inactivated serum, and that the contribution of components from this material to drusenogenesis, as “dietary” contribution, is highly likely (Bretillon et al., 2008; Pikuleva and Curcio, 2014; Pilgrim et al., 2017).

Wang and coworkers found that, after simultaneous mass spectrometry analysis of both archived drusen and RPE material, similar protein profiles, but with higher intensities and greater variability in the drusen. Within the limits of unavoidable sample contamination, these data suggest that other than RPE alone, additional local cells or tissues contribute to formation of debris in the sub-RPE-BL space (Wang et al., 2010).

### *3.2. The systemic side of drusen.*

Drusenogenesis theories have focused on the role of lipids and immune-mediated effects. Lipoproteins, neutral lipids (Curcio et al., 2011), complement-activating molecules and other immune mediators as well as monocyte-derived cellular processes have been identified within drusen (Hageman et al., 2001; Penfold et al., 2001; Anderson et al., 2010; Molins et al., 2018), which indicates the biogenesis or propagation of drusen from the systemic side.

#### *3.2.1. Bruch’s membrane.*

The main functions of BrM are structural, to support the RPE, and to regulate the transport of fluid, ions and biomolecules from the choroid to the RPE, and *vice versa* (Curcio and Johnson, 2012). BrM thickening and decline of hydraulic conductivity have been observed during aging (Hussain et al., 2010; Cankova et al., 2011). Studies suggest diffuse thickening of the inner aspect of BrM is associated with retinal pigment epithelial hypopigmentation, focal atrophy, and soft (large) drusen formation (Bressler et al., 1994). A variety of extracellular matrix components have been detected in diffuse thickenings of BrM (Fernandez-Godino et al., 2016). Immunohistochemical reactivity of BrM showed age-related accumulation of type I collagen and localized changes associated with some drusen (Newsome et al., 1987; Curcio and Johnson, 2012). The tissue inhibitor of metalloproteinases-3 (TIMP-3) protein, a major component of the drusen proteome, showed high immune-reactivity in human drusen and in BrM (Fariss et al., 1997). The continuous turnover of BrM during life could provide a continuous local supply of BrM proteins. Some of the remnants may be cleared to the blood but some of them might end up in drusen. Please note, that most studies on the aspects of BrM thickening have been performed by light microscopy on paraffin sections. In future studies, it will require TEM or high resolution light microscopy to confirm the majority of these findings, and to distinguish, for example, between “BrM thickening” and basal laminar deposits.

### *3.2.2. Choroidal capillaries.*

The choriocapillaris is located directly underneath the RPE and BrM. It is composed of a unique vascular network which provides nutrients and fluid for the RPE and the retina (Bernstein and Hollenberg, 1965). The abundance of fenestrations on the RPE aspect of the choriocapillaris endothelium makes this vascular bed much leakier than non-fenestrated vessels (Bernstein and Hollenberg, 1965). A compromised interface can result in various abnormalities such as choroidal neovascularization (CNV) and AMD (Lutty et al., 2010).

With age and in AMD, the choroid thins. The choriocapillaris loses density and covers an increasingly smaller portion of BrM. At the same time, increased drusen deposition occurs, as witnessed by histopathological evidence (Ramrattan et al., 1994; Ida et al., 2004). OCT Angiography (OCTA) showed atrophy of choriocapillaris underneath and beyond the region of photoreceptors and RPE loss (Wakatsuki et al., 2015; Moreira-Neto

et al., 2018), in agreement with previous and parallel histopathological studies (McLeod et al., 2009; Biesemeier et al., 2014). In human macular sections, histopathological evaluation of the sub-RPE-BL deposits together with potential vascular changes, showed that vascular density was inversely correlated with sub-RPE-BL deposit density (Biesemeier et al., 2014). Curcio and coworkers observed that modest endothelial cell loss in the choriocapillaris also occurred directly adjacent to basal linear deposits and subretinal drusenoid deposits (Curcio et al., 2013). Sub-RPE-BL deposits showed a positive correlation with the number of ghost vessels in the choroid, suggesting that vascular endothelial cell loss could contribute to deposit formation (Mullins et al., 2011). It has also been shown that the presence of complement components and specifically, MAC, in the choroid increases with aging, and increases even more in AMD-affected eyes (Mullins et al., 2014; Chirco et al., 2016). In fact, C5b-9 complement complexes are present in hard drusen, BrM, and extend to the choriocapillaris in some cases (Johnson et al., 2000; Anderson et al., 2002). C5b-9 complexes were not observed in soft drusen (Mullins et al., 2014).

On whole-mount hydrated preparations of the choroid and BrM, (hard) drusen were located to the intercapillary pillars of the choroid, suggesting a close relationship between drusen formation and the capillary bed (Lengyel et al., 2004). This was observed in earlier studies, but not systematically examined (Friedman et al., 1963). It was suggested that drusen are a manifestation of (a) disturbed transport mechanism(s) of substances across the capillary wall or BrM (Penfold et al., 2001). Whether this indicates that drusen deposition is the result of slower clearance at the intercapillary pillars or a manifestation of a disturbed transport mechanism of substances across the capillary wall, or both, needs additional investigation. Of note, further pathological compromise of the vascular bed and BrM leads eventually to the development of subretinal neovascularization and wet AMD.

### *3.2.3. Contribution of blood proteins.*

Penfold and coworkers suggested that breakdown of the normal choroidal vascular function allows the movement of plasma proteins to the sub-RPE-BL space and this leakiness is one of the cause of initiating the progression to AMD (Penfold et al., 2001). Another study involved the analysis of age-related changes in various proteins and lipids in the BrM using multiplexed Raman spectroscopy and found age dependent change in

heme signals (Beattie et al., 2010). However, there are no detailed and definitive studies how these plasma molecules end up in the sub-RPE-BL space. Involvement of fenestrations, breakdown of tight junctions, active vesicle transport (caveola) and receptor-mediated endocytosis (for macromolecules) have been suggested. Fenestrations are found predominantly on the endothelial vessel wall closest to the RPE (Bernstein and Hollenberg, 1965; Pino, 1985; Mancini et al., 1986). Rodent studies suggested that the number of fenestrae initially increases with age; but in advanced age and in AMD the number of fenestrae decreases (Burns and Hartz, 1992; McLeod et al., 2009). Transport through fenestrae is likely to be tightly regulated but it is not yet fully characterized (Pino and Essner, 1981; Essner and Gordon, 1983). Tight junctions of the choroidal capillaries show a tendency to become leaky with age, and lack transport regulation which may facilitate movement of plasma proteins from the choroid towards to the RPE (Nakanishi et al., 2016) (Aiello et al., 1998). Finally, vesicle- or receptor-mediated transport of proteins also exist in the choroid. (Smith et al., 1989). Taken together, transport of proteins at the choroid/BrM interface is complex and warrants further investigation.

It has long been speculated that both blood plasma and incomplete digestion of photoreceptor outer segments contribute to the buildup of drusen material (Farkas et al., 1971a). It has also been suggested that drusen formation in the retina may be similar to plaque formation in arterial walls (Curcio et al., 2001), which, again, suggests that the contribution of blood proteins may be more important than previously thought (see section 8 on “drusen and plaques”). However, there is a paucity of information as to what extent proteins from the blood really contribute to drusen formation. It is thus plausible that some molecules exit the choroidal vessels into the extracellular space adjacent to the RPE, especially as the barriers in place to prevent such an event from happening, become compromised with age.

## 4. Selection of transcriptomic and proteomic datasets to determine the origin of drusen proteins

### 4.1. Exclusion criteria and considerations.

One of the main goals of this study was to compare subretinal cellular transcriptomics and proteomics as well as the blood proteome with proteins that are present in drusen. To achieve this, we made use of a subset of studies from the literature as well as our own data. Apart from the drusen protein studies, which date back to 2002, we only considered here mRNA and protein studies published over the last 8 years; we did not include retinal microRNA studies, non-coding RNA, metabolomics, imprinting studies and data from (differences in) single-cell expression studies, simply because there are relatively few confirmed and validated studies for the various types of retinal tissues available yet.

Multiple excellent transcriptomics and proteomics studies have been published on different layers of the retina/RPE/choroid complex, these are reviewed by a number of authors recently (Skeie and Mahajan, 2014; Tian et al., 2015; Zhang et al., 2015a). However, the studies currently available differ in many aspects, including study design, retinal area and retinal cell type examined, sample source selection, sample handling, sample numbers investigated, probe labeling methodology, microarray- or RNA sequencing- methodology as well as the platform, quality and type of bioinformatics programs used for analysis. It is not our goal here to describe and compare all the retinal transcriptomic or proteomic data in the literature. Nonetheless, if one wants to compare different sources (subretinal transcriptomics and proteomics, blood proteomics) and/or outcomes (drusen proteins), similarity of the components and parameters of the comparison(s) is obviously, highly desirable (Ahmad et al., 2018).

In the relevant transcriptomics literature, at least three phases can be observed: studies before and after the introduction of the MIAME (Minimum Information About a Microarray Experiment) quality guidelines studies (Brazma et al., 2001); studies before and after the introduction of whole genome microarrays (at least 22000 genes (22 K or more)) and studies before and after the introduction of RNA-Seq and GTex criteria. Over time, a similar technological development has taken place in the proteomics field: from 2-D gels to high pressure liquid chromatography columns coupled and high throughput

mass-spectrometry-based studies (Geyer et al., 2016). In principle, the quality of large-scale transcriptomics and proteomics studies has continued to improve, and better and more complete datasets may become available in time that may change some of the interpretations described here.

There are several obvious differences between transcriptomics and proteomics studies. In principle, transcriptomics techniques are highly sensitive and highly quantitative, but as such, highly susceptible to RNA contamination or degradation. In addition, transcriptome changes may not equate with changes on coded proteins and as such are further away from biological function.

Proteomics studies, however, are usually less sensitive and quantitation can only be achieved under certain circumstances, but proteomes per se are closer to function. During disease progression, transcriptomics and proteomics profiles of a tissue can change rapidly depending on disease stage. Also, a single tissue under study can be affected by two or more consecutive disease stages at the same time. For example, in AMD, new hard drusen continue to appear in the sub-RPE-BL space, while other drusen in the same tissue already become confluent, and perhaps part of the same retina is already prone to neovascularization. Consequently, for a disease like AMD, where the RPE is subject to consecutive, insidious and overlapping disease stages, it is very difficult to sift out useful and consistent healthy and disease stage specific expression profiles for this cell layer.

Obviously, transcriptomics and proteomics studies cannot be translated one-to-one, due to, for example, differences in RNA and protein synthesis and turnover rates. The sound interpretation of both transcriptomics and proteomics is highly dependent on the use of advanced bioinformatics and knowledge databases, which combine millions of data-points from human, mouse, and rat studies. Nonetheless, it is the investigator, with knowledge of disease pathology, molecular biology and bioinformatics alike, who can make the difference.

There are two goals with most transcriptomics (or proteomics) studies: One type of study aims to find a complete molecular blueprint of the cells or tissues of interest; these studies usually yield an enriched expression data set for the cell of interest. This type of study usually includes both genes specifically expressed in the cell type of interest, but also genes expressed in similar cell types. For example, the RPE is probably defined by a few hundred RPE-specifically expressed genes, a few thousand neural cell-type

expressed genes, many expressed housekeeping genes for basic functions, as well as many genes which are on “standby”. The genes that are on “standby” have a very low (leaky) expression if the cell is in a state of homeostasis. However, if the environment changes, these very low expressed genes can rapidly be expressed to adapt the cell to a changing environment. For example, the RPE shares most likely the RNA expression of a large portion of its transcriptome: neural cell type genes, the household genes, and low-level expressed genes, with the other (neural) cell types in the retina (own observations). Finally, there are many specific non-expressed genes in a certain cell-type. An example of expression studies which aim to find a molecular blueprint of the cell is the uncurated RPE expression dataset, RPE-ET (Table 3), which contains 10% of the biologically highest expressed genes in the RPE (Booij et al., 2009). The other type of study aims to find only a maximum of genes specifically expressed in only the cells or tissue of interest. These few hundred genes, in the context of the more generally expressed genes, give the cells of interest their specific cell type-associated functionalities. An example is the dataset, RPE-ST (Bennis et al., 2015), which contains 170 RPE-specific expressed genes derived from previous RPE expression studies (Booij et al., 2009; Booij et al., 2010b; Strunnikova et al., 2010) (STable 2).

#### *4.2. Description of expression datasets used for drusenomics.*

Apart from the 89 drusen protein data set, we used in this review 11 additional subretinal and blood data-sets derived from previous transcriptomics and proteomics studies; this is summarized in Table 3. We found that these transcriptomics and proteomics databases complement each other and, together, give a more complete overview of relevant expressed genes/proteins per tissue investigated. A common feature of all high throughput studies is that they generate, by default, a small percentage of misidentifications. This is due to cellular or molecular contaminations, or mis-representation due to experimental sample handling. Therefore, individual gene findings usually need to be confirmed by at least a second technique which focuses on the analysis of single genes or proteins.

We used pure, enriched and curated cellular expression datasets. Pure datasets are those without possible contaminations of other cell types while enriched datasets are those datasets that have a certain degree of contamination of adjacent cell types. Finally, curated datasets are those which are manually enriched either by bioinformatics or by

literature search to remove inevitable contaminations or irrelevant data as much as possible. The curation strategies employed are presented in Figure 3.

Most of the (non-curated) data were used for qualitative studies, have been published and analyzed elsewhere, and are mentioned below for reference. For the quantitative studies, we used curated datasets. The photoreceptors and choroidal transcriptome datasets, cPR-ET and cChor/ET (Booij et al., 2010b) (GEO database accession number GSE20191) have not been fully published before and therefore, their description will receive a little more attention here.

First of all, we used (1) a combined data set for drusen proteins, curated by hand as described above (Table 1). Furthermore, we used (2) a photoreceptor outer segment proteomics dataset published by Kiel and coworkers (Kiel et al., 2011), which contains proteins reflecting a multiscale signaling network associated with rhodopsin, the major protein component of rod photoreceptor outer segments. It was constructed by combining relevant proteomics datasets, structural and functional literature mining and bioinformatics approaches (Table 3; STable3). Most likely, this database listing contains some contamination from adjacent cell types, the RPE and choroid. Therefore, a curated list was used for the quantitative studies: we subtracted the most highly expressed sequences of the choroid (top 10% chor Booij; Chor-ET; and the uniquely expressed sequences of the RPE (RPE-ST, Bennis)) from this database listing. The acronym used for this dataset in this manuscript is P<sub>ROS</sub>-EP (Photoreceptor outer segment-enriched proteomics). The annotation of the curated version (c) of this dataset is cP<sub>ROS</sub>-EP.

(3) The RPE-specific database with 170 entries was constructed by bioinformatic curating and combining other (highly) enriched RPE gene expression databases (Booij et al., 2010b; Strunnikova et al., 2010; Bennis et al., 2015). This database listing should be viewed as a minimal number of RPE-specific expressed genes based on previous -omics studies; the acronym used here is RPE-ST (Specific Transcriptomics) (Table 3; STable 2).

(4) The RPE secretome data from (Pao et al., 2018) that was published recently. RPE cells were grown *in vitro* to confluency while adding various amounts of zinc to the culture medium. Both the apically and basally secreted RPE proteomes were determined. Here, we use the basal secretome proteomics listing which contains 276 entries. (Table 3; STable 1). Due to its nature, this dataset does not contain contamination from other cell types but may contain contaminants from the culture



medium. In addition, its *in vitro* basis may not be fully representative of the *in vivo* situation, particularly in the disease state. The acronym for this database in this study is RPE-IVS (*in vitro* secreted) (Table 3).

(5) The RPE/choroid proteomics dataset from Zhang and coworkers that contain proteins extracted from RPE/choroid tissues of eyes from five individuals, fractionated and separated using SDS-PAGE and analyzed using mass spectrometry (Zhang et al., 2016). In the RPE/choroid the authors identified 2755 non-redundant proteins. This dataset is rather large in components and is likely to contain entries from multiple cell-types (RPE, choroid, blood and possibly PR), and not only (RPE/choroid), given the inevitable contaminations of the PR sample with RPE and *vice versa*, and the contamination of the choroid with blood. The authors deposited their data to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers PXD001424 and PXD002194. The acronym for this database in this manuscript is RPE/chor-EP (RPE/choroid-enriched proteomics) Table 3.

(6) The blood proteome listing by Geyer and coworkers was produced by a new efficient plasma proteome profiling pipeline (Geyer et al., 2016). Using a modified mass spectrometry-based workflow they were able to identify and quantify at least 1000 plasma proteins. Given the nature of the samples, it is unlikely to contain other retinal cells or proteins as contamination. The acronym for this database in this study is BL-SP1 (Blood plasma-specific proteomics; no 1) (Table 3; STable 4) (Geyer et al., 2016).

(7) The blood proteome dataset by Farrah and coworkers contains a non-redundant set of 1929 protein sequences from human plasma detected by tandem MS (Farrah et al., 2011). The full data are available via PeptideAtlas, a large, international database of publicly accessible peptides identified in tandem MS experiments in a multitude of organisms. This is also a “pure” database listing. The original dataset contains endogenous chemicals, which we removed for our analyses. The acronym for this database in this study is BL-SP2 (Blood plasma-specific proteomics, no 2); (Table 3).

(8) The BL-PHP blood proteome dataset consists of 262 HAP binding proteins from AMD patients and controls, as recently described (Arya et al., 2018). Plasma samples were taken from 23 individuals aged 65-90 with late stage AMD, each displaying drusen and choroidal neovascularization in clinical images and attending the anti-VEGF injection clinic at Moorfields Eye Hospital, London (STable 5).

(9) The atherosclerosis plaque proteomics dataset contains 3196 entries based on a comprehensive review of the literature in this field (Bleijerveld et al., 2013). The acronym used in this study is AS-EP (Atherosclerosis-enriched proteomics) (Table 3). The (large) dataset is available as supplementary file to the authors' publication. (10-12) Transcriptomics datasets of the photoreceptor (acronym: PR-ET: Photoreceptor; enriched transcriptomics), the choroid (acronym: Chor-ET: Choroid-enriched transcriptomics.) (Table 3), and RPE (acronym: RPE-ET: RPE-enriched transcriptomics) were produced using the same Agilent methodology and platform. For functional annotation and quantitative analyses, curated versions of these databases were constructed, named, respectively, cPR-ET (STable 6) and cChor-ET (STable 7). The (c)RPE(-ET) database has been extensively published elsewhere (Booij et al., 2009; Booij et al., 2010b).

#### *4.3. Functional annotation photoreceptor (cPR-ET) and choroidal (cChor-ET) datasets.*

The PR-ET and Chor-ET datasets contain, respectively, the averaged top 10% highest expressed genes in the photoreceptor and choroid. The isolation methods, study design and methodological issues for these datasets have been extensively discussed elsewhere (Booij et al., 2009; Booij et al., 2010b). These raw datasets were used for the qualitative studies in this manuscript. The experimental studies were performed in agreement with the declaration of Helsinki concerning the use of human material for research and followed both MIAME and GTex criteria (Brazma et al., 2001; Consortium, 2013). We curated both datasets PR-ET and Chor-ET according to scheme C in Figure 3. In order to obtain cell-specific datasets for photoreceptor and choroid, which are useful for both cell-specific functional annotation and for quantitative studies described elsewhere in this manuscript. Consequently, we removed from the PR-ET and Chor-ET datasets all expressed genes that overlap between them (either contaminations or truly shared gene expression). This resulted in two smaller curated datasets. Subsequently, we also removed all potentially present RPE-expressed unique sequences (RPE-ST dataset) to generate the cPR-ET and cChor-ET datasets. Thus, the resulting cPR-ET and cChor-ET datasets contain less, but highly cell-specific entries compared to PR-ET and Chor-ET. Hence, we ended up with a highly photoreceptor-enriched gene expression dataset consisting of 745 genes (STable 6) and a highly enriched expression dataset for the choroid of 848 entries (STable 7).

We ran an Ingenuity core analysis ([www.ingenuity.com](http://www.ingenuity.com)) on both cPR-ET and cChor-ET datasets. This type of analysis typically yields data-driven functional annotations (i.e. it produces biological motifs, canonical pathways and molecular networks enriched in the dataset). The results of the cPR-ET analysis are presented in Table 4; PDF summary. We found some very basic and very specific functional features related to established photoreceptor function. The basic annotations included “cancer”, “cellular function and maintenance” as well as “tissue morphology”. One could speculate that these relate to the unique shape of the photoreceptor cell, and its unique ability to renew its photoreceptor outer segments. More specific (highly ranked) annotations included “photo transduction cascade”, “visual system development and function” and “neurological disease”. These data-driven results clearly fit with reported specific photoreceptor functionalities from the literature (Diamond, 2017; Musser and Arendt, 2017; Fain and Sampath, 2018).

The choroidal transcriptomics dataset cChor-ET was generated in a similar way to the photoreceptor cPR-ET dataset described above. Obviously, the choroid is not a single tissue, but consists of multiple cell types, including endothelial cells, fibroblast cells, melanocytes, macrophages, and resident lymphocytes. The choroid is unavoidably contaminated with blood cells and proteins. Nevertheless, after curation, we obtained 848 genes with a highly enriched choroidal expression in the cChor-ET dataset (STable 7). Following Ingenuity core analysis, the resulting functional picture of the choroid is, as expected, completely different from that of the photoreceptors (Table 5; PDF summary). We found that two of the top five biological motifs (“inflammatory response” and “inflammatory disease”) and three canonical pathways (“antigen presentation pathway”, “acute phase response signaling” and “complement system”) are all involved with the immune system. This confirms the crucial role of the choroid and blood in external immune surveillance of the eye (Dick, 2017). The second highlight of this analysis was the canonical pathway “atherosclerosis signaling” which again points to an important resemblance between healthy or disease processes going on at the BrM (choroidal-RPE interface) and the vessel walls (see also section 8).

Finally, both the canonical pathways and the highest ranked networks identified in this cChor-ET analysis indicate tissue damage and injury. One possible explanation is that this damage refers to early molecular complement attack already present or setting in, which may be well before any morphological changes or damage may be visible.

820 Alternatively, although we used data from healthy post-mortem eyes, performed the  
821 studies according to MIAME and GTex guidelines, 3' primer design which avoids  
822 potential problems due to 5' directed degradation, as well as very stringent RNA quality  
823 controls, the tissue damage and injury might still be due to post-mortem damage.  
824 Detailed data relating to both cPR-ET and cChor-ET analyses are available on request.

## 5. Drusenomics, part II: Qualitative analysis.

### *5.1. Comparative study design considerations.*

From the previous sections, it has become clear that a systematic investigation into the origin of proteins in drusen is lacking in the literature. Authors suggest a variety of protein sources, frequently on the basis of single observations. Systematic investigation of this phenomenon is hampered by the heterogeneity of source samples, methodology, and analysis. Large scale transcriptomics or proteomics studies frequently end up with a rather abstract annotation analysis, allowing a certain error rate and lack of detail; small scale studies frequently lack sufficient technical, methodological or biological replicates. In a first attempt to investigate the origin of drusen-proteins systematically, we used the presence of functional protein clusters identified in drusen (described in section 2). Subsequently, we investigated whether expression of entities in these clusters also (partly) occurs in the various non-curated expression database sets selected for this study. An overview of this comparison is presented in Table 3. This comparison serves two purposes: Firstly, the presence or absence of clusters in subcellular databases or blood may give a qualitative indication of the origin of (the proteins in) the cluster and secondly, it gives an indication of the completeness, quality, and contamination in each of the databases listed.

We argued above (section 4.2.) in detail that all individual transcriptomic and proteomics database lists used here (and those in the literature) are incomplete and, as a rule, have a degree of RNA/protein/cellular contamination due to original mixed cell sampling. How do we compare incomplete, contaminated datasets? First of all, one should have some knowledge of the study-design and character of the dataset under study, to understand why certain entries do, or do not, appear. The characteristics of the databases used are described in section 4.2 above. As an example, in the study of RPE/Chor-EP expression dataset (Table 3) we systematically identified that a large number of functional cluster queries/entries are indeed present. However, this is most likely due to the fact that the RPE/Chor-EP study contains proteins from photoreceptor, RPE, choroid and blood. Thus, we decided to use this dataset as a positive control (i.e., a dataset where almost all genes relevant to the study are expressed/present). Similarly, we used either the unique sequences from the RPE-ST

dataset, or the consequent absence of an entry in a set of similar dataset listings, as a negative control.

In our qualitative comparison, the incompleteness and potential contaminations of the various non-curated datasets (Table 3) may be largely overcome by considering similar data from different studies at the same time. For example, a specific query may be present in all photoreceptor studies, and, at the same time be absent from all blood proteomics studies.

## *5.2. Where do proteins in drusen come from? A qualitative comparison.*

We will now turn to the interpretation of the highlights of the comparative study results presented in Table 3. In the first column (top to bottom) the functional gene clusters from the molecular networks of drusen (Figure 2a-2d) are presented together with their individual gene content (column 2) and functional annotation (column 3). On the top rows (fourth column onward), subretinal transcriptomics and proteomics as well as blood proteomics data(sets) from the literature are given. For full length names of the abbreviated gene/proteins, see Table 1.

### *5.2.1. Network 1.1: The complement gene cluster.*

The first functional cluster (Table 3; Figure 2a), in our analysis consists of the complement end proteins: C7, C8 isoforms as part of the/and the Membrane Attack (MAC) protein group in general as well as the multifunctional PRELP protein. Mutations in PRELP cause myasthenic syndrome (Engel, 2018). Among other functions, PRELP is involved in regulation of the complement cascade (Engel, 2018). As expected, we observed that the (alternative pathway) complement gene transcripts/proteins are absent from all photoreceptor and/or RPE transcription and proteomics datasets (PROs-EP, PR-ET, RPE-ET, RPE-ST, RPE-IVS). The only possible exception is the presence of these proteins in the RPE/chor-EP dataset (positive control), where they most likely originate from the choroid/blood component of the sample (please note again that the choroid sample is inevitably contaminated with blood). In contrast, in 2 out of 3 blood-plasma datasets (BLP-SP1 and BLPHP) this cluster is present, except for PRELP. The latter entry is apparently uniquely present in the Chor-ET listing (and in the positive control RPE/Chor-EP) and is probably produced in the choroid. Interestingly, this leads us to suggest that the systemic driven complement attack from the blood is locally regulated by PRELP produced by choroidal cells (Happonen et al., 2012).

888

889 *5.2.2. Network 1.2: The collagen cluster.*

890 The second functional cluster is that of the collagens and related molecules (Table 3;  
891 Figure 2a). Here, the picture directly becomes, perhaps understandably, more  
892 complicated. Collagen proteins are likely to be produced (RNA, protein) by the basal  
893 secretion of the RPE and apical secretion of choroidal cells, and become part of the a-  
894 cellular BrM (Booij et al., 2010a) and, at least theoretically, by the apical RPE and by the  
895 PR for the interphotoreceptor matrix (IPM). Indeed, proteomics of apical RPE secretion  
896 *in vitro* (Fort and Lampi, 2011) and functional annotation of the *in vivo* human RPE and  
897 photoreceptor predicted secretomes (based on transcriptomics of the RPE and  
898 photoreceptor cells; Bergen, unpublished), suggest that several specific collagen  
899 proteins may (transiently) be present in the IPM, although their presence was never  
900 detected by immunohistochemistry (yet).

901 During life, there is a constant turnover of ECM's, resulting in a mix of newly synthesized  
902 and (partly) digested collagen fragments shuttling around the subretinal area.

903 Interestingly, the unique RPE-ST database (170 entries) does not contain any collagen  
904 related entries, thereby confirming that, if the RPE produces collagen, none of these  
905 collagens are made exclusively by the RPE (but also by adjacent tissues like the choroid).  
906 Further to this, it is of interest to note that collagen (type 8A1) is produced or present in  
907 the PR-ET, RPE-ET, Chor-ET and the RPE/CHOR-ET datasets, which supports the  
908 hypothesis that the (two collagenous layers of the) BrM, at least in part, are built from  
909 both the RPE and choroid sides side (Booij et al., 2010a). The data in Table 3 further  
910 suggest that the BrM proteins COL1A2, COLA1 and COLA2 are produced or are present  
911 exclusively (or at least mainly) in the Chor/blood, and not in the PR and RPE datasets.  
912 COL6A1 is secreted basally by the RPE *in vitro* (Pao et al., 2018) (Table 3), and is part of  
913 the BrM (Booij et al., 2010a). Consequently, the protein may end up in the drusen  
914 dataset either as a contamination, or as a remnant of the turnover of BrM components.  
915 The proteins THBS4 and TNC occur only in one of the blood proteomics datasets (BL-  
916 SP1). The presence of other entities (RBP3, EFEMP1, PLG, GPNMB, SEMA3B, TBHS4)  
917 from this cluster in multiple PR/RPE and Chor/blood listings suggest that these  
918 genes/proteins can be derived from different sources.

919 *5.2.3. Network 1.3: The crystallin cluster.*

The third cluster of drusen proteins to be discussed are the crystallins (Crabb et al., 2002; Nakata et al., 2005) (Figure 2a), frequently referred to as heat-shock proteins, which act as chaperones to prevent or reduce protein degradation in stressed or aging cells. Although they may have a more structural role, it is possible that the expression of crystallins is increased only in those studies in which cells or tissues have been exposed to a relatively large amount of stress. This would mean that further systematic and methodological analysis of consistent (differences in) expression does not make sense. It is remarkable however, that the CRYBB2 protein is present in the PROS-PT, RPE-IVS, and the RPE/Chor-EP studies and in drusen. Consequently, this protein may originate from the PR outer segments, processed, transported and secreted by the RPE and then accumulates in drusen. To our knowledge, this is the only photoreceptor protein known to possibly make it through phagocytosis and lysosomal processing in the RPE and end up in drusen (Feeney-Burns et al., 1988; Hoppe et al., 2001).

#### *5.2.4. Network 2.4: Genetic and developmental ophthalmic disorders.*

The fourth functional gene cluster (Network 2, Figure 2b) can be considered as a pathobiological cluster of developmental and ocular disease. The comparative analysis (Table 3) shows that ATP5F1B, ACTB and annexin2 (ANXA2), are present in a number of PR/RPE and Chor/blood expression datasets. These entries may thus be expressed in multiple cell types or blood. ANXA2 is included here “within brackets”, since it was initially assigned to drusen using proteomics, but later the same authors stained for ANXA2 in human donor eyes and concluded it was not present in drusen (Crabb et al., 2002; Nakata et al., 2005). The CRYAB, ENO2 and SPTAN1 proteins cannot be clearly assigned, but appear to be of a local cellular origin (PR, RPE, or Chor) and not from the blood. The subcellular/systemic assignment of the FN1 and MYH9 entries are not clear. The BFSBP1 and BFSP2 proteins neither occur in the subretinal datasets, the blood proteomics lists, nor the positive control (RPE/Chor-EP; Table 3). According to the literature, both are structural proteins that specifically form filaments in the cytoskeleton of lens-cells (www.ingenuity.com). We therefore conclude that these are very weakly expressed genes which express proteins that build up slowly and/or with a long half-life. The only other explanation that could be offered is that they are contaminations within the drusen dataset.

#### *5.2.5. Network 3.5: Injury, inflammation and dermatological disease.*



The fifth functional drusen cluster (Network 3; Figure 2c) is related to interacting genes and proteins involved in injury, inflammation and dermatological disease. A substantial number of entries of this group seem to have both a cellular as well as a systemic presence or origin since they are present in at least two database listings from PR/RPE and Chor/blood category. These include ANXA1, ANXA5, CKB, GAPDH, PRDX1 and S100A8.

The SERPINA3 and ALDH1A1 proteins appear only in at least two of the RPE-Chor-EP, Chor-ET, BL-SP1, BL-SP2 and the BL-PHP datasets, but not in the PR/RPE dataset. Thus, both proteins appear to come from the systemic side of drusen. FRZB (SFRP3) ([www.genecard.org](http://www.genecard.org)) is present in 3 PR/RPE listings (Table 3), including the RPE-specific listing (RPE-ST), and in only one choroid-enriched list (Chor-ET). We tentatively assign this drusen protein primarily to the RPE, and as a contamination in the (PR and/or) Chor database listings. S100A7 is only once present in the PROs-EP proteomics dataset. Assignment of S100A9, TYRP1, LAMB2, APOE, and FrzB or LUM to a single source cannot be done on the basis of this comparison.

#### *5.2.6. Network 4.6: Cell to cell signaling; systemic involvement.*

As can be expected from the functional annotation “cell to cell signaling; systemic involvement”, almost all of the entries of this category of drusen proteins, appear in the Chor/blood datasets (Table 3). The exceptions are clusterin (CLU), ANXA6 and HRG. From the literature, we know that CLU is a ubiquitously expressed gene that is expressed in all cell types (Wilson and Zoubeidi, 2017). It is therefore not surprising that it features in both the PR/RPE as well as the Chor/blood listings. The final assignment of ANXA6 and HRG, on the basis of this comparison is not clear. The role of the systemically derived HRG drusen protein is discussed in detail below (section 7). Of particular interest is the expression of CFH, given its central regulatory role in the complement attack on (chemically modified) drusen components. There is compelling evidence in the literature that CFH is present in the blood, the neural retina and that it is also expressed by the RPE (Li et al., 2014; Mullins et al., 2014; Whitmore et al., 2014; Chirco et al., 2016; Chirco and Potempa, 2018; Toomey et al., 2018). The presence of CFH protein in the blood corresponds with the data and proteomics listings of blood in Table 3. What is not entirely clear is why CFH does not pop up in the RPE listings. This can perhaps be explained as follows: The enriched RPE-ET transcriptomics list contains only the highest

10% expressed genes in the RPE. Apparently, CFH is somewhat lower expressed and so does not belong to this group (Warwick et al., 2014). Also, the RPE-ST specific listing only contains 170 entries uniquely expressed by the RPE; whilst CFH is produced in other cells or blood as well. Finally, CFH does not occur in the RPE-IVS basal secretion proteomics listing, which is not entirely unexpected as recent evidence suggests that CFH is secreted apically, not basally by the RPE (Kim et al., 2009; Pao et al., 2018).

#### *5.2.7: Conclusion.*

On the basis of our qualitative comparison, we suggest that a number of (functional clusters of) drusen proteins come from the blood, while others come from a subretinal cellular compartment. These results are in line with the findings in the literature. However, it is not clear yet how many of the drusen proteins come from each particular compartment. The latter may be estimated by a more quantitative analysis, which is the subject of the next section.

## 6. Drusenomics, part III: A quantitative approach

### 6.1. Quantitative analysis and curation of datasets.

In this chapter, we quantitatively compare drusen proteins with transcripts and proteins from adjacent retinal compartments (photoreceptor, RPE, choroid) and blood. As described in section 2 above, the drusen protein list was compiled manually according to the curation strategy presented in Figure 3, scheme A. Similar to the qualitative studies, the quantitative analysis of the origin of drusen proteins is also hampered by two problems: (a) most large scale cellular transcriptomics and proteomics datasets contain some contamination (both RNA and/or protein) from adjacent cells or tissues, and (b) most of the datasets are incomplete due to differences in the study design and methodology used in contributing studies. In other words, we need to use a quantitative comparison strategy that maximizes the signal (number of entries to be compared) and minimizes the noise (number of contaminations in datasets). We overcame the incompleteness of various datasets by pooling the entries from various similar (cell-type specific) studies, to get a more complete numerical picture (Figure 3, scheme 3A). With regard to possible contaminations, we used two types of datasets. The first category includes datasets that, by definition or by previous curation in the literature, contain cell-specific expressed entries only, such as the RPE-ST, RPE-IVS, BL-SP1 and the BL-SP2 datasets (section 4.2 and/or Table 3). The curation of datasets PR-ET and Chor-ET into cPR-ET (STable 6) and cChor-ET (STable 7) was already described above (section 4.2). The other category datasets used (PRos-EP, PR-ET, Chor-ET) were newly curated, as presented in Figure 3 and 4, in such a way that they, after curation, also only contained cell-type specific entries

The PRos-EP dataset was curated according to the curation strategy presented in Figure 3, scheme 3C: We removed from the PRos-EP dataset (in principle containing photoreceptor outer segment expressed genes only) all choroidal highly expressed genes (from Chor-ET) as well as potentially present uniquely RPE expressed entries (from RPE-ST) resulting in the curated cPRos-EP dataset (STable 6). The removed choroidal and RPE entries were (potentially) present in the PRos-EP dataset due to truly overlapping gene expression between these different cell types and/or due to contaminations in the original cell sample. Of note, cPRos-EP does still contain entries from both photoreceptor and RPE since contamination between these two is inevitable.

Together, the database listings cPROs-EP, cPR-ET, RPE-ST and RPE-IVS form the neural side of drusen database listings (Figure 4). Similarly, the cChor-ET, the BL-SP1 and the BL-SP2 constitute the systemic side of proteins found in the drusen dataset. In summary, we ended up with three large datasets suitable for further robust analysis: The drusen protein dataset, the “neural source of drusen” database, and the ‘systemic source’ of drusen dataset (Figure 4).

Next, we compared the entries present in the “neural source listing” and in “the systemic source listing” with the proteins present in drusen. The result of this analysis is summarized in the Venn-diagram in Figure 5. The comparison revealed that 10 proteins appeared to be uniquely derived from the neural side (Table 6) and 37 proteins are derived from the systemic drusen side (STable 8). In addition, there were 23 proteins that come (potentially) from both the neural and systemic side (STable 9). For 19 drusen proteins (out of the 89), the origin remained unclear as they were neither present in the “neural source” nor in the “systemic source” expression datasets (STable 10).

#### *6.1.1. Ten out of 89 drusen proteins originate uniquely from the PR/RPE.*

Our analysis yielded 10 drusen proteins that originate from the PR or RPE (Figure 5; Table 6). They are both uniquely present in the drusen proteomics dataset and the neural source of drusen database listing. We traced these proteins back to their original source(s), and we observed that three of them (FRZB, RDH5 and RGR) originally came from the unique entries in the RPE-ST dataset, five came from the RPE-IVS dataset (CRYBA1, CRYBA4, CRYBB2, ENO2 and TUBB3), and the remainder from the cPROs; cPR-ET datasets. Taken together, 8 out of the 89 drusen proteins originated uniquely from the RPE, while 2 came from the curated PR/RPE database listings (cPROs; CPR-ET) (Table 3). Finally, we also reviewed the psychochemical properties and molecular weight (Mw) of these 10 proteins (Table 6). We do not know the HAP binding properties of these proteins, but they do not occur in the BH-PLP HAP-binders’ dataset (STable 5). In conclusion,, we did not observe any common signatures of these proteins that would explain why they in particular are trapped in the sub-RPE-BL space (whilst other proteins are not).

#### *6.1.2. Twenty-three of 89 drusen proteins originate from both neural and systemic sources.*

From our analysis, 23 drusen proteins were present in both the “neural source” as the “systemic source” datasets (Figure 5; STable 9). From these, only 1 protein (S100A9) falls in the curated PR/RPE category (Figure 4). Additional groups of two and twenty proteins come from the unique RPE RPE-ST and the RPE-IVS datasets, respectively. At the same time, all 23 of these proteins are also present in the blood. Remarkably, in this shared category the majority of proteins are either secreted basally by the RPE or present in a soluble form in the blood plasma. We hypothesize that the proteins in this category enter the sub-RPE-BL from both sides, where they “meet, greet and stick”, i.e. form aggregates that cannot be cleared and therefore contribute to drusenogenesis. Functional and pathobiological annotation of (combinations of) these proteins can be found in STable 9a.

### *6.1.3. Thirty-seven out of 89 drusen proteins originate from the choroid/blood.*

We found that 37 out of 89 drusen proteins uniquely originate from choroid or blood datasets (STable 8). From these, 31 proteins came from the plasma-proteomics datasets (BL1-SP1 and BL-SP2). The remaining six entries (ANXA6, FLBN5, HLA-DRA, MFAP4, PRELP, SEMA3B) are present in cChor-ET database listing and thus originate from either the choroid or blood. Functional and pathobiological annotation of (combinations of) these proteins can be found in STable 8a.

In summary, we again observed a large proportion of drusen proteins are most likely originating from the blood. If we take this unique category (31 proteins from plasma) and the shared contribution of plasma (23 proteins) from the previous paragraph into account, we can conclude that as many as 54 out of 89 drusen proteins (>60 %) are (co-) derived from blood plasma.

### *6.2. Nineteen drusen proteins out of 89 were not assigned.*

We can, in the end, still not determine the possible origin of 19 out of 89 drusen proteins (STable 10) Why is this not possible? Do these proteins have a number of characteristics in common that prevents us to determine their origin? To attempt to answer these questions we need to take a closer look at these remaining drusen proteins. The functional annotation of these proteins is presented in STable 10a and they can be divided in five groups: (1) a gamma-crystallin group; (2) a histone cluster group; (3) (remnants from) BrM turnover group (4) a beaded filament group; (5) a rest group containing a variety of proteins that do not belong to a specific functional group.

1094 In group one, we observed several gamma-crystallin-isoforms in drusen, which have not  
1095 been assigned to a specific source (as yet). Crystallins are commonly found in the lens  
1096 but are also present in soluble form in the retina (Jones et al., 1999) and probably act as  
1097 chaperone proteins after (oxidative) stress. Indeed, in the mouse retina, crystallin  
1098 expression has a binary nature in which either they are highly upregulated, or their  
1099 expression is extremely low (Templeton et al., 2013). Gamma-crystallins may have a  
1100 neuroprotective role (Thanos et al., 2014). At least one specific type of crystalline  
1101 (alphaB type) is known to be secreted by the RPE through micro-vesicle release (Kannan  
1102 et al., 2016). In conclusion, the source assignment of gamma-crystallin isoforms in  
1103 drusen, in our comparison, may be hampered by this binary expression. More  
1104 specifically, it will simply be absent from a number of subretinal expression datasets  
1105 and, as such, too little evidence exists to make a definite assignment.

1106 Next, we found a group consisting of HIST1H1E, HIST1H2BJ, HIST1H2BL and  
1107 HIST2H2BE. Histones are highly basic proteins that have an essential role in the  
1108 maintenance of nuclear DNA structure and gene transcription. HIST1H1E is a 219-amino  
1109 acid protein that binds to the linker DNA stretch between nucleosomes, while HIST2,  
1110 together with HIST3 and HIST 4, are part of the nucleosome core (Tessarz and  
1111 Kouzarides, 2014). Damaged or dying cells (potentially RPE or endothelial cells of the  
1112 choroid) can release cellular as well as nuclear fragments that may contain histones.  
1113 Alternatively, high concentrations of serum histones have been detected in several  
1114 human diseases (Yang et al., 2015). These extracellular histones may get trapped in BrM  
1115 and drusen. Interestingly, extracellular histones trigger activation of multiple signaling  
1116 pathways related to cell death, growth and inflammation and may play a role in auto-  
1117 immunity, aging and disease (Allam et al., 2014; Kalbitz et al., 2015; Zhang et al., 2015b).  
1118 Why these specific histone proteins (and not others) are trapped in drusen and cannot  
1119 be assigned to a source remains to be elucidated.

1120 The third drusen protein group with an as yet unassigned source contains elastin (ELN),  
1121 collagen 8A1 (COL8A1), biglycan (BGN) and tissue inhibitor of metalloproteinase 3  
1122 (TIMP-3) proteins. These proteins may come from an as yet little considered drusen  
1123 protein source: the BrM and its (turnover) components (Booij et al., 2010a; Curcio and  
1124 Johnson, 2012). TIMP-3 is expressed in the RPE (Ruiz et al., 1996) and is crucial for the  
1125 maintenance of BrM. Mutations in TIMPO-3 caused Sorsby Fundus dystrophy, a

1126 monogenic disease that resembles the phenotype of AMD (Weber et al., 1994). Indeed,  
1127 as described previously, BrM is dynamic in nature, not only in a physiological sense, but  
1128 its composition and properties vary with age. Proteins involved in BrM and its turnover  
1129 may be absent from (some of) our subretinal transcriptomics and proteomics datasets, if  
1130 the relative expression levels of such entries are low. The middle layer of the BrM  
1131 consists of elastin so it is conceivable that the RPE and/or choroidal cells make this  
1132 protein. Within the BrM, elastin turnover might be relatively low, thus little “new”  
1133 elastin is needed. While elastin protein fragments (tropo-elastin) might be present in  
1134 some drusen as a remnant from BrM-turnover, there is little evidence in the literature  
1135 that they accumulate in drusen.

1136 Fourth, two members of the beaded filament structural protein family, BFSP1 and  
1137 BFSP2, remain unassigned. Similar to crystallins, these proteins were initially  
1138 discovered as lens fiber proteins. To our knowledge, it is not clear whether they also  
1139 play a role in retina/RPE or maybe even the BrM. How these proteins end up in drusen  
1140 and their origin remains unclear.

1141 The fifth, yet unassigned group contains a number of, apparently, unrelated proteins,  
1142 including retinol binding protein 3 (RBP3), tyrosinase protein-like 1 (TYRP1), spectrin  
1143 alpha, non-erythrocytic 1 (SPTAN1), disco interacting protein homologue (DIP2C),  
1144 forkhead-associated phosphor peptide (FHAD1), and scavenger receptor class B  
1145 member 2 (SCARB2).

1146 The RBP3 gene is transcribed in the PR and its protein is located in the  
1147 interphotoreceptor matrix (IPM). It binds to retinoids which are shuttled from the PR to  
1148 the RPE, and *vice versa* (Gonzalez-Fernandez et al., 1993). The TYRP1 gene belongs to  
1149 the tyrosinase family transcribed in the RPE and encodes an enzyme in the melanin  
1150 biosynthetic pathway (Lai et al., 2018). Mutations in this gene are one of the causes of  
1151 albinism (Kamaraj and Purohit, 2014; Kruijt et al., 2018). Both RBP3 and TYRP1 genes  
1152 may be absent from our datasets given their relatively low, transient or binary  
1153 expression in the relevant tissues.

1154 Finally, FHAD1 is a small protein that recognizes phosphorylated epitopes on a wide  
1155 range of proteins as part of an evolutionarily ancient mechanism enabling assembly of  
1156 protein complexes (Durocher and Jackson, 2002). The expression of FHAD1 is very low  
1157 in many tissues including the retina but is high in the testis and lungs. Since the

expression is very low, the transcript and protein production or presence may go undetected in the subretinal and blood transcriptomics and proteomics studies we used in this study. However, once the FHAD1 protein has accumulated, as apparently in drusen, it may be (more) detectable there. DIPC2 is a ubiquitously expressed protein that shares homology with a *Drosophila* protein that interacts with the transcription factor disco ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)). It is possible that the expression of this type of protein is transient or binary; and it may go undetected in our retinal compartment and blood transcriptomics and proteomics studies for that reason.

Finally, the last two proteins, SPTAN1 and SCARB2 may have related functionalities. The SPTAN1 protein is a part of the cytoskeletal spectrin protein family that is involved in stabilizing membranes of both cell and organelles (Tohyama et al., 2015). It is highly expressed in the brain, and still expressed to a significant level in multiple other tissues. *SCARB2* is a ubiquitously expressed gene that encodes a lysosomal type III plasma membrane glycoprotein (Gonzalez et al., 2014). Given the involvement of this type of proteins in the lysosomal digestion of cellular material, it is tempting to speculate that these proteins come from (transiently present in high numbers) lysosomal membrane fragments basally secreted by the RPE.

### *6.3. Blood proteins are an important source of drusen proteins.*

If we summarize the combined data from our literature search and our qualitative and quantitative analyses, we conclude that blood proteins are an important protein source for drusen development. Further studies are needed to confirm and enhance our data, especially on the single-protein level. Given the apparent contribution of blood to the formation of drusen, the next chapters will discuss the role of hydroxyapatite as a retainer of blood proteins during drusen formation, and the similarities that exist between drusen and atherosclerotic plaques, which occur exclusively in the vasculature.



## 7. Drusen and hydroxyapatite

Our analyses provide strong evidence that proteins in drusen come from multiple sources. The next logical step was to consider how proteins arrive and how they are retained in the sub-RPE-BL space. One possibility is that proteins may bind to constituents of the BrM (Tabas et al., 2007). Another is the formation of large oligomers in the sub-RPE-BL space in the presence of the high concentration of trace metals (Lengyel et al., 2007; Nan et al., 2013; Flinn et al., 2014). In addition, it was recently hypothesized that proteins might be retained in the sub-RPE-BL space due to their binding to hydroxyapatite spherules recently identified in human drusen (Thompson et al., 2015) (Figure 6). Since this hypothesis is relatively new, it is described in more detail below.

Using confocal microscopy and hydroxyapatite (HAP)-specific fluorescent dyes, small hollow spherical structures ranging from 0.5  $\mu\text{m}$  to 20  $\mu\text{m}$  in diameter were identified within sub-RPE-BL deposits in retinal tissue sections of human cadaveric eyes (Thompson et al., 2015). The HAP spherules were present in all deposits examined (Thompson et al., 2015). Protein constituents of drusen, such as amyloid-beta, vitronectin and complement factor H, were localized to the surface of the HAP spherules, either individually or in combination (Thompson et al., 2015). Although not all investigated drusen proteins appeared to bind to the surface of HAP (Thompson et al., 2015), this finding proved that the retention of proteins can, at least partly, occur through this protein-HAP interaction. These results also suggested that the binding of proteins to HAP spherules is a wide ranging, though selective, process and thus understanding which proteins can bind to HAP might be important. The plasma protein-binding capacity and selectivity of HAP was recently examined using a quantitative proteomic approach called Sequential Window Acquisition of all theoretical fragmentation spectra-Mass Spectrometry (SWATH-MS) (Arya et al., 2018). Using this approach, 242 proteins with the propensity to binding HAP were identified and quantified (Table 3; STable 5) (Arya et al., 2018). Taking advantage of the quantitative nature of the analysis the binding of samples from participants with wild type and the AMD associated high risk CFH variant, T1277C were compared. Quantitative differences in the abundance of at least 34 proteins were identified, suggesting that the genetic background is likely to affect the protein composition of drusen “simply” due to the

availability of proteins in the blood. This approach also highlighted that there are proteins, whose presence and potential role in sub-RPE deposit formation and in AMD had not previously been explored. One such example is the pregnancy zone protein (Arya et al., 2018), a plasma protein whose levels are known to increase in pregnancy and some disease states such as AD (Nijholt et al., 2015).

It appears therefore that while drusen deposition is a hallmark of AMD, HAP deposition is a hallmark of drusen formation. The study by Thompson and coworkers was not the first to identify calcified components of drusen (Thompson et al., 2015). Spherical particles of similar size were previously identified within drusen and BLinD (Green and Key, 1977), and electron microscopy (Ulshafer et al., 1987; van der Schaft et al., 1992; van der Schaft et al., 1993; Thompson et al., 2015). Particles size observed in these studies ranged from 0.5  $\mu\text{m}$  to 10  $\mu\text{m}$  in diameter and contained calcium and phosphate as determined by elemental analysis (Ulshafer et al., 1987). More recent studies using von Kossa staining, a silver enhancement technique that identifies phosphates salts also indicated that calcium phosphates were present within deposits in the sub-RPE-BL space (Suzuki et al., 2015).

The precipitation of calcium phosphate from an aqueous solution is a complex process (Kani et al., 1983; Tas, 2000; Jang et al., 2014). At neutral pH, HAP is considered the most thermodynamically stable form of calcium phosphate. In fact, it is possible that HAP is stable enough that once the lipid or protein components of the drusen regress (Sallo et al., 2009; Toy et al., 2013; Novais et al., 2015), HAP still remains and continues to interact with its environment. This may suggest that HAP interactions, not only with the BrM and the RPE but also with the remanence of photoreceptor cells or other parts of the neurosensory retina (Bird et al., 2014) may require further investigation.

Figure 7 summarizes the model of HAP associated deposit initiation. Under normal circumstances, there is a physiological exchange of material between the RPE and the choroidal circulation (Fig.7A and A'), and this includes the exchange of lipid particles (Curcio et al., 2011). With age and disease lipid particles start accumulating in the sub-RPE space including the BrM (Fig.7B and B') (Curcio et al., 2011). In the presence of lipid droplets and homeostatic changes in calcium and phosphate availability in the sub-RPE-BL space, HAP can precipitate on the surface of the lipid droplets (Fig.7C and C'). Then, on the surface of the HAP spherules drusen proteins can accumulate (Fig.7D and D') via

1248 directly interacting with HAP (Arya et al., 2018). Based on fluorescence labeling of HAP  
1249 in human eyes, it is appeared that HAP spherules can exist without drusen (Fig.7C'), but  
1250 drusen have not been seen without HAP spherules (Fig.7D and D') (when specifically  
1251 looked for) thus far (Thompson et al., 2015). Based on these observations it was  
1252 proposed that HAP deposition is a seeding point for drusen formation (Thompson et al.,  
1253 2015).

1254 The next obvious question to ask is where the HAP spherules are originating from?  
1255 Could they be blood or RPE derived? Do they exist as spherules only in the sub-RPE-BL  
1256 space or is the material present in the surrounding tissues? Spherules have not been  
1257 detected in any of the cellular or intercellular spaces although the calcium phosphate  
1258 crystals had been showed in mitochondria (Carafoli, 2010). Therefore, it appears that  
1259 HAP spherules are deposited in the retina exclusively in the sub-RPE-BL space. In fact, it  
1260 had been shown that HAP deposition can occur in primary RPE cell models which  
1261 showed that HAP deposition can be initiated by the RPE alone, although contribution of  
1262 the culture medium cannot be ruled out (Pilgrim et al., 2017). Whether spherical  
1263 structures can develop in a cell culture system that are co-cultured with endothelial cells  
1264 and/or fed with photoreceptor outer segments will need to be investigated.

1265 HAP mineralization in the retina clearly differs from classical mineralization in bone, but  
1266 it may, or may not, share some key features with general soft tissue/elastin calcification  
1267 (Figure 8). Obviously, the retina lacks extracellular matrix forming osteoblasts. Also, no  
1268 relationship has been found between spherule mineralization and general HAP  
1269 deposition on elastin and/or collagen. However, systemic driven HAP deposition can  
1270 take place in the BrM, as reported before (Gorgels et al., 2012). Indeed, a systemic lack of  
1271 inorganic PPI in the blood (Jansen et al., 2013) may be involved in local HAP deposition  
1272 in BrM, facilitated by local conditions, such as oxidative stress (Mungrue et al., 2011).  
1273 Interestingly, investigation of the ultrastructure and composition of vascular micro-  
1274 calcifications associated with uremia showed the presence of spherical particles in the  
1275 media of the kidney, with internal structures comparable to those observed in the  
1276 human eye (Schlieper et al., 2010). Similarly, the loose stroma of the choroid plexus of  
1277 the aging or Alzheimer's disease brain contain psammoma bodies, which are entities  
1278 with distinct HAP cores and multiple concentric rings or swirls of collagen wrapped  
1279 around it (Alcolado et al., 1986). More recently, similarly structured spherules were also

1280 identified within patients with osteoporosis and in cardiovascular disease (Bertazzo et  
1281 al., 2013; Shah et al., 2017). Thus, comparable mineralization mechanisms in a variety of  
1282 non-osseous tissues appear to be associated with a number of different disease  
1283 conditions.

1284 Alternatively, transcriptomic data suggests that part of the elements of the physiological  
1285 mineralization process are (also) present in the RPE cells (Booij et al., 2009), or at the  
1286 RPE/choroid interface (Whitmore et al., 2014). This evidence suggests that the  
1287 molecular machinery required for general physiological mineralization (depicted in  
1288 Figure 8) could (also in part) be assembled in the outer retina. Given that the bulk of the  
1289 calcium is extracellular, while phosphate is mainly localized intracellularly, the  
1290 conditions that allow mineralization to happen could be present locally, in the sub-RPE-  
1291 BL space. This concept is novel and has not been investigated previously but may lead to  
1292 HAP-based treatment strategies and/or new early detection mechanisms.

## **8. Drusen and plaques: age-related macular degeneration and atherosclerosis**

The finding that a substantial number of drusen proteins are blood-borne prompted us to re-summarize a possible relationship between initiation and propagation of drusen and atherosclerotic plaques. A possible link between these two diseases was previously suggested based on (controversial) epidemiological evidence, the involvement of similar lipoproteins in the formation of extracellular deposits in AMD and atherosclerosis and structural commonalities between the vessel wall and Bruch's membrane (Curcio et al., 2001; Sivaprasad et al., 2005).

AMD is a disease starting with (multiple macular) drusen formation. Drusen consist of (oxidatively-modified) lipids and proteins as well as minerals (Sarks et al., 1988; Green and Enger, 1993; Curcio and Millican, 1999; Crabb, 2014; Flinn et al., 2014; Handa et al., 2017; Pilgrim et al., 2017; Spaide et al., 2018). Drusen constituents most likely invoke a complement attack and sustain a continuous low-grade inflammation, which leads to serious events such as RPE cell loss, neovascularization and ultimately, central vision loss (Bird et al., 1995; de Jong, 2006).

Atherosclerosis is a disease associated with the build-up of plaques also composed of (oxidatively-modified) lipids, proteins as well as minerals in the vessel wall of arteries that, via complement attack and low-grade inflammation, can lead to serious events including heart attack, stroke or aneurysm (Simmons et al., 2016).

There are a number of clear differences between AMD and atherosclerosis, such as location of the deposition, the local metabolic physiology (Stefansson et al., 2011), involvement of other (different) genes or molecules and obviously, aspects of the pathological consequences of deposition build up (Hageman et al., 2001; Hopkins, 2013). For example, other than in plaques in atherosclerosis, deposit (drusen) formation in AMD most likely blocks the exchange of biomolecules between the retina and the choroid. It is thought that this interferes with the "nourishment" of the sensory cells in the retina causing them to die. Over time the cells cannot be replaced leading to a loss of vision, typically within the macula, which progressively deteriorates over time contributing to the AMD pathology (Bhutto and Luty, 2012).

Nonetheless, a relatively large number of commonalities have been found between both drusen and atherosclerotic plaque formation and their associated diseases. Available

evidence comes from clinical, epidemiological, genetic, histological and pathobiological investigations (see below).

### *8.1. Clinical and epidemiological studies.*

Verhoeff and Grossmann were the first to suggest a relationship between vascular disease and AMD (Verhoeff and Grossman, 1937). Except for a few reports (Gass, 1967; Kornzweig, 1977), this observation was largely ignored for over forty years when Maltzman and Hyman (Maltzman et al., 1979; Hyman et al., 1983) pioneered a plethora of subsequent epidemiological studies on the subject (Vidaurre et al., 1984; Vingerling et al., 1995; Snow and Seddon, 1999). Some studies between atherosclerosis (and similar diseases) and AMD showed positive associations (The Eye Disease Case-Control Study, 1992; Klein et al., 1993), while others did not (Hyman et al., 1983). These controversial results, especially in the early investigations, were partly due to differences in description of the clinical phenotype, use of different end phenotypes, study design, population size, lack of suitable replication populations, and insufficient knowledge of possible confounders. Nonetheless, this issue has not been resolved up until today. A wide range of epidemiological studies have also suggested that there are certain risk factors which are common to both AMD and atherosclerosis (-associated cardiovascular disease). These most consistently include environmental factors, such as age and tobacco smoking (Woodell and Rohrer, 2014). These studies indicate that, mechanistically, oxidative stress and potentially lipid metabolism may play an important role in both disorders (Serban and Dragan, 2014; Gehlbach et al., 2016; George et al., 2018; van Leeuwen et al., 2018; Wilson et al., 2018).

### *8.2. Histological and pathobiological similarities.*

Histological and pathobiological similarities between drusen and atherosclerotic plaques and their associated diseases include similarities of lipid and mineral content and structural similarities between the BrM and the vascular wall, endothelial cell dysfunction, and proteoglycan turnover. Curcio and coworkers proposed, for the first time, a relationship between drusen and atherosclerotic plaques since both contain similar neutral lipids and both accumulate cholesterol esters (Curcio et al., 2001). This finding was confirmed by others (Chung et al., 2005; Wang et al., 2010). These and subsequent studies made clear that diseases related to this type of accumulations may be mediated by genetic variation, oxidative stress and inflammation. The accumulation

of lipids in drusen and atherosclerosis has recently been reviewed elsewhere in detail (Pikuleva and Curcio, 2014; van Leeuwen et al., 2018; Xu et al., 2018).

Sivaprasad and coworkers observed that the BrM and the vascular intima share a number of common structural modalities, and age-related changes (Sivaprasad et al., 2005). Indeed, similar to the vessel wall, and given the presence of local fenestrated choroidal capillaries, BrM acts a collagen and elastin rich physical barrier for the blood. Both the BrM and vascular intima thicken through accumulation of extracellular lipids and other debris and become less flexible with age (Chung et al., 2005; Curcio and Johnson, 2012).

Another important feature of the ECM of both the vessel wall and BrM are the presence and turnover of a variety of proteoglycans. In BrM, the ratio between several proteoglycan types, most notably heparan sulfate and chondroitin sulfate, changes dramatically during aging and the development of AMD (Barzegar-befroei et al., 2012). In atherosclerosis and AMD, (oxidatively) modified proteoglycans may bind and retain specific apolipoproteins from the circulation in, respectively the artery wall (Williams and Tabas, 1995; Tabas et al., 2007) and the BrM (Curcio et al., 2009; Al Gwairi et al., 2016) BrM. Indeed, proteoglycans may play an, as so far underestimated, role in regulating the complement response and the development of both AMD and atherosclerosis pathology (Tate et al., 1993; Toomey et al., 2018). Happonen and coworkers (2012) recently showed that small proteoglycans, such as PRELP, are regulators of the complement cascade (Happonen et al., 2012). Please note that choroidal cells produce PRELP (as suggested in the current study) and that this protein apparently accumulates in drusen. There are a few reports which have established the different patterns of distribution of large (Clark et al., 2011) and small proteoglycans (Keenan et al., 2012); the latter including biglycan, decorin, fibromodulin, lumican, mimecan, opticin, and prolargin in post-mortem eye or vascular tissue.

Both atherosclerosis and AMD patients may suffer from endothelial cell dysfunction. Accumulating evidence suggests that endothelial cell dysfunction may be the initiating step in atherosclerosis (Miteva et al., 2018). In their AMD studies, Schaumberg and coworkers provided epidemiological evidence that at least one marker for endothelial dysfunction and inflammation, sICAM-1 is linked to drusen formation and neovascularization (Schaumberg et al., 2007). Interestingly, higher levels of circulating endothelial cells (CECs), a biomarker for a diversity of systemic complications, including

vascular disorders, were found in AMD patients compared to controls (Machalinska et al., 2011).

While these studies focused on common risk factors and parallel development of drusen and plaques, the possibility that atherosclerosis plays a direct role in the development of AMD cannot be ruled out. Using FA, a slow filling of the choroidal capillaries over time has been observed in AMD patients (Pauleikhoff et al., 1990). This may be due to (a combination of) thickening of the BrM, a declining function of the RPE or by decreased atherosclerosis-driven perfusion of these capillaries. Reduced capillary blood flow could directly enhance the initiation of drusen or development of AMD.

As with drusen, deposition of calcified mineral, that includes hydroxyapatite (Lee et al., 2012) is associated with the formation of atherosclerotic plaques (Doherty et al., 2003). Such mineral is readily quantifiable using radiography and even serves as a marker for atherosclerosis. It has been reported that the presence of mineral in cardiovascular soft tissue can be used to predict mortality (Okuno et al., 2007; Kestenbaum et al., 2009), and morbidity of cardiovascular disease in various forms (Arad et al., 2000; Keelan et al., 2001). The specific molecular mechanisms underlying mineral formation in such tissues remains to be fully elucidated. However, both AMD and atherosclerosis are associated with low grade inflammation in the respective affected tissues (Hansson et al., 2006; Kauppinen et al., 2016), and it has been proposed that soft tissue mineralization may be best conceptualized as a convergence of bone biology with inflammatory pathobiology (Doherty et al., 2003).

### *8.3. Genetics and molecular biology.*

Early candidate gene association studies found an association between genetic variation in APOE in both AMD (Klaver et al., 1998; Toops et al., 2016) and atherosclerosis (Zhang et al., 2018), thereby implicating lipid metabolism and transport in both disorders.

Genetic variations in apolipoproteins and complement factors showed strong associations with AMD and CVD conditions. For example, polymorphisms in the CFH and a number of other complement factor genes confer at-risk genotypes for AMD (Klein et al., 2005), whilst similar associations between complement C5 and the complement receptor 1 genes confer an increased risk of atherosclerosis (Hoke et al., 2012; de Vries et al., 2017). Of note, although the same genes may be frequently associated with both (or other) diseases, different alleles are frequently implicated in the associations found



between these disorders. A well-known example is the APOE4 allele, that increases the risk of Alzheimer's disease, and perhaps atherosclerosis (Mahley, 2016), but is protective in age-related macular degeneration (Klaver et al., 1998). Indeed, these observations were confirmed and extended by large GWAS studies that implicated regulation of lipid metabolism, extracellular matrix remodeling and the immune system low-grade inflammation in both AMD and atherosclerosis (Fritsche et al., 2016; Schunkert et al., 2018). A recent study by the International AMD consortium explored the overlap between 34 AMD-associated loci with other complex diseases (Grassmann et al., 2017). Surprisingly, the authors found that an increased risk of AMD correlates with a *reduced* risk for cardiovascular disease.

A key similarity between atherosclerotic plaque and drusen formation are the molecular components involved. Both types of deposit have a significant lipid component (including cholesterol and neutral fats) and mineral content, as described above. It has also been reported that drusen contains a number of proteins that are also common to atherosclerotic deposits (Mullins et al., 2000; Klein et al., 2005; Booi et al., 2010a). To gain information as to the degree of this overlap in proteins contributing to these pathologies we compared a dataset of 3196 proteins known to be present in atherosclerotic plaques from Bleijerveld and coworkers (Table 3) with our drusen data set, as shown in Figure 9a (Bleijerveld et al., 2013). The resultant Venn-diagram revealed that out of the 89 drusen-associated proteins, 64 of these (72%) were also present in atherosclerotic plaques. Indeed, 50 out of 60 drusen proteins derived from blood are also present in atherosclerotic plaques (Figure 9b). Details of proteins found to be common to both plaques and drusen can be found in STable 11 and STable 11a.

Closer inspection of proteins common to both atherosclerotic plaques and drusen as defined in this manuscript revealed a number of functional classes of protein in this group including apolipoproteins (APOA1, A2 and E), complement factors (C7, C8A, C8B, C8G and complement factor H), as well as lipid- and  $\text{Ca}^{2+}$ -binding annexins (annexins-1, 2, 5 and 6). Obviously, our analysis may not be fully comprehensive, since it is limited to the entries which are present in both database listings. Another limitation is that similar proteins still may originate from different sources. For example, the previously suggested presence of APOB as principal protein of LDL in both sub-RPE-BL deposits and cardiovascular plaques (Curcio et al., 2001) is missing from the current overlap,

1454 since detailed investigation of the (presence and origin) of this lipoprotein (Li et al.,  
1455 2005a) suggested that APOB isolated from BrM thickenings is (also) present in a  
1456 distinct, non-LDL lipid profile. Consequently, it was suggested that APOB in BrM  
1457 thickenings is made locally, while APOB in plaques is probably from systemic origin.  
1458 Cytoskeletal proteins (actinin  $\alpha$ 1, tubulin  $\alpha$ 1c and tubulin  $\beta$ 3) as well as extracellular  
1459 matrix proteins such as collagens (type 1  $\alpha$ 2, type 6  $\alpha$ 1, type 6  $\alpha$ 2 and type 8  $\alpha$ 1),  
1460 tenascin C, microfibril-associated protein 4 and vimentin were found to be present in  
1461 both BlamD deposits and atherosclerotic plaques (Fernandez-Godino et al., 2016;  
1462 Pelisek et al., 2016). Analysis of proteins common to both plaques and drusen in  
1463 biological processes revealed significant contribution of this group of proteins to other  
1464 diseases and processes including various cancers, development of the vasculature, cell  
1465 movement and AD (tauopathy and amyloidosis; see STable 11a). The involvement of  
1466 these proteins in AD is particularly interesting as it is another disorder of which  
1467 extracellular deposits are a feature (Figure 9c). Furthermore, drusen reside on the  
1468 interface between the neural and cardiovascular system, so it may share properties of  
1469 both types of atherosclerosis and Alzheimer's plaques (Booij et al., 2010a).

## 9. Future directions and conclusions.

Our review of the literature and the qualitative and quantitative meta-analysis of retinal and blood transcriptomic and proteomic data all point in the same direction: proteins in drusen originate from multiple sources. Based on the data we have available, the largest number of protein contribution from a single source appears to be the blood. The second-most prominent source of number of specific proteins in drusen is from the RPE, while the contribution from the choroid and the photoreceptors appears to be relatively modest. However, the varying number of proteins cannot be directly translated to concentration. There is the possibility that a relatively small number of proteins contribute the bulk of proteins in drusen.

How proteins get recruited to and retained in the sub-RPE-BL space is still not fully understood. *In vivo* and *in vitro* BrM conductance studies suggest that human proteins of average size, such as proteins of 53 kDa (source: NCBI) , can readily diffuse through healthy BrM, while macromolecular migration through BrM is slower and/or limited (Curcio and Johnson, 2012). Moore and Clover found that proteins of 200 kDa could readily cross young BrM (Moore and Clover, 2001). More recent work suggested that the transport exclusion size limit in healthy young BrM can be as high as 180-500 kDa, well over the size of macro molecules like HDL (Hussain et al., 2010; Cankova et al., 2011). In our current study, we found that 9 out of 10 drusen proteins that are uniquely derived from the RPE had a Mw of less than 50 kDa (Table 6). Moreover, we took a random sample of 30 proteins from the RPE-IVS basal secretion dataset (Table 3), containing proteins which are likely to encounter BrM *in vivo*, and determined their average Mw: 95 kDa). After taking three extremely large proteins out (APOB, AHNAK, and C4B; proteins that we did not identify in drusen in this study) that average dropped to 60 kDa (data not shown). Six of these 30 proteins are present in drusen (ALB, ANXA1, ANXA2, APOA4, APOE, ATP5F1B) and have a MW <66.5 kDa. Although the overall transport capability BrM decreases substantially in the AMD-affected and aging retina (Hussain et al., 2010; Cankova et al., 2011; Curcio and Johnson, 2012; Lee et al., 2015), older BrM was found to be still permeable to proteins in excess of 100 kDa (Moore and Clover, 2001). Taken together, entrapment of proteins in the sub-RPE-BL space is unlikely to be due to size if single molecules. They might become entrapped by forming aggregates that are no longer capable of leaving through BrM, as was suggested for CFH (Nan et al.,

2008; Nan et al., 2011; Nan et al., 2013). Therefore, drusen proteins, especially the ones that come from multiple sources, “meet, greet and stick” to form sub-RPE-BL space deposits.

There are several ways proteins can interact in BrM to form larger aggregates: they can interact among themselves, with other lipids, proteins and/or mineral deposits, or stick to the ECM of BrM itself. These interactions may be enhanced by chemical modification, (Blaum et al., 2010) including oxidative damage and glycosylation of lipids, proteins and carbohydrates (Crabb et al., 2002; Hollyfield et al., 2010) and they may be further facilitated by the structure and dynamic nature of BrM (Booij et al., 2010a). Over time, several changes in BrM occur, that may hinder protein clearance from the sub-RPE-BL space. Remodeling of BrM ECM takes place, including proteoglycan changes and turnover, elastin changes and eventually mineralization takes place. BrM becomes laden with lipids to form a hydrophobic barrier (“lipid wall”) and accumulates other debris (Curcio and Johnson, 2012). Consequently, the role of the structure and function of BrM and the chemical state of the sub-RPE-BL space may be even more important in sub-RPE-BL space deposit formation than its exact protein composition.

An important source of entrapment of proteins in BrM may be the formation of HAP surfaces in the sub-RPE-BL space (Thompson et al., 2015). In our current study, at least 30% of the 89 drusen proteins can bind to HAP. This percentage increases towards at least 50% if only the blood borne proteins are counted (data not shown). Thus, HAP readily binds a substantial number, but not all drusen proteins (Arya et al., 2018).

The finding that blood proteins are seemingly the most important contributors to drusen formation provides a new target to prevent the initiation and propagation of sub-RPE-BL space deposits. Reducing the concentration of blood proteins that interact with HAP may lead to a reduction of the source of drusen components and ultimately postpone, or potentially even stop, the progression to AMD.

Finally, it is also important to mention that the non-specific interaction of proteins with HAP will also affect their ability to carry out their physiological function. For example, once CFH binds to the HAP surface it may not be able to regulate the alternative complement pathway. Therefore, this interaction with HAP could be a double whammy: it increases the bulk of sub-RPE-BL space deposits and stops the local protein function. It will be important to understand the role of the blood-derived proteins in the sub-RPE-

1535 BL space, if any. The study and potential modification of these interactions is now  
1536 possible and could lead to intervention strategies through modified diet,  
1537 supplementation or through manipulation of retinal molecular or cellular processes.

1538 An important specific question in the context of this study that needs still to be resolved  
1539 is how plasma proteins find their way into the sub-RPE-BL space. Apart from the  
1540 mechanisms already described above (chemical modification of interacting  
1541 biomolecules, dynamic structure and functional changes BrM, and HAP-binding) it is  
1542 tempting to speculate that not only blood composition but also blood pressure plays a  
1543 role. Why blood pressure? It was previously shown that a relationship exists between  
1544 drusen location and choriocapillary pillars. Indeed, by investigating retina whole  
1545 mounts, initially Friedman, and subsequently, Lengyel and coworkers concluded that  
1546 drusen deposition is the result of a lower clearance at the choroidal intercapillary pillars  
1547 (Friedman et al., 1963; Lengyel et al., 2004). Thus, in other words, higher clearance of  
1548 sub-RPE-BL space debris corresponds with the vascular lumen, through which the blood  
1549 flows and directly encounters BrM. Much in line with the reflections of Penfold and  
1550 others (Penfold et al., 2001) , we hypothesize that the pulsating blood pushes debris  
1551 through endothelial fenestrations into BrM, through relatively open BrM pores; and at  
1552 the same time, clears debris which was already present in BrM. One could compare that,  
1553 by analogy, with the sea bringing and taking, wave after wave, debris to and from the  
1554 beach. Changes in blood composition, choroidal endothelial cell compromise and rising  
1555 blood pressure with age (Pinto, 2007) may negatively change the dynamics of this  
1556 proposed “debris-exchange”.

1557 Our review further underlines the importance of comparative studies between drusen  
1558 deposition and atherosclerosis plaque formation. Clinical, (genetic) epidemiological  
1559 pathobiological and molecular similarities between these two disorders have been  
1560 highlighted previously (see section 8). Such similarities include that both are  
1561 extracellular lipid/protein/mineral-based depositions that invoke a low-grade immune  
1562 response leading to further disease. Several molecular similarities between drusen and  
1563 plaques have also been described. We currently add the observation that most drusen  
1564 (and plaque) components are blood-borne. Therefore, the genesis of drusen and plaques  
1565 may be similar, and should be subject of further multidisciplinary studies.

While studying the literature for this review, we have made a number of additional observations that may guide future research directions: First, while the number of retinal (cell-type-specific) transcriptomics studies are large and proteomics information is emerging, there are very few proteomics studies on different types of (human) sub-RPE-BL space deposits (types). For example, additional proteomics studies of hard versus soft drusen or macular versus peripheral drusen might improve our understanding of deposition formation in the sub-RPE-BL space and their association with different disorders or disease stages. Next, transcriptomics, proteomics, and immunohistochemical studies have their own conceptual and technical advantages and limitations. However, in the literature, the description of these strengths and weaknesses are not always clear and standardization is lacking. International agreements such as MIAME and MISFISHIE (minimum information specification for in situ hybridization and immunohistochemistry experiments) guidelines (Deutsch et al., 2008) are a step in the right direction, but must be seen as initial steps for further standardization. A few examples for illustration: How many confirmatory transcriptomics or proteomics studies should be performed before a definite subcellular assignment can be made? How do we define cellular specificity and cellular enrichment? How many drusen types should be screened and how many different antibodies should be used before proteins are clearly assigned as drusen proteins (or as sub-types). When should we designate labeling drusen specific? Do we consider staining of the border of hydroxyapatite or drusen important; or is only the staining of the whole inner mass of drusen relevant? Given the heterogeneity of drusen: what is the exact location of the drusen under study and its appearance? Indeed, in line with recent similar calls by Curcio and co-workers (Curcio, 2018a, b) we call here for better considerations, agreements and definitions of these issues.

Last but not least, it will be interesting to understand whether drusen heterogeneity is a direct feature of a disease or a reflection of the change in the (micro-) environment that results in initiation and growth of the deposits. While drusen deposition clearly is a hallmark of AMD and is associated with a number of other diseases (Khan et al., 2016), its actual composition might reflect the disease state at the RPE/choroid interface more than (cause) the disease. The identification of why and not necessarily what proteins

1597 and lipids are deposited in the sub-RPE-BL space might therefore an important question  
1598 to consider for future studies.

## References

1. Abdelsalam, A., Del Priore, L., Zarbin, M.A., 1999. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. *Surv Ophthalmol* 44, 1-29.
2. Ahmad, M.T., Zhang, P., Dufresne, C., Ferrucci, L., Semba, R.D., 2018. The Human Eye Proteome Project: Updates on an Emerging Proteome. *Proteomics* 18, e1700394.
3. Aiello, L.P., Gardner, T.W., King, G.L., Blankenship, G., Cavallerano, J.D., Ferris, F.L., 3rd, Klein, R., 1998. Diabetic retinopathy. *Diabetes Care* 21, 143-156.
4. Al Gwairi, O., Thach, L., Zheng, W., Osman, N., Little, P.J., 2016. Cellular and Molecular Pathology of Age-Related Macular Degeneration: Potential Role for Proteoglycans. *J Ophthalmol* 2016, 2913612.
5. Alcolado, J.C., Moore, I.E., Weller, R.O., 1986. Calcification in the human choroid plexus, meningiomas and pineal gland. *Neuropathol Appl Neurobiol* 12, 235-250.
6. Alge, C.S., Suppmann, S., Priglinger, S.G., Neubauer, A.S., May, C.A., Hauck, S., Welge-Lussen, U., Ueffing, M., Kampik, A., 2003. Comparative proteome analysis of native differentiated and cultured dedifferentiated human RPE cells. *Investigative ophthalmology & visual science* 44, 3629-3641.
7. Allam, R., Kumar, S.V., Darisipudi, M.N., Anders, H.J., 2014. Extracellular histones in tissue injury and inflammation. *J Mol Med (Berl)* 92, 465-472.
8. An, E., Lu, X., Flippin, J., Devaney, J.M., Halligan, B., Hoffman, E.P., Strunnikova, N., Csaky, K., Hathout, Y., 2006. Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. *J Proteome Res* 5, 2599-2610.
9. Anders, F., Liu, A., Mann, C., Teister, J., Lauzi, J., Thanos, S., Grus, F.H., Pfeiffer, N., Prokosch, V., 2017. The Small Heat Shock Protein alpha-Crystallin B Shows Neuroprotective Properties in a Glaucoma Animal Model. *Int J Mol Sci* 18.
10. Anderson, D.H., Mullins, R.F., Hageman, G.S., Johnson, L.V., 2002. A role for local inflammation in the formation of drusen in the aging eye. *Am J Ophthalmol* 134, 411-431.
11. Anderson, D.H., Ozaki, S., Nealon, M., Neitz, J., Mullins, R.F., Hageman, G.S., Johnson, L.V., 2001. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. *Am J Ophthalmol* 131, 767-781.
12. Anderson, D.H., Radeke, M.J., Gallo, N.B., Chapin, E.A., Johnson, P.T., Curletti, C.R., Hancox, L.S., Hu, J., Ebright, J.N., Malek, G., Hauser, M.A., Rickman, C.B., Bok, D., Hageman, G.S., Johnson, L.V., 2010. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. *Prog Retin Eye Res* 29, 95-112.
13. Arad, Y., Spadaro, L.A., Goodman, K., Newstein, D., Guerci, A.D., 2000. Prediction of coronary events with electron beam computed tomography. *J Am Coll Cardiol* 36, 1253-1260.
14. Arya, S., Emri, E., Synowsky, S.A., Shirran, S.L., Barzegar-Befroei, N., Peto, T., Botting, C.H., Lengyel, I., Stewart, A.J., 2018. Quantitative analysis of hydroxyapatite-binding plasma proteins in genotyped individuals with late-stage age-related macular degeneration. *Exp Eye Res* 172, 21-29.
15. Ashford, J.W., 2004. APOE genotype effects on Alzheimer's disease onset and epidemiology. *J Mol Neurosci* 23, 157-165.
16. Balaratnasingam, C., Hoang, Q.V., Inoue, M., Curcio, C.A., Dolz-Marco, R., Yannuzzi, N.A., Dhrami-Gavazi, E., Yannuzzi, L.A., Freund, K.B., 2016. Clinical Characteristics, Choroidal Neovascularization, and Predictors of Visual Outcomes in Acquired Vitelliform Lesions. *Am J Ophthalmol* 172, 28-38.
17. Barzegar-befroei, N., Peto, T., Bergen, A.A., Lengyel, I., 2012. Understanding the Role of Bruch's Membrane in Cnv. *Retinal Physician* 9, 20-25.
18. Beattie, J.R., Pawlak, A.M., Boulton, M.E., Zhang, J., Monnier, V.M., McGarvey, J.J., Stitt, A.W., 2010. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 24, 4816-4824.
19. Bennis, A., Gorgels, T.G., Ten Brink, J.B., van der Spek, P.J., Bossers, K., Heine, V.M., Bergen, A.A., 2015. Comparison of Mouse and Human Retinal Pigment Epithelium Gene Expression Profiles: Potential Implications for Age-Related Macular Degeneration. *PLoS One* 10, e0141597.



20. Bernstein, M.H., Hollenberg, M.J., 1965. Fine structure of the choriocapillaris and retinal capillaries. *Invest Ophthalmol* 4, 1016-1025.
21. Bertazzo, S., Gentleman, E., Cloyd, K.L., Chester, A.H., Yacoub, M.H., Stevens, M.M., 2013. Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. *Nat Mater* 12, 576-583.
22. Bhutto, I., Luty, G., 2012. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. *Mol Aspects Med* 33, 295-317.
23. Biesemeier, A., Taubitz, T., Julien, S., Yoeruek, E., Schraermeyer, U., 2014. Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. *Neurobiol Aging* 35, 2562-2573.
24. Bird, A.C., Bressler, N.M., Bressler, S.B., Chisholm, I.H., Coscas, G., Davis, M.D., de Jong, P.T., Klaver, C.C., Klein, B.E., Klein, R., et al., 1995. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. *Surv Ophthalmol* 39, 367-374.
25. Bird, A.C., Phillips, R.L., Hageman, G.S., 2014. Geographic atrophy: a histopathological assessment. *JAMA Ophthalmol* 132, 338-345.
26. Blaum, B.S., Deakin, J.A., Johansson, C.M., Herbert, A.P., Barlow, P.N., Lyon, M., Uhrin, D., 2010. Lysine and arginine side chains in glycosaminoglycan-protein complexes investigated by NMR, cross-linking, and mass spectrometry: a case study of the factor H-heparin interaction. *J Am Chem Soc* 132, 6374-6381.
27. Bleijerveld, O.B., Zhang, Y.N., Beldar, S., Hoefer, I.E., Sze, S.K., Pasterkamp, G., de Kleijn, D.P., 2013. Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis. *Proteomics Clin Appl* 7, 490-503.
28. Booi, J.C., Baas, D.C., Beisekeeva, J., Gorgels, T.G., Bergen, A.A., 2010a. The dynamic nature of Bruch's membrane. *Prog Retin Eye Res* 29, 1-18.
29. Booi, J.C., ten Brink, J.B., Swagemakers, S.M., Verkerk, A.J., Essing, A.H., van der Spek, P.J., Bergen, A.A., 2010b. A new strategy to identify and annotate human RPE-specific gene expression. *PLoS One* 5, e9341.
30. Booi, J.C., van Soest, S., Swagemakers, S.M., Essing, A.H., Verkerk, A.J., van der Spek, P.J., Gorgels, T.G., Bergen, A.A., 2009. Functional annotation of the human retinal pigment epithelium transcriptome. *BMC Genomics* 10, 164.
31. Boon, C.J., van de Kar, N.C., Klevering, B.J., Keunen, J.E., Cremers, F.P., Klaver, C.C., Hoyng, C.B., Daha, M.R., den Hollander, A.I., 2009. The spectrum of phenotypes caused by variants in the CFH gene. *Mol Immunol* 46, 1573-1594.
32. Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P., Stoeckert, C., Aach, J., Ansorge, W., Ball, C.A., Causton, H.C., Gaasterland, T., Glenisson, P., Holstege, F.C., Kim, I.F., Markowitz, V., Matese, J.C., Parkinson, H., Robinson, A., Sarkans, U., Schulze-Kremer, S., Stewart, J., Taylor, R., Vilo, J., Vingron, M., 2001. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. *Nat Genet* 29, 365-371.
33. Bressler, N.M., Munoz, B., Maguire, M.G., Vitale, S.E., Schein, O.D., Taylor, H.R., West, S.K., 1995. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. *Arch Ophthalmol* 113, 301-308.
34. Bressler, N.M., Silva, J.C., Bressler, S.B., Fine, S.L., Green, W.R., 1994. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. *Retina* 14, 130-142.
35. Bretillon, L., Thuret, G., Gregoire, S., Acar, N., Joffre, C., Bron, A.M., Gain, P., Creuzot-Garcher, C.P., 2008. Lipid and fatty acid profile of the retina, retinal pigment epithelium/choroid, and the lacrimal gland, and associations with adipose tissue fatty acids in human subjects. *Exp Eye Res* 87, 521-528.
36. Burns, M.S., Hartz, M.J., 1992. The retinal pigment epithelium induces fenestration of endothelial cells in vivo. *Curr Eye Res* 11, 863-873.

37. Burns, R.P., Feeney-Burns, L., 1980. Clinico-morphologic correlations of drusen of Bruch's membrane. *Trans Am Ophthalmol Soc* 78, 206-225.
38. Cankova, Z., Huang, J.D., Kruth, H.S., Johnson, M., 2011. Passage of low-density lipoproteins through Bruch's membrane and choroid. *Exp Eye Res* 93, 947-955.
39. Cao, S., Walker, G.B., Wang, X., Cui, J.Z., Matsubara, J.A., 2013. Altered cytokine profiles of human retinal pigment epithelium: oxidant injury and replicative senescence. *Mol Vis* 19, 718-728.
40. Carafoli, E., 2010. The fateful encounter of mitochondria with calcium: how did it happen? *Biochim Biophys Acta* 1797, 595-606.
41. Chen, M., Forrester, J.V., Xu, H., 2007. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. *Exp Eye Res* 84, 635-645.
42. Chen, M., Hombrebueno, J.R., Luo, C., Penalva, R., Zhao, J., Colhoun, L., Pandi, S.P., Forrester, J.V., Xu, H., 2013. Age- and light-dependent development of localised retinal atrophy in CCL2(-/-)CX3CR1(GFP/GFP) mice. *PLoS One* 8, e61381.
43. Chirco, K.R., Flamme-Wiese, M.J., Wiley, J.S., Potempa, L.A., Stone, E.M., Tucker, B.A., Mullins, R.F., 2018. Evaluation of serum and ocular levels of membrane attack complex and C-reactive protein in CFH-genotyped human donors. *Eye (Lond)*.
44. Chirco, K.R., Potempa, L.A., 2018. C-Reactive Protein As a Mediator of Complement Activation and Inflammatory Signaling in Age-Related Macular Degeneration. *Front Immunol* 9, 539.
45. Chirco, K.R., Tucker, B.A., Stone, E.M., Mullins, R.F., 2016. Selective accumulation of the complement membrane attack complex in aging choriocapillaris. *Exp Eye Res* 146, 393-397.
46. Chung, B.H., Franklin, F., Liang, P., Doran, S., Cho, B.H., Curcio, C.A., 2005. Phosphatidylcholine-rich acceptors, but not native HDL or its apolipoproteins, mobilize cholesterol from cholesterol-rich insoluble components of human atherosclerotic plaques. *Biochim Biophys Acta* 1733, 76-89.
47. Clark, S.J., Keenan, T.D., Fielder, H.L., Collinson, L.J., Holley, R.J., Merry, C.L., van Kuppevelt, T.H., Day, A.J., Bishop, P.N., 2011. Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. *Investigative ophthalmology & visual science* 52, 6511-6521.
48. Coats, G., 1905. The structure of the membrane of Bruch, and its relation to the formation of colloid excrescences. *J. & A. Churchill*.
49. Consortium, c.G., 2013. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45, 580-585.
50. Coppen, E.M., van der Grond, J., Hart, E.P., Lakke, E., Roos, R.A.C., 2018. The visual cortex and visual cognition in Huntington's disease: An overview of current literature. *Behav Brain Res* 351, 63-74.
51. Crabb, J.W., 2014. The proteomics of drusen. *Cold Spring Harb Perspect Med* 4, a017194.
52. Crabb, J.W., Miyagi, M., Gu, X., Shadrach, K., West, K.A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M.E., Salomon, R.G., Hollyfield, J.G., 2002. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. *Proc Natl Acad Sci U S A* 99, 14682-14687.
53. Cryan, L.M., O'Brien, C., 2008. Proteomics as a research tool in clinical and experimental ophthalmology. *Proteomics Clin Appl* 2, 762-775.
54. Csincsik, L., MacGillivray, T.J., Flynn, E., Pellegrini, E., Papanastasiou, G., Barzegar-Befroei, N., Csutak, A., Bird, A.C., Ritchie, C.W., Peto, T., Lengyel, I., 2018. Peripheral Retinal Imaging Biomarkers for Alzheimer's Disease: A Pilot Study. *Ophthalmic Res* 59, 182-192.
55. Cunden, L.S., Brophy, M.B., Rodriguez, G.E., Flaxman, H.A., Nolan, E.M., 2017. Biochemical and Functional Evaluation of the Intramolecular Disulfide Bonds in the Zinc-Chelating Antimicrobial Protein Human S100A7 (Psoriasin). *Biochemistry* 56, 5726-5738.
56. Cunningham, A., Kotagiri, A., 2018. A long history of dense deposit disease. *BMC Ophthalmol* 18, 228.
57. Curcio, C.A., 2018a. Antecedents of Soft Drusen, the Specific Deposits of Age-Related Macular Degeneration, in the Biology of Human Macula. *Investigative ophthalmology & visual science* 59, Amd182-amd194.
58. Curcio, C.A., 2018b. Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies. *Investigative ophthalmology & visual science* 59, Amd160-amd181.

1755 59. Curcio, C.A., Johnson, M., 2012. Structure, function, and pathology of Bruch's membrane, in: S. J.  
1756 Ryan, A.P.S., C. P. Wilkinson, D. R. Hinton, S. Sadda, P. Wiedemann (Ed.), *Retina*, London. Elsevier, pp.  
1757 465-481.

1758 60. Curcio, C.A., Johnson, M., Huang, J.D., Rudolf, M., 2009. Aging, age-related macular degeneration,  
1759 and the response-to-retention of apolipoprotein B-containing lipoproteins. *Prog Retin Eye Res* 28,  
1760 393-422.

1761 61. Curcio, C.A., Johnson, M., Rudolf, M., Huang, J.D., 2011. The oil spill in ageing Bruch membrane.  
1762 *The British journal of ophthalmology* 95, 1638-1645.

1763 62. Curcio, C.A., Medeiros, N.E., Millican, C.L., 1998. The Alabama Age-Related Macular Degeneration  
1764 Grading System for donor eyes. *Investigative ophthalmology & visual science* 39, 1085-1096.

1765 63. Curcio, C.A., Messinger, J.D., Sloan, K.R., McGwin, G., Medeiros, N.E., Spaide, R.F., 2013.  
1766 Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology,  
1767 prevalence, topography, and biogenesis model. *Retina* 33, 265-276.

1768 64. Curcio, C.A., Millican, C.L., 1999. Basal linear deposit and large drusen are specific for early age-  
1769 related maculopathy. *Arch Ophthalmol* 117, 329-339.

1770 65. Curcio, C.A., Millican, C.L., Bailey, T., Kruth, H.S., 2001. Accumulation of cholesterol with age in  
1771 human Bruch's membrane. *Investigative ophthalmology & visual science* 42, 265-274.

1772 66. Curcio, C.A., Zanzottera, E.C., Ach, T., Balaratnasingam, C., Freund, K.B., 2017. Activated Retinal  
1773 Pigment Epithelium, an Optical Coherence Tomography Biomarker for Progression in Age-Related  
1774 Macular Degeneration. *Investigative ophthalmology & visual science* 58, Bio211-bio226.

1775 67. de Jong, P.T., 2006. Age-related macular degeneration. *N Engl J Med* 355, 1474-1485.

1776 68. De, S., Rabin, D.M., Salero, E., Lederman, P.L., Temple, S., Stern, J.H., 2007. Human retinal  
1777 pigment epithelium cell changes and expression of alphaB-crystallin: a biomarker for retinal pigment  
1778 epithelium cell change in age-related macular degeneration. *Arch Ophthalmol* 125, 641-645.

1779 69. de Vries, M.A., Trompet, S., Mooijaart, S.P., Smit, R.A., Bohringer, S., Castro Cabezas, M., Jukema,  
1780 J.W., 2017. Complement receptor 1 gene polymorphisms are associated with cardiovascular risk.  
1781 *Atherosclerosis* 257, 16-21.

1782 70. Del Priore, L.V., Tezel, T.H., Kaplan, H.J., 2006. Maculoplasty for age-related macular  
1783 degeneration: reengineering Bruch's membrane and the human macula. *Prog Retin Eye Res* 25, 539-  
1784 562.

1785 71. Despret, D.D., Klaver, C.C., Witteman, J.C., Bergen, A.A., Kardys, I., de Maat, M.P., Boekhoorn,  
1786 S.S., Vingerling, J.R., Hofman, A., Oostra, B.A., Uitterlinden, A.G., Stijnen, T., van Duijn, C.M., de Jong,  
1787 P.T., 2006. Complement factor H polymorphism, complement activators, and risk of age-related  
1788 macular degeneration. *Jama* 296, 301-309.

1789 72. Deutsch, E.W., Ball, C.A., Berman, J.J., Bova, G.S., Brazma, A., Bumgarner, R.E., Campbell, D.,  
1790 Causton, H.C., Christiansen, J.H., Daian, F., Duga, D., Davidson, D.R., Gimenez, G., Goo, Y.A.,  
1791 Grimmond, S., Henrich, T., Herrmann, B.G., Johnson, M.H., Korb, M., Mills, J.C., Oudes, A.J.,  
1792 Parkinson, H.E., Pascal, L.E., Pollet, N., Quackenbush, J., Ramialison, M., Ringwald, M., Salgado, D.,  
1793 Sansone, S.A., Sherlock, G., Stoeckert, C.J., Jr., Swedlow, J., Taylor, R.C., Walashek, L., Warford, A.,  
1794 Wilkinson, D.G., Zhou, Y., Zon, L.I., Liu, A.Y., True, L.D., 2008. Minimum information specification for  
1795 in situ hybridization and immunohistochemistry experiments (MISFISHIE). *Nat Biotechnol* 26, 305-  
1796 312.

1797 73. Diamond, J.S., 2017. Inhibitory Interneurons in the Retina: Types, Circuitry, and Function. *Annu*  
1798 *Rev Vis Sci* 3, 1-24.

1799 74. Dick, A.D., 2017. Doyne lecture 2016: intraocular health and the many faces of inflammation. *Eye*  
1800 (Lond) 31, 87-96.

1801 75. Doherty, T.M., Asotra, K., Fitzpatrick, L.A., Qiao, J.H., Wilkin, D.J., Detrano, R.C., Dunstan, C.R.,  
1802 Shah, P.K., Rajavashisth, T.B., 2003. Calcification in atherosclerosis: bone biology and chronic  
1803 inflammation at the arterial crossroads. *Proc Natl Acad Sci U S A* 100, 11201-11206.

1804 76. Domalpally, A., Clemons, T.E., Danis, R.P., Sadda, S.R., Cukras, C.A., Toth, C.A., Friberg, T.R., Chew,  
1805 E.Y., 2017. Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-  
1806 Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related

1807 Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group. *Ophthalmology* 124,  
1808 479-487.

1809 77. Doyle, S.L., Campbell, M., Ozaki, E., Salomon, R.G., Mori, A., Kenna, P.F., Farrar, G.J., Kiang, A.S.,  
1810 Humphries, M.M., Lavelle, E.C., O'Neill, L.A., Hollyfield, J.G., Humphries, P., 2012. NLRP3 has a  
1811 protective role in age-related macular degeneration through the induction of IL-18 by drusen  
1812 components. *Nat Med* 18, 791-798.

1813 78. Durocher, D., Jackson, S.P., 2002. The FHA domain. *FEBS Lett* 513, 58-66.

1814 79. Duvall, J., Tso, M.O., 1985. Cellular mechanisms of resolution of drusen after laser coagulation. An  
1815 experimental study. *Arch Ophthalmol* 103, 694-703.

1816 80. Duvall-Young, J., MacDonald, M.K., McKechnie, N.M., 1989. Fundus changes in (type II)  
1817 mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. *The British*  
1818 *journal of ophthalmology* 73, 297-302.

1819 81. Edwards, A.O., Malek, G., 2007. Molecular genetics of AMD and current animal models.  
1820 *Angiogenesis* 10, 119-132.

1821 82. Edwards, A.O., Ritter, R., 3rd, Abel, K.J., Manning, A., Panhuysen, C., Farrer, L.A., 2005.  
1822 Complement factor H polymorphism and age-related macular degeneration. *Science* 308, 421-424.

1823 83. Engel, A.G., 2018. Congenital Myasthenic Syndromes in 2018. *Curr Neurol Neurosci Rep* 18, 46.

1824 84. Essner, E., Gordon, S.R., 1983. Observations on the permeability of the choriocapillaris of the eye.  
1825 *Cell Tissue Res* 231, 571-577.

1826 85. Fain, G., Sampath, A.P., 2018. Rod and cone interactions in the retina. *F1000Res* 7.

1827 86. Fariss, R.N., Apte, S.S., Olsen, B.R., Iwata, K., Milam, A.H., 1997. Tissue inhibitor of  
1828 metalloproteinases-3 is a component of Bruch's membrane of the eye. *Am J Pathol* 150, 323-328.

1829 87. Farkas, T.G., Sylvester, V., Archer, D., 1971a. The ultrastructure of drusen. *Am J Ophthalmol* 71,  
1830 1196-1205.

1831 88. Farkas, T.G., Sylvester, V., Archer, D., Altona, M., 1971b. The histochemistry of drusen. *Am J*  
1832 *Ophthalmol* 71, 1206-1215.

1833 89. Farrah, T., Deutsch, E.W., Omenn, G.S., Campbell, D.S., Sun, Z., Bletz, J.A., Mallick, P., Katz, J.E.,  
1834 Malmstrom, J., Ossola, R., Watts, J.D., Lin, B., Zhang, H., Moritz, R.L., Aebersold, R., 2011. A high-  
1835 confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas.  
1836 *Mol Cell Proteomics* 10, M110.006353.

1837 90. Feeney-Burns, L., Gao, C.L., Berman, E.R., 1988. The fate of immunoreactive opsin following  
1838 phagocytosis by pigment epithelium in human and monkey retinas. *Investigative ophthalmology &*  
1839 *visual science* 29, 708-719.

1840 91. Fernandez-Godino, R., Pierce, E.A., Garland, D.L., 2016. Extracellular Matrix Alterations and  
1841 Deposit Formation in AMD. *Adv Exp Med Biol* 854, 53-58.

1842 92. Fine, B.S., 1981. Lipoidal degeneration of the retinal pigment epithelium. *Am J Ophthalmol* 91,  
1843 469-473.

1844 93. Flinn, J.M., Kakalec, P., Tappero, R., Jones, B., Lengyel, I., 2014. Correlations in distribution and  
1845 concentration of calcium, copper and iron with zinc in isolated extracellular deposits associated with  
1846 age-related macular degeneration. *Metallomics* 6, 1223-1228.

1847 94. Forrest, D., Swaroop, A., 2012. Minireview: the role of nuclear receptors in photoreceptor  
1848 differentiation and disease. *Mol Endocrinol* 26, 905-915.

1849 95. Fort, P.E., Lampi, K.J., 2011. New focus on alpha-crystallins in retinal neurodegenerative diseases.  
1850 *Exp Eye Res* 92, 98-103.

1851 96. Friedman, E., Smith, T.R., Kuwabara, T., 1963. Senile choroidal vascular patterns and drusen. *Arch*  
1852 *Ophthalmol* 69, 220-230.

1853 97. Fritsche, L.G., Igl, W., Bailey, J.N., Grassmann, F., Sengupta, S., Bragg-Gresham, J.L., Burdon, K.P.,  
1854 Hebbaring, S.J., Wen, C., Gorski, M., Kim, I.K., Cho, D., Zack, D., Souied, E., Scholl, H.P., Bala, E., Lee,  
1855 K.E., Hunter, D.J., Sardell, R.J., Mitchell, P., Merriam, J.E., Cipriani, V., Hoffman, J.D., Schick, T.,  
1856 Lechanteur, Y.T., Guymer, R.H., Johnson, M.P., Jiang, Y., Stanton, C.M., Buitendijk, G.H., Zhan, X.,  
1857 Kwong, A.M., Boleda, A., Brooks, M., Gieser, L., Ratnapriya, R., Branham, K.E., Foerster, J.R.,  
1858 Heckenlively, J.R., Othman, M.I., Vote, B.J., Liang, H.H., Souzeau, E., McAllister, I.L., Isaacs, T., Hall, J.,

1859 Lake, S., Mackey, D.A., Constable, I.J., Craig, J.E., Kitchner, T.E., Yang, Z., Su, Z., Luo, H., Chen, D.,  
 1860 Ouyang, H., Flagg, K., Lin, D., Mao, G., Ferreyra, H., Stark, K., von Strachwitz, C.N., Wolf, A., Brandl, C.,  
 1861 Rudolph, G., Olden, M., Morrison, M.A., Morgan, D.J., Schu, M., Ahn, J., Silvestri, G., Tsironi, E.E.,  
 1862 Park, K.H., Farrer, L.A., Orlin, A., Brucker, A., Li, M., Curcio, C.A., Mohand-Said, S., Sahel, J.A., Audo, I.,  
 1863 Benchaboune, M., Cree, A.J., Rennie, C.A., Goverdhan, S.V., Grunin, M., Hagbi-Levi, S., Campochiaro,  
 1864 P., Katsanis, N., Holz, F.G., Blond, F., Blanche, H., Deleuze, J.F., Igo, R.P., Jr., Truitt, B., Peachey, N.S.,  
 1865 Meuer, S.M., Myers, C.E., Moore, E.L., Klein, R., Hauser, M.A., Postel, E.A., Courtenay, M.D.,  
 1866 Schwartz, S.G., Kovach, J.L., Scott, W.K., Liew, G., Tan, A.G., Gopinath, B., Merriam, J.C., Smith, R.T.,  
 1867 Khan, J.C., Shahid, H., Moore, A.T., McGrath, J.A., Laux, R., Brantley, M.A., Jr., Agarwal, A., Ersoy, L.,  
 1868 Caramoy, A., Langmann, T., Saksens, N.T., de Jong, E.K., Hoyng, C.B., Cain, M.S., Richardson, A.J.,  
 1869 Martin, T.M., Blangero, J., Weeks, D.E., Dhillon, B., van Duijn, C.M., Doheny, K.F., Romm, J., Klaver,  
 1870 C.C., Hayward, C., Gorin, M.B., Klein, M.L., Baird, P.N., den Hollander, A.I., Fauser, S., Yates, J.R.,  
 1871 Allikmets, R., Wang, J.J., Schaumberg, D.A., Klein, B.E., Hagstrom, S.A., Chowers, I., Lotery, A.J.,  
 1872 Leveillard, T., Zhang, K., Brilliant, M.H., Hewitt, A.W., Swaroop, A., Chew, E.Y., Pericak-Vance, M.A.,  
 1873 DeAngelis, M., Stambolian, D., Haines, J.L., Iyengar, S.K., Weber, B.H., Abecasis, G.R., Heid, I.M., 2016.  
 1874 A large genome-wide association study of age-related macular degeneration highlights contributions  
 1875 of rare and common variants. *Nat Genet* 48, 134-143.  
 1876 98. Garcia-Aranda, M., Serrano, A., Redondo, M., 2018. Regulation of Clusterin Gene Expression. *Curr*  
 1877 *Protein Pept Sci* 19, 612-622.  
 1878 99. Gass, J.D., 1967. Pathogenesis of disciform detachment of the neuroepithelium. *Am J Ophthalmol*  
 1879 63, Suppl:1-139.  
 1880 100. Gehlbach, P., Li, T., Hatef, E., 2016. Statins for age-related macular degeneration. *Cochrane*  
 1881 *Database Syst Rev*, Cd006927.  
 1882 101. George, A.K., Singh, M., Homme, R.P., Majumder, A., Sandhu, H.S., Tyagi, S.C., 2018. A  
 1883 hypothesis for treating inflammation and oxidative stress with hydrogen sulfide during age-related  
 1884 macular degeneration. *Int J Ophthalmol* 11, 881-887.  
 1885 102. German, O.L., Monaco, S., Agnolazza, D.L., Rotstein, N.P., Politi, L.E., 2013. Retinoid X receptor  
 1886 activation is essential for docosahexaenoic acid protection of retina photoreceptors. *J Lipid Res* 54,  
 1887 2236-2246.  
 1888 103. Geyer, P.E., Kulak, N.A., Pichler, G., Holdt, L.M., Teupser, D., Mann, M., 2016. Plasma Proteome  
 1889 Profiling to Assess Human Health and Disease. *Cell Syst* 2, 185-195.  
 1890 104. Gonzalez, A., Valeiras, M., Sidransky, E., Tayebi, N., 2014. Lysosomal integral membrane protein-  
 1891 2: a new player in lysosome-related pathology. *Mol Genet Metab* 111, 84-91.  
 1892 105. Gonzalez-Fernandez, F., Kittredge, K.L., Rayborn, M.E., Hollyfield, J.G., Landers, R.A., Saha, M.,  
 1893 Grainger, R.M., 1993. Interphotoreceptor retinoid-binding protein (IRBP), a major 124 kDa  
 1894 glycoprotein in the interphotoreceptor matrix of *Xenopus laevis*. Characterization, molecular cloning  
 1895 and biosynthesis. *J Cell Sci* 105 ( Pt 1), 7-21.  
 1896 106. Gorgels, T.G., Teeling, P., Meeldijk, J.D., Nillesen, S.T., van der Wal, A.C., van Kuppevelt, T.H.,  
 1897 Bergen, A.A., 2012. Abcc6 deficiency in the mouse leads to calcification of collagen fibers in Bruch's  
 1898 membrane. *Exp Eye Res* 104, 59-64.  
 1899 107. Grassmann, F., Kiel, C., Zimmermann, M.E., Gorski, M., Grassmann, V., Stark, K., Heid, I.M.,  
 1900 Weber, B.H., 2017. Genetic pleiotropy between age-related macular degeneration and 16 complex  
 1901 diseases and traits. *Genome Med* 9, 29.  
 1902 108. Green, W.R., Enger, C., 1993. Age-related macular degeneration histopathologic studies. The  
 1903 1992 Lorenz E. Zimmerman Lecture. *Ophthalmology* 100, 1519-1535.  
 1904 109. Green, W.R., Key, S.N., 3rd, 1977. Senile macular degeneration: a histopathologic study. . *Retina*  
 1905 25, 180-250; discussion 250-184.  
 1906 110. Gross, S.R., Sin, C.G., Barraclough, R., Rudland, P.S., 2014. Joining S100 proteins and migration:  
 1907 for better or for worse, in sickness and in health. *Cell Mol Life Sci* 71, 1551-1579.  
 1908 111. Guo, L., Hussain, A.A., Limb, G.A., Marshall, J., 1999. Age-dependent variation in  
 1909 metalloproteinase activity of isolated human Bruch's membrane and choroid. *Investigative*  
 1910 *ophthalmology & visual science* 40, 2676-2682.

1911 112. Guymer, R., Luthert, P., Bird, A., 1999. Changes in Bruch's membrane and related structures with  
1912 age. *Prog Retin Eye Res* 18, 59-90.

1913 113. Hageman, G.S., Anderson, D.H., Johnson, L.V., Hancox, L.S., Taiber, A.J., Hardisty, L.I., Hageman,  
1914 J.L., Stockman, H.A., Borchardt, J.D., Gehrs, K.M., Smith, R.J., Silvestri, G., Russell, S.R., Klaver, C.C.,  
1915 Barbazetto, I., Chang, S., Yannuzzi, L.A., Barile, G.R., Merriam, J.C., Smith, R.T., Olsh, A.K., Bergeron, J.,  
1916 Zernant, J., Merriam, J.E., Gold, B., Dean, M., Allikmets, R., 2005. A common haplotype in the  
1917 complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular  
1918 degeneration. *Proc Natl Acad Sci U S A* 102, 7227-7232.

1919 114. Hageman, G.S., Luthert, P.J., Victor Chong, N.H., Johnson, L.V., Anderson, D.H., Mullins, R.F.,  
1920 2001. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes  
1921 at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. *Prog Retin*  
1922 *Eye Res* 20, 705-732.

1923 115. Hageman, G.S., Mullins, R.F., Russell, S.R., Johnson, L.V., Anderson, D.H., 1999. Vitronectin is a  
1924 constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented  
1925 epithelial cells. *FASEB journal : official publication of the Federation of American Societies for*  
1926 *Experimental Biology* 13, 477-484.

1927 116. Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., Spencer, K.L., Kwan,  
1928 S.Y., Noureddine, M., Gilbert, J.R., Schnetz-Boutaud, N., Agarwal, A., Postel, E.A., Pericak-Vance,  
1929 M.A., 2005. Complement factor H variant increases the risk of age-related macular degeneration.  
1930 *Science* 308, 419-421.

1931 117. Handa, J.T., Cano, M., Wang, L., Datta, S., Liu, T., 2017. Lipids, oxidized lipids, oxidation-specific  
1932 epitopes, and Age-related Macular Degeneration. *Biochim Biophys Acta Mol Cell Biol Lipids* 1862,  
1933 430-440.

1934 118. Hansson, G.K., Robertson, A.K., Soderberg-Naucler, C., 2006. Inflammation and atherosclerosis.  
1935 *Annu Rev Pathol* 1, 297-329.

1936 119. Happonen, K.E., Furst, C.M., Saxne, T., Heinegard, D., Blom, A.M., 2012. PRELP protein inhibits  
1937 the formation of the complement membrane attack complex. *J Biol Chem* 287, 8092-8100.

1938 120. Hiebl, V., Ladurner, A., Latkolik, S., Dirsch, V.M., 2018. Natural products as modulators of the  
1939 nuclear receptors and metabolic sensors LXR, FXR and RXR. *Biotechnol Adv.*

1940 121. Hogan, M.J., 1965. MACULAR DISEASES: PATHOGENESIS. ELECTRON MICROSCOPY OF BRUCH'S  
1941 MEMBRANE. *Trans Am Acad Ophthalmol Otolaryngol* 69, 683-690.

1942 122. Hogan, M.J., 1972. Role of the retinal pigment epithelium in macular disease. *Trans Am Acad*  
1943 *Ophthalmol Otolaryngol* 76, 64-80.

1944 123. Hoke, M., Speidl, W., Schillinger, M., Minar, E., Zehetmayer, S., Schonherr, M., Wagner, O.,  
1945 Mannhalter, C., 2012. Polymorphism of the complement 5 gene and cardiovascular outcome in  
1946 patients with atherosclerosis. *Eur J Clin Invest* 42, 921-926.

1947 124. Hollyfield, J.G., Perez, V.L., Salomon, R.G., 2010. A hapten generated from an oxidation fragment  
1948 of docosahexaenoic acid is sufficient to initiate age-related macular degeneration. *Mol Neurobiol* 41,  
1949 290-298.

1950 125. Hollyfield, J.G., Salomon, R.G., Crabb, J.W., 2003. Proteomic approaches to understanding age-  
1951 related macular degeneration. *Adv Exp Med Biol* 533, 83-89.

1952 126. Hopkins, P.N., 2013. Molecular biology of atherosclerosis. *Physiol Rev* 93, 1317-1542.

1953 127. Hoppe, G., Marmorstein, A.D., Pennock, E.A., Hoff, H.F., 2001. Oxidized low density lipoprotein-  
1954 induced inhibition of processing of photoreceptor outer segments by RPE. *Investigative*  
1955 *ophthalmology & visual science* 42, 2714-2720.

1956 128. Hultgardh-Nilsson, A., Boren, J., Chakravarti, S., 2015. The small leucine-rich repeat  
1957 proteoglycans in tissue repair and atherosclerosis. *J Intern Med* 278, 447-461.

1958 129. Hussain, A.A., Lee, Y., Zhang, J.J., Marshall, J., 2011. Disturbed matrix metalloproteinase activity  
1959 of Bruch's membrane in age-related macular degeneration. *Investigative ophthalmology & visual*  
1960 *science* 52, 4459-4466.

1961 130. Hussain, A.A., Starita, C., Hodgetts, A., Marshall, J., 2010. Macromolecular diffusion  
1962 characteristics of ageing human Bruch's membrane: implications for age-related macular  
1963 degeneration (AMD). *Exp Eye Res* 90, 703-710.

1964 131. Hyman, L.G., Lilienfeld, A.M., Ferris, F.L., 3rd, Fine, S.L., 1983. Senile macular degeneration: a  
1965 case-control study. *Am J Epidemiol* 118, 213-227.

1966 132. Ida, H., Ishibashi, K., Reiser, K., Hjelmeland, L.M., Handa, J.T., 2004. Ultrastructural aging of the  
1967 RPE-Bruch's membrane-choriocapillaris complex in the D-galactose-treated mouse. *Investigative*  
1968 *ophthalmology & visual science* 45, 2348-2354.

1969 133. Ito, N., Ohashi, R., Nagata, M., 2017. C3 glomerulopathy and current dilemmas. *Clin Exp Nephrol*  
1970 21, 541-551.

1971 134. Jang, H.L., Jin, K., Lee, J., Kim, Y., Nahm, S.H., Hong, K.S., Nam, K.T., 2014. Revisiting whitlockite,  
1972 the second most abundant biomineral in bone: nanocrystal synthesis in physiologically relevant  
1973 conditions and biocompatibility evaluation. *ACS Nano* 8, 634-641.

1974 135. Jansen, R.S., Kucukosmanoglu, A., de Haas, M., Sapthu, S., Otero, J.A., Hegman, I.E., Bergen,  
1975 A.A., Gorgels, T.G., Borst, P., van de Wetering, K., 2013. ABCC6 prevents ectopic mineralization seen  
1976 in pseudoxanthoma elasticum by inducing cellular nucleotide release. *Proc Natl Acad Sci U S A* 110,  
1977 20206-20211.

1978 136. Jobling, A.I., Guymier, R.H., Vessey, K.A., Greferath, U., Mills, S.A., Brassington, K.H., Luu, C.D.,  
1979 Aung, K.Z., Trogrlic, L., Plunkett, M., Fletcher, E.L., 2015. Nanosecond laser therapy reverses  
1980 pathologic and molecular changes in age-related macular degeneration without retinal damage.  
1981 *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*  
1982 29, 696-710.

1983 137. Johnson, L.V., Forest, D.L., Banna, C.D., Radeke, C.M., Maloney, M.A., Hu, J., Spencer, C.N.,  
1984 Walker, A.M., Tsie, M.S., Bok, D., Radeke, M.J., Anderson, D.H., 2011. Cell culture model that mimics  
1985 drusen formation and triggers complement activation associated with age-related macular  
1986 degeneration. *Proc Natl Acad Sci U S A* 108, 18277-18282.

1987 138. Johnson, L.V., Ozaki, S., Staples, M.K., Erickson, P.A., Anderson, D.H., 2000. A potential role for  
1988 immune complex pathogenesis in drusen formation. *Exp Eye Res* 70, 441-449.

1989 139. Johnson, P.T., Lewis, G.P., Talaga, K.C., Brown, M.N., Kappel, P.J., Fisher, S.K., Anderson, D.H.,  
1990 Johnson, L.V., 2003. Drusen-associated degeneration in the retina. *Investigative ophthalmology &*  
1991 *visual science* 44, 4481-4488.

1992 140. Jones, S.E., Jomary, C., Grist, J., Makwana, J., Neal, M.J., 1999. Retinal expression of gamma-  
1993 crystallins in the mouse. *Investigative ophthalmology & visual science* 40, 3017-3020.

1994 141. Kalbitz, M., Grailer, J.J., Fattahi, F., Jajou, L., Herron, T.J., Campbell, K.F., Zetoune, F.S., Bosmann,  
1995 M., Sarma, J.V., Huber-Lang, M., Gebhard, F., Loaiza, R., Valdivia, H.H., Jalife, J., Russell, M.W., Ward,  
1996 P.A., 2015. Role of extracellular histones in the cardiomyopathy of sepsis. *FASEB journal : official*  
1997 *publication of the Federation of American Societies for Experimental Biology* 29, 2185-2193.

1998 142. Kamaraj, B., Purohit, R., 2014. Mutational analysis of oculocutaneous albinism: a compact  
1999 review. *Biomed Res Int* 2014, 905472.

2000 143. Kamei, M., Hollyfield, J.G., 1999. TIMP-3 in Bruch's membrane: changes during aging and in age-  
2001 related macular degeneration. *Investigative ophthalmology & visual science* 40, 2367-2375.

2002 144. Kani, T., Kani, M., Moriwaki, Y., Doi, Y., 1983. Microbeam x-ray diffraction analysis of dental  
2003 calculus. *J Dent Res* 62, 92-95.

2004 145. Kannan, R., Sreekumar, P.G., Hinton, D.R., 2016. Alpha crystallins in the retinal pigment  
2005 epithelium and implications for the pathogenesis and treatment of age-related macular  
2006 degeneration. *Biochim Biophys Acta* 1860, 258-268.

2007 146. Kauppinen, A., Paterno, J.J., Blasiak, J., Salminen, A., Kaarniranta, K., 2016. Inflammation and its  
2008 role in age-related macular degeneration. *Cell Mol Life Sci* 73, 1765-1786.

2009 147. Keelan, P.C., Bielak, L.F., Ashai, K., Jamjoum, L.S., Denktas, A.E., Rumberger, J.A., Sheedy, I.P.,  
2010 Peyser, P.A., Schwartz, R.S., 2001. Long-term prognostic value of coronary calcification detected by  
2011 electron-beam computed tomography in patients undergoing coronary angiography. *Circulation* 104,  
2012 412-417.

2013 148. Keenan, T.D., Clark, S.J., Unwin, R.D., Ridge, L.A., Day, A.J., Bishop, P.N., 2012. Mapping the  
2014 differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera.  
2015 *Investigative ophthalmology & visual science* 53, 7528-7538.

2016 149. Kestenbaum, B.R., Adeney, K.L., de Boer, I.H., Ix, J.H., Shlipak, M.G., Siscovick, D.S., 2009.  
2017 Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study  
2018 of Atherosclerosis. *Kidney Int* 76, 991-998.

2019 150. Khan, K.N., Mahroo, O.A., Khan, R.S., Mohamed, M.D., McKibbin, M., Bird, A., Michaelides, M.,  
2020 Tufail, A., Moore, A.T., 2016. Differentiating drusen: Drusen and drusen-like appearances associated  
2021 with ageing, age-related macular degeneration, inherited eye disease and other pathological  
2022 processes. *Prog Retin Eye Res* 53, 70-106.

2023 151. Kiel, C., Vogt, A., Campagna, A., Chatr-aryamontri, A., Swiatek-de Lange, M., Beer, M., Bolz, S.,  
2024 Mack, A.F., Kinkl, N., Cesareni, G., Serrano, L., Ueffing, M., 2011. Structural and functional protein  
2025 network analyses predict novel signaling functions for rhodopsin. *Mol Syst Biol* 7, 551.

2026 152. Kim, Y.H., He, S., Kase, S., Kitamura, M., Ryan, S.J., Hinton, D.R., 2009. Regulated secretion of  
2027 complement factor H by RPE and its role in RPE migration. *Graefes Arch Clin Exp Ophthalmol* 247,  
2028 651-659.

2029 153. Kinnunen, K., Petrovski, G., Moe, M.C., Berta, A., Kaarniranta, K., 2012. Molecular mechanisms  
2030 of retinal pigment epithelium damage and development of age-related macular degeneration. *Acta*  
2031 *Ophthalmol* 90, 299-309.

2032 154. Klaver, C.C., Kliffen, M., van Duijn, C.M., Hofman, A., Cruts, M., Grobbee, D.E., van Broeckhoven,  
2033 C., de Jong, P.T., 1998. Genetic association of apolipoprotein E with age-related macular  
2034 degeneration. *Am J Hum Genet* 63, 200-206.

2035 155. Klein, R., Klein, B.E., Franke, T., 1993. The relationship of cardiovascular disease and its risk  
2036 factors to age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology* 100, 406-414.

2037 156. Klein, R.J., Zeiss, C., Chew, E.Y., Tsai, J.Y., Sackler, R.S., Haynes, C., Henning, A.K., SanGiovanni,  
2038 J.P., Mane, S.M., Mayne, S.T., Bracken, M.B., Ferris, F.L., Ott, J., Barnstable, C., Hoh, J., 2005.  
2039 Complement factor H polymorphism in age-related macular degeneration. *Science* 308, 385-389.

2040 157. Kobayashi, H., Okamoto, H., Murakami, A., Iwata, T., 2014. Plasma proteome analysis on  
2041 cynomolgus monkey (*Macaca fascicularis*) pedigrees with early onset drusen formation. *Exp Anim* 63,  
2042 305-310.

2043 158. Kornzweig, A.L., 1977. Changes in the choriocapillaris associated with senile macular  
2044 degeneration. *Ann Ophthalmol* 9, 753-756, 759-762.

2045 159. Kruijt, C.C., de Wit, G.C., Bergen, A.A., Florijn, R.J., Schalijs-Delfos, N.E., van Genderen, M.M.,  
2046 2018. The Phenotypic Spectrum of Albinism. *Ophthalmology*.

2047 160. Kunchithapautham, K., Atkinson, C., Rohrer, B., 2014. Smoke exposure causes endoplasmic  
2048 reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and  
2049 complement activation. *J Biol Chem* 289, 14534-14546.

2050 161. Lai, X., Wichers, H.J., Soler-Lopez, M., Dijkstra, B.W., 2018. Structure and Function of Human  
2051 Tyrosinase and Tyrosinase-Related Proteins. *Chemistry* 24, 47-55.

2052 162. Lee, J.S., Morrisett, J.D., Tung, C.H., 2012. Detection of hydroxyapatite in calcified cardiovascular  
2053 tissues. *Atherosclerosis* 224, 340-347.

2054 163. Lee, Y., Hussain, A.A., Seok, J.H., Kim, S.H., Marshall, J., 2015. Modulating the Transport  
2055 Characteristics of Bruch's Membrane With Steroidal Glycosides and its Relevance to Age-Related  
2056 Macular Degeneration (AMD). *Investigative ophthalmology & visual science* 56, 8403-8418.

2057 164. Lengyel, I., Csutak, A., Florea, D., Leung, I., Bird, A.C., Jonasson, F., Peto, T., 2015. A Population-  
2058 Based Ultra-Widefield Digital Image Grading Study for Age-Related Macular Degeneration-Like  
2059 Lesions at the Peripheral Retina. *Ophthalmology* 122, 1340-1347.

2060 165. Lengyel, I., Flinn, J.M., Peto, T., Linkous, D.H., Cano, K., Bird, A.C., Lanzirotti, A., Frederickson,  
2061 C.J., van Kuijk, F.J., 2007. High concentration of zinc in sub-retinal pigment epithelial deposits. *Exp*  
2062 *Eye Res* 84, 772-780.



166. Lengyel, I., Tufail, A., Hosaini, H.A., Luthert, P., Bird, A.C., Jeffery, G., 2004. Association of drusen deposition with choroidal intercapillary pillars in the aging human eye. *Investigative ophthalmology & visual science* 45, 2886-2892.
167. Li, C.M., Chung, B.H., Presley, J.B., Malek, G., Zhang, X., Dashti, N., Li, L., Chen, J., Bradley, K., Kruth, H.S., Curcio, C.A., 2005a. Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. *Investigative ophthalmology & visual science* 46, 2576-2586.
168. Li, C.M., Presley, J.B., Zhang, X., Dashti, N., Chung, B.H., Medeiros, N.E., Guidry, C., Curcio, C.A., 2005b. Retina expresses microsomal triglyceride transfer protein: implications for age-related maculopathy. *J Lipid Res* 46, 628-640.
169. Li, M., Dolz-Marco, R., Messinger, J.D., Wang, L., Feist, R.M., Girkin, C.A., Gattoussi, S., Ferrara, D., Curcio, C.A., Freund, K.B., 2018. Clinicopathologic Correlation of Anti-Vascular Endothelial Growth Factor-Treated Type 3 Neovascularization in Age-Related Macular Degeneration. *Ophthalmology* 125, 276-287.
170. Li, M., Jia, C., Kazmierkiewicz, K.L., Bowman, A.S., Tian, L., Liu, Y., Gupta, N.A., Gudiseva, H.V., Yee, S.S., Kim, M., Dentchev, T., Kimble, J.A., Parker, J.S., Messinger, J.D., Hakonarson, H., Curcio, C.A., Stambolian, D., 2014. Comprehensive analysis of gene expression in human retina and supporting tissues. *Human molecular genetics* 23, 4001-4014.
171. Loeffler, K.U., Lee, W.R., 1998. Terminology of sub-RPE deposits: do we all speak the same language? *The British journal of ophthalmology* 82, 1104-1105.
172. Lutty, G.A., Hasegawa, T., Baba, T., Grebe, R., Bhutto, I., McLeod, D.S., 2010. Development of the human choriocapillaris. *Eye (Lond)* 24, 408-415.
173. Machalinska, A., Safranow, K., Dziedziejko, V., Mozolewska-Piotrowska, K., Paczkowska, E., Klos, P., Pius, E., Grymula, K., Wiszniewska, B., Karczewicz, D., Machalinski, B., 2011. Different populations of circulating endothelial cells in patients with age-related macular degeneration: a novel insight into pathogenesis. *Investigative ophthalmology & visual science* 52, 93-100.
174. Mahley, R.W., 2016. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. *J Mol Med (Berl)* 94, 739-746.
175. Malek, G., Li, C.M., Guidry, C., Medeiros, N.E., Curcio, C.A., 2003. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. *Am J Pathol* 162, 413-425.
176. Maltzman, B.A., Mulvihill, M.N., Greenbaum, A., 1979. Senile macular degeneration and risk factors: a case-control study. *Ann Ophthalmol* 11, 1197-1201.
177. Mancini, M.A., Frank, R.N., Keirn, R.J., Kennedy, A., Khoury, J.K., 1986. Does the retinal pigment epithelium polarize the choriocapillaris? *Investigative ophthalmology & visual science* 27, 336-345.
178. Marshall, G.E., Konstas, A.G., Reid, G.G., Edwards, J.G., Lee, W.R., 1992. Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula. *The British journal of ophthalmology* 76, 607-614.
179. McLeod, D.S., Grebe, R., Bhutto, I., Merges, C., Baba, T., Lutty, G.A., 2009. Relationship between RPE and choriocapillaris in age-related macular degeneration. *Investigative ophthalmology & visual science* 50, 4982-4991.
180. Miteva, K., Madonna, R., De Caterina, R., Van Linthout, S., 2018. Innate and adaptive immunity in atherosclerosis. *Vascul Pharmacol*.
181. Molins, B., Romero-Vazquez, S., Fuentes-Prior, P., Adan, A., Dick, A.D., 2018. C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. *Front Immunol* 9, 808.
182. Moore, D.J., Clover, G.M., 2001. The effect of age on the macromolecular permeability of human Bruch's membrane. *Investigative ophthalmology & visual science* 42, 2970-2975.
183. Moore, D.J., Hussain, A.A., Marshall, J., 1995. Age-related variation in the hydraulic conductivity of Bruch's membrane. *Investigative ophthalmology & visual science* 36, 1290-1297.
184. Moreira-Neto, C.A., Moul, E.M., Fujimoto, J.G., Waheed, N.K., Ferrara, D., 2018. Choriocapillaris Loss in Advanced Age-Related Macular Degeneration. *J Ophthalmol* 2018, 8125267.

2113 185. Mullins, R.F., Johnson, M.N., Faidley, E.A., Skeie, J.M., Huang, J., 2011. Choriocapillaris vascular  
2114 dropout related to density of drusen in human eyes with early age-related macular degeneration.  
2115 *Investigative ophthalmology & visual science* 52, 1606-1612.

2116 186. Mullins, R.F., Russell, S.R., Anderson, D.H., Hageman, G.S., 2000. Drusen associated with aging  
2117 and age-related macular degeneration contain proteins common to extracellular deposits associated  
2118 with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB journal : official  
2119 publication of the Federation of American Societies for Experimental Biology* 14, 835-846.

2120 187. Mullins, R.F., Schoo, D.P., Sohn, E.H., Flamme-Wiese, M.J., Workamela, G., Johnston, R.M.,  
2121 Wang, K., Tucker, B.A., Stone, E.M., 2014. The membrane attack complex in aging human  
2122 choriocapillaris: relationship to macular degeneration and choroidal thinning. *Am J Pathol* 184, 3142-  
2123 3153.

2124 188. Mungrue, I.N., Zhao, P., Yao, Y., Meng, H., Rau, C., Havel, J.V., Gorgels, T.G., Bergen, A.A.,  
2125 MacLellan, W.R., Drake, T.A., Bostrom, K.I., Lusi, A.J., 2011. Abcc6 deficiency causes increased infarct  
2126 size and apoptosis in a mouse cardiac ischemia-reperfusion model. *Arterioscler Thromb Vasc Biol* 31,  
2127 2806-2812.

2128 189. Musser, J.M., Arendt, D., 2017. Loss and gain of cone types in vertebrate ciliary photoreceptor  
2129 evolution. *Dev Biol* 431, 26-35.

2130 190. Nakanishi, M., Grebe, R., Bhutto, I.A., Edwards, M., McLeod, D.S., Luty, G.A., 2016. Albumen  
2131 Transport to Bruch's Membrane and RPE by Choriocapillaris Caveolae. *Investigative ophthalmology &  
2132 visual science* 57, 2213-2224.

2133 191. Nakata, K., Crabb, J.W., Hollyfield, J.G., 2005. Crystallin distribution in Bruch's membrane-  
2134 choroid complex from AMD and age-matched donor eyes. *Exp Eye Res* 80, 821-826.

2135 192. Nan, R., Farabella, I., Schumacher, F.F., Miller, A., Gor, J., Martin, A.C., Jones, D.T., Lengyel, I.,  
2136 Perkins, S.J., 2011. Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible  
2137 implications for age-related macular degeneration. *J Mol Biol* 408, 714-735.

2138 193. Nan, R., Gor, J., Lengyel, I., Perkins, S.J., 2008. Uncontrolled zinc- and copper-induced  
2139 oligomerisation of the human complement regulator factor H and its possible implications for  
2140 function and disease. *J Mol Biol* 384, 1341-1352.

2141 194. Nan, R., Tetchner, S., Rodriguez, E., Pao, P.J., Gor, J., Lengyel, I., Perkins, S.J., 2013. Zinc-induced  
2142 self-association of complement C3b and Factor H: implications for inflammation and age-related  
2143 macular degeneration. *J Biol Chem* 288, 19197-19210.

2144 195. Narumi, K., Miyakawa, R., Ueda, R., Hashimoto, H., Yamamoto, Y., Yoshida, T., Aoki, K., 2015.  
2145 Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE. *J Immunol*  
2146 194, 5539-5548.

2147 196. Newsome, D.A., Hewitt, A.T., Huh, W., Robey, P.G., Hassell, J.R., 1987. Detection of specific  
2148 extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body. *Am J Ophthalmol* 104,  
2149 373-381.

2150 197. Nijholt, D.A., Ijsselstijn, L., van der Weiden, M.M., Zheng, P.P., Sillevs Smitt, P.A., Koudstaal, P.J.,  
2151 Luiders, T.M., Kros, J.M., 2015. Pregnancy Zone Protein is Increased in the Alzheimer's Disease Brain  
2152 and Associates with Senile Plaques. *J Alzheimers Dis* 46, 227-238.

2153 198. Nordgaard, C.L., Berg, K.M., Kapphahn, R.J., Reilly, C., Feng, X., Olsen, T.W., Ferrington, D.A.,  
2154 2006. Proteomics of the retinal pigment epithelium reveals altered protein expression at progressive  
2155 stages of age-related macular degeneration. *Investigative ophthalmology & visual science* 47, 815-  
2156 822.

2157 199. Novais, E.A., Badaro, E., Regatieri, C.V., Duker, J., de Oliveira Bonomo, P.P., 2015. Regression of  
2158 drusen after combined treatment using photodynamic therapy with verteporfin and ranibizumab.  
2159 *Ophthalmic Surg Lasers Imaging Retina* 46, 275-278.

2160 200. Okuno, S., Ishimura, E., Kitatani, K., Fujino, Y., Kohno, K., Maeno, Y., Maekawa, K., Yamakawa, T.,  
2161 Imanishi, Y., Inaba, M., Nishizawa, Y., 2007. Presence of abdominal aortic calcification is significantly  
2162 associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. *Am J  
2163 Kidney Dis* 49, 417-425.

2164 201. Oshikawa, M., Tsutsui, C., Ikegami, T., Fuchida, Y., Matsubara, M., Toyama, S., Usami, R.,  
2165 Ohtoko, K., Kato, S., 2011. Full-length transcriptome analysis of human retina-derived cell lines ARPE-  
2166 19 and Y79 using the vector-capping method. *Investigative ophthalmology & visual science* 52, 6662-  
2167 6670.

2168 202. Pao, P.J., Emri, E., Abdirahman, S.B., Soorma, T., Zeng, H.H., Hauck, S.M., Thompson, R.B.,  
2169 Lengyel, I., 2018. The effects of zinc supplementation on primary human retinal pigment epithelium.  
2170 *J Trace Elem Med Biol* 49, 184-191.

2171 203. Pauleikhoff, D., Chen, J.C., Chisholm, I.H., Bird, A.C., 1990. Choroidal perfusion abnormality with  
2172 age-related Bruch's membrane change. *Am J Ophthalmol* 109, 211-217.

2173 204. Pelisek, J., Wendorff, H., Wendorff, C., Kuehn, A., Eckstein, H.H., 2016. Age-associated changes  
2174 in human carotid atherosclerotic plaques. *Ann Med* 48, 541-551.

2175 205. Penfold, P.L., Madigan, M.C., Gillies, M.C., Provis, J.M., 2001. Immunological and aetiological  
2176 aspects of macular degeneration. *Prog Retin Eye Res* 20, 385-414.

2177 206. Pikuleva, I.A., Curcio, C.A., 2014. Cholesterol in the retina: the best is yet to come. *Prog Retin*  
2178 *Eye Res* 41, 64-89.

2179 207. Pilgrim, M.G., Lengyel, I., Lanzirotti, A., Newville, M., Fearn, S., Emri, E., Knowles, J.C., Messinger,  
2180 J.D., Read, R.W., Guidry, C., Curcio, C.A., 2017. Subretinal Pigment Epithelial Deposition of Drusen  
2181 Components Including Hydroxyapatite in a Primary Cell Culture Model. *Investigative ophthalmology*  
2182 *& visual science* 58, 708-719.

2183 208. Pino, R.M., 1985. Restriction to endogenous plasma proteins by a fenestrated capillary  
2184 endothelium: an ultrastructural immunocytochemical study of the choriocapillary endothelium. *Am J*  
2185 *Anat* 172, 279-289.

2186 209. Pino, R.M., Essner, E., 1981. Permeability of rat choriocapillaris to hemeproteins. Restriction of  
2187 tracers by a fenestrated endothelium. *J Histochem Cytochem* 29, 281-290.

2188 210. Pinto, E., 2007. Blood pressure and ageing. *Postgrad Med J* 83, 109-114.

2189 211. Radu, R.A., Hu, J., Jiang, Z., Bok, D., 2014. Bisretinoid-mediated complement activation on retinal  
2190 pigment epithelial cells is dependent on complement factor H haplotype. *J Biol Chem* 289, 9113-  
2191 9120.

2192 212. Rakoczy, P.E., Sarks, S.H., Daw, N., Constable, I.J., 1999. Distribution of cathepsin D in human  
2193 eyes with or without age-related maculopathy. *Exp Eye Res* 69, 367-374.

2194 213. Ramrattan, R.S., van der Schaft, T.L., Mooy, C.M., de Bruijn, W.C., Mulder, P.G., de Jong, P.T.,  
2195 1994. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging.  
2196 *Investigative ophthalmology & visual science* 35, 2857-2864.

2197 214. Rayborn, M.E., Sakaguchi, H., Shadrach, K.G., Crabb, J.W., Hollyfield, J.G., 2006. Annexins in  
2198 Bruch's membrane and drusen. *Adv Exp Med Biol* 572, 75-78.

2199 215. Ronchetti, I., Boraldi, F., Annovi, G., Cianciulli, P., Quagliano, D., 2013. Fibroblast involvement in  
2200 soft connective tissue calcification. *Front Genet* 4, 22.

2201 216. Ruiz, A., Brett, P., Bok, D., 1996. TIMP-3 is expressed in the human retinal pigment epithelium.  
2202 *Biochemical and biophysical research communications* 226, 467-474.

2203 217. Sakaguchi, H., Miyagi, M., Shadrach, K.G., Rayborn, M.E., Crabb, J.W., Hollyfield, J.G., 2002.  
2204 Clusterin is present in drusen in age-related macular degeneration. *Exp Eye Res* 74, 547-549.

2205 218. Sallo, F.B., Rechtman, E., Peto, T., Stanescu-Segall, D., Vogt, G., Bird, A.C., Fitzke, F.W., 2009.  
2206 Functional aspects of drusen regression in age-related macular degeneration. *The British journal of*  
2207 *ophthalmology* 93, 1345-1350.

2208 219. Sarks, J.P., Sarks, S.H., Killingsworth, M.C., 1988. Evolution of geographic atrophy of the retinal  
2209 pigment epithelium. *Eye (Lond)* 2 ( Pt 5), 552-577.

2210 220. Sarks, J.P., Sarks, S.H., Killingsworth, M.C., 1994. Evolution of soft drusen in age-related macular  
2211 degeneration. *Eye (Lond)* 8 ( Pt 3), 269-283.

2212 221. Sarks, S.H., 1976. Ageing and degeneration in the macular region: a clinico-pathological study.  
2213 *The British journal of ophthalmology* 60, 324-341.

2214 222. Sarks, S.H., Arnold, J.J., Killingsworth, M.C., Sarks, J.P., 1999. Early drusen formation in the  
2215 normal and aging eye and their relation to age related maculopathy: a clinicopathological study. *The*  
2216 *British journal of ophthalmology* 83, 358-368.

2217 223. Sarks, S.H., Van Driel, D., Maxwell, L., Killingsworth, M., 1980. Softening of drusen and subretinal  
2218 neovascularization. *Trans Ophthalmol Soc U K* 100, 414-422.

2219 224. Schaumberg, D.A., Christen, W.G., Buring, J.E., Glynn, R.J., Rifai, N., Ridker, P.M., 2007. High-  
2220 sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular  
2221 degeneration in women. *Arch Ophthalmol* 125, 300-305.

2222 225. Schlanitz, F., Baumann, B., Sacu, S., Baumann, L., Pircher, M., Hitzenberger, C.K., Schmidt-  
2223 Erfurth, U.M., 2018. Impact of drusen and drusenoid retinal pigment epithelium elevation size and  
2224 structure on the integrity of the retinal pigment epithelium layer. *The British journal of*  
2225 *ophthalmology*.

2226 226. Schlieper, G., Aretz, A., Verberckmoes, S.C., Kruger, T., Behets, G.J., Ghadimi, R., Weirich, T.E.,  
2227 Rohrmann, D., Langer, S., Tordoir, J.H., Amann, K., Westenfeld, R., Brandenburg, V.M., D'Haese, P.C.,  
2228 Mayer, J., Ketteler, M., McKee, M.D., Floege, J., 2010. Ultrastructural analysis of vascular  
2229 calcifications in uremia. *J Am Soc Nephrol* 21, 689-696.

2230 227. Schunkert, H., von Scheidt, M., Kessler, T., Stiller, B., Zeng, L., Vilne, B., 2018. Genetics of  
2231 coronary artery disease in the light of genome-wide association studies. *Clin Res Cardiol* 107, 2-9.

2232 228. Serban, C., Dragan, S., 2014. The relationship between inflammatory and oxidative stress  
2233 biomarkers, atherosclerosis and rheumatic diseases. *Curr Pharm Des* 20, 585-600.

2234 229. Serhan, C.N., Dalli, J., Colas, R.A., Winkler, J.W., Chiang, N., 2015. Protectins and maresins: New  
2235 pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome.  
2236 *Biochim Biophys Acta* 1851, 397-413.

2237 230. Shah, F.A., Lee, B.E.J., Tedesco, J., Larsson Wexell, C., Persson, C., Thomsen, P., Grandfield, K.,  
2238 Palmquist, A., 2017. Micrometer-Sized Magnesium Whitlockite Crystals in Micropetrosis of  
2239 Bisphosphonate-Exposed Human Alveolar Bone. *Nano Lett* 17, 6210-6216.

2240 231. Simmons, R.D., Kumar, S., Thabet, S.R., Sur, S., Jo, H., 2016. Omics-based approaches to  
2241 understand mechanosensitive endothelial biology and atherosclerosis. *Wiley Interdiscip Rev Syst Biol*  
2242 *Med* 8, 378-401.

2243 232. Sivaprasad, S., Bailey, T.A., Chong, V.N., 2005. Bruch's membrane and the vascular intima: is  
2244 there a common basis for age-related changes and disease? *Clin Exp Ophthalmol* 33, 518-523.

2245 233. Skeie, J.M., Mahajan, V.B., 2014. Proteomic landscape of the human choroid-retinal pigment  
2246 epithelial complex. *JAMA Ophthalmol* 132, 1271-1281.

2247 234. Smith, S.S., Pino, R.M., Thouron, C.L., 1989. Binding and transport of transthyretin-gold by the  
2248 endothelium of the rat choriocapillaris. *J Histochem Cytochem* 37, 1497-1502.

2249 235. Snow, K.K., Seddon, J.M., 1999. Do age-related macular degeneration and cardiovascular disease  
2250 share common antecedents? *Ophthalmic Epidemiol* 6, 125-143.

2251 236. Sohn, E.H., Wang, K., Thompson, S., Riker, M.J., Hoffmann, J.M., Stone, E.M., Mullins, R.F., 2015.  
2252 Comparison of drusen and modifying genes in autosomal dominant radial drusen and age-related  
2253 macular degeneration. *Retina* 35, 48-57.

2254 237. Song, Y., Stampfer, M.J., Liu, S., 2004. Meta-analysis: apolipoprotein E genotypes and risk for  
2255 coronary heart disease. *Ann Intern Med* 141, 137-147.

2256 238. Spaide, R.F., Ooto, S., Curcio, C.A., 2018. Subretinal Drusenoid Deposits AKA Pseudodrusen. *Surv*  
2257 *Ophthalmol*.

2258 239. Spraul, C.W., Lang, G.E., Grossniklaus, H.E., Lang, G.K., 1999. Histologic and morphometric  
2259 analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with  
2260 age-related macular degeneration and histologic examination of surgically excised choroidal  
2261 neovascular membranes. *Surv Ophthalmol* 44 Suppl 1, S10-32.

2262 240. Starita, C., Hussain, A.A., Patmore, A., Marshall, J., 1997. Localization of the site of major  
2263 resistance to fluid transport in Bruch's membrane. *Investigative ophthalmology & visual science* 38,  
2264 762-767.

2265 241. Stefansson, E., Geirsdottir, A., Sigurdsson, H., 2011. Metabolic physiology in age related macular  
2266 degeneration. *Prog Retin Eye Res* 30, 72-80.

2267 242. Strauss, O., 2005. The retinal pigment epithelium in visual function. *Physiol Rev* 85, 845-881.

2268 243. Strunnikova, N.V., Maminishkis, A., Barb, J.J., Wang, F., Zhi, C., Sergeev, Y., Chen, W., Edwards,  
2269 A.O., Stambolian, D., Abecasis, G., Swaroop, A., Munson, P.J., Miller, S.S., 2010. Transcriptome  
2270 analysis and molecular signature of human retinal pigment epithelium. *Human molecular genetics*  
2271 19, 2468-2486.

2272 244. Suzuki, M., Curcio, C.A., Mullins, R.F., Spaide, R.F., 2015. REFRACTILE DRUSEN: Clinical Imaging  
2273 and Candidate Histology. *Retina* 35, 859-865.

2274 245. Tabas, I., Williams, K.J., Boren, J., 2007. Subendothelial lipoprotein retention as the initiating  
2275 process in atherosclerosis: update and therapeutic implications. *Circulation* 116, 1832-1844.

2276 246. Tas, A.C., 2000. Synthesis of biomimetic Ca-hydroxyapatite powders at 37 degrees C in synthetic  
2277 body fluids. *Biomaterials* 21, 1429-1438.

2278 247. Tate, D.J., Jr., Oliver, P.D., Miceli, M.V., Stern, R., Shuster, S., Newsome, D.A., 1993. Age-  
2279 dependent change in the hyaluronic acid content of the human chorioretinal complex. *Arch*  
2280 *Ophthalmol* 111, 963-967.

2281 248. Templeton, J.P., Wang, X., Freeman, N.E., Ma, Z., Lu, A., Hejtmancik, F., Geisert, E.E., 2013. A  
2282 crystallin gene network in the mouse retina. *Exp Eye Res* 116, 129-140.

2283 249. Tessarz, P., Kouzarides, T., 2014. Histone core modifications regulating nucleosome structure  
2284 and dynamics. *Nat Rev Mol Cell Biol* 15, 703-708.

2285 250. Thanos, S., Bohm, M.R., Meyer zu Horste, M., Prokosch-Willing, V., Hennig, M., Bauer, D.,  
2286 Heiligenhaus, A., 2014. Role of crystallins in ocular neuroprotection and axonal regeneration. *Prog*  
2287 *Retin Eye Res* 42, 145-161.

2288 251. The Eye Disease Case-Control Study, C., 1992. Risk factors for neovascular age-related macular  
2289 degeneration. *Arch Ophthalmol* 110, 1701-1708.

2290 252. Thompson, R.B., Reffatto, V., Bundy, J.G., Kortvely, E., Flinn, J.M., Lanzirotti, A., Jones, E.A.,  
2291 McPhail, D.S., Fearn, S., Boldt, K., Ueffing, M., Ratu, S.G., Pauleikhoff, L., Bird, A.C., Lengyel, I., 2015.  
2292 Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial  
2293 deposit formation in the aging eye. *Proc Natl Acad Sci U S A* 112, 1565-1570.

2294 253. Tian, L., Kazmierkiewicz, K.L., Bowman, A.S., Li, M., Curcio, C.A., Stambolian, D.E., 2015.  
2295 Transcriptome of the human retina, retinal pigmented epithelium and choroid. *Genomics* 105, 253-  
2296 264.

2297 254. Tikellis, G., Sun, C., Gorin, M.B., Klein, R., Klein, B.E., Larsen, E.K., Siscovick, D.S., Hubbard, L.D.,  
2298 Wong, T.Y., 2007. Apolipoprotein e gene and age-related maculopathy in older individuals: the  
2299 cardiovascular health study. *Arch Ophthalmol* 125, 68-73.

2300 255. Tohyama, J., Nakashima, M., Nabatame, S., Gaik-Siew, C., Miyata, R., Rener-Primec, Z., Kato, M.,  
2301 Matsumoto, N., Saitsu, H., 2015. SPTAN1 encephalopathy: distinct phenotypes and genotypes. *J Hum*  
2302 *Genet* 60, 167-173.

2303 256. Toomey, C.B., Johnson, L.V., Bowes Rickman, C., 2018. Complement factor H in AMD: Bridging  
2304 genetic associations and pathobiology. *Prog Retin Eye Res* 62, 38-57.

2305 257. Toops, K.A., Tan, L.X., Lakkaraju, A., 2016. Apolipoprotein E Isoforms and AMD. *Adv Exp Med*  
2306 *Biol* 854, 3-9.

2307 258. Toy, B.C., Krishnadev, N., Indaram, M., Cunningham, D., Cukras, C.A., Chew, E.Y., Wong, W.T.,  
2308 2013. Drusen regression is associated with local changes in fundus autofluorescence in intermediate  
2309 age-related macular degeneration. *Am J Ophthalmol* 156, 532-542.e531.

2310 259. Tu, H., Okamoto, A.Y., Shan, B., 2000. FXR, a bile acid receptor and biological sensor. *Trends*  
2311 *Cardiovasc Med* 10, 30-35.

2312 260. Ulshafer, R.J., Allen, C.B., Nicolaissen, B., Jr., Rubin, M.L., 1987. Scanning electron microscopy of  
2313 human drusen. *Investigative ophthalmology & visual science* 28, 683-689.

2314 261. van der Schaft, T.L., de Bruijn, W.C., Mooy, C.M., Ketelaars, D.A., de Jong, P.T., 1992. Element  
2315 analysis of the early stages of age-related macular degeneration. *Arch Ophthalmol* 110, 389-394.

262. van der Schaft, T.L., Mooy, C.M., de Bruijn, W.C., de Jong, P.T., 1993. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. *The British journal of ophthalmology* 77, 657-661.
263. van Leeuwen, E.M., Emri, E., Merle, B.M.J., Colijn, J.M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F.M., de Jong, E.K., Delcourt, C., Rodriguez-Bocanegra, E., Biarnes, M., Luthert, P.J., Ueffing, M., Klaver, C.C.W., Nogoceke, E., den Hollander, A.I., Lengyel, I., 2018. A new perspective on lipid research in age-related macular degeneration. *Prog Retin Eye Res.*
264. Verhoeff, F.H., Grossman, H.P., 1937. The Pathogenesis of Disciform Degeneration of the Macula. *Trans Am Ophthalmol Soc* 35, 262-294.
265. Vidaurri, J.S., Pe'er, J., Halfon, S.T., Halperin, G., Zauberman, H., 1984. Association between drusen and some of the risk factors for coronary artery disease. *Ophthalmologica* 188, 243-247.
266. Vingerling, J.R., Dielemans, I., Bots, M.L., Hofman, A., Grobbee, D.E., de Jong, P.T., 1995. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. *Am J Epidemiol* 142, 404-409.
267. Wakatsuki, Y., Shinojima, A., Kawamura, A., Yuzawa, M., 2015. Correlation of Aging and Segmental Choroidal Thickness Measurement using Swept Source Optical Coherence Tomography in Healthy Eyes. *PLoS One* 10, e0144156.
268. Wang, J., Gu, B.J., Masters, C.L., Wang, Y.J., 2017. A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain. *Nat Rev Neurol* 13, 612-623.
269. Wang, L., Clark, M.E., Crossman, D.K., Kojima, K., Messinger, J.D., Mobley, J.A., Curcio, C.A., 2010. Abundant lipid and protein components of drusen. *PLoS One* 5, e10329.
270. Warwick, A., Khandhadia, S., Ennis, S., Lotery, A., 2014. Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation? *J Clin Med* 3, 1234-1257.
271. Wasmuth, S., Lueck, K., Baehler, H., Lommatzsch, A., Pauleikhoff, D., 2009. Increased vitronectin production by complement-stimulated human retinal pigment epithelial cells. *Investigative ophthalmology & visual science* 50, 5304-5309.
272. Weber, B.H., Vogt, G., Pruett, R.C., Stohr, H., Felbor, U., 1994. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. *Nature genetics* 8, 352-356.
273. Whitmore, S.S., Wagner, A.H., DeLuca, A.P., Drack, A.V., Stone, E.M., Tucker, B.A., Zeng, S., Braun, T.A., Mullins, R.F., Scheetz, T.E., 2014. Transcriptomic analysis across nasal, temporal, and macular regions of human neural retina and RPE/choroid by RNA-Seq. *Exp Eye Res* 129, 93-106.
274. Williams, K.J., Tabas, I., 1995. The response-to-retention hypothesis of early atherogenesis. *Arterioscler Thromb Vasc Biol* 15, 551-561.
275. Wilson, C.J., Das, M., Jayaraman, S., Gursky, O., Engen, J.R., 2018. Effects of Disease-Causing Mutations on the Conformation of Human Apolipoprotein A-I in Model Lipoproteins. *Biochemistry.*
276. Wilson, M.R., Zoubeidi, A., 2017. Clusterin as a therapeutic target. *Expert Opin Ther Targets* 21, 201-213.
277. Woodell, A., Rohrer, B., 2014. A mechanistic review of cigarette smoke and age-related macular degeneration. *Adv Exp Med Biol* 801, 301-307.
278. Xu, H., Chen, M., Forrester, J.V., 2009. Para-inflammation in the aging retina. *Prog Retin Eye Res* 28, 348-368.
279. Xu, Q., Cao, S., Rajapakse, S., Matsubara, J.A., 2018. Understanding AMD by analogy: systematic review of lipid-related common pathogenic mechanisms in AMD, AD, AS and GN. *Lipids Health Dis* 17, 3.
280. Yang, J., Xu, Z., Sui, M., Han, J., Sun, L., Jia, X., Zhang, H., Han, C., Jin, X., Gao, F., Liu, Y., Li, Y., Cao, J., Ling, H., Zhang, F., Ren, H., 2015. Co-Positivity for Anti-dsDNA, -Nucleosome and -Histone Antibodies in Lupus Nephritis Is Indicative of High Serum Levels and Severe Nephropathy. *PLoS One* 10, e0140441.
281. Yehoshua, Z., Wang, F., Rosenfeld, P.J., Penha, F.M., Feuer, W.J., Gregori, G., 2011. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. *Ophthalmology* 118, 2434-2441.

2368 282. Young, R.W., 1987. Pathophysiology of age-related macular degeneration. *Surv Ophthalmol* 31,  
2369 291-306.

2370 283. Yuan, X., Gu, X., Crabb, J.S., Yue, X., Shadrach, K., Hollyfield, J.G., Crabb, J.W., 2010. Quantitative  
2371 proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular  
2372 degeneration and normal eyes. *Mol Cell Proteomics* 9, 1031-1046.

2373 284. Zamiri, P., Masli, S., Streilein, J.W., Taylor, A.W., 2006. Pigment epithelial growth factor  
2374 suppresses inflammation by modulating macrophage activation. *Investigative ophthalmology & visual  
2375 science* 47, 3912-3918.

2376 285. Zhang, J.J., Sun, Y., Hussain, A.A., Marshall, J., 2012. Laser-mediated activation of human retinal  
2377 pigment epithelial cells and concomitant release of matrix metalloproteinases. *Investigative  
2378 ophthalmology & visual science* 53, 2928-2937.

2379 286. Zhang, P., Dufresne, C., Turner, R., Ferri, S., Venkatraman, V., Karani, R., Lutty, G.A., Van Eyk, J.E.,  
2380 Semba, R.D., 2015a. The proteome of human retina. *Proteomics* 15, 836-840.

2381 287. Zhang, P., Kirby, D., Dufresne, C., Chen, Y., Turner, R., Ferri, S., Edward, D.P., Van Eyk, J.E.,  
2382 Semba, R.D., 2016. Defining the proteome of human iris, ciliary body, retinal pigment epithelium, and  
2383 choroid. *Proteomics* 16, 1146-1153.

2384 288. Zhang, Y., Wen, Z., Guan, L., Jiang, P., Gu, T., Zhao, J., Lv, X., Wen, T., 2015b. Extracellular  
2385 histones play an inflammatory role in acid aspiration-induced acute respiratory distress syndrome.  
2386 *Anesthesiology* 122, 127-139.

2387 289. Zhang, Z., Chen, X.Y., Baum, L., Ng, H.K., Mok, V., Wong, K.S., 2018. Association Between the  
2388 Apolipoprotein E Gene Polymorphism and Atherosclerotic Middle Cerebral Artery Stenosis.  
2389 *Neurologist* 23, 47-50.

2390 290. Zheng, W., Mast, N., Saadane, A., Pikuleva, I.A., 2015. Pathways of cholesterol homeostasis in  
2391 mouse retina responsive to dietary and pharmacologic treatments. *J Lipid Res* 56, 81-97.

2392 291. Zweifel, S.A., Spaide, R.F., Curcio, C.A., Malek, G., Imamura, Y., 2010. Reticular pseudodrusen are  
2393 subretinal drusenoid deposits. *Ophthalmology* 117, 303-312.e301.

2394

## **Legends to Figures and (S)Tables.**

### **Figure legends:**

Figure 1. Heterogeneity of drusen. Imaging of drusen and drusen content with various clinical and laboratory methods. On color fundus images, the yellow spots identify drusen (A). On OCT image the elongated RPE is reflective. Drusen appear as homogeneous and hyper-reflective sub-RPE-BL space focal entities. (B); scale bar: 500  $\mu$ m. On hematoxylin-eosin staining, drusen appears between the brown pigments of the RPE and the Bruch's membrane (C); scale bar: 10  $\mu$ m. Note the inclusions without staining. Drusen contain numerous von Kossa positive spherule structures identifying hydroxyapatite spherules (D); scale bar: 10  $\mu$ m. Auto-fluorescence of the more or less circular drusen is indicative of the protein and lipid accumulation. Auto-fluorescence of the RPE is more intense and yellowish. Auto-fluorescence of the BrM adjacent to the RPE is greenish (E); scale bar: 10  $\mu$ m.

Figure 2 a-d. Functional molecular network analysis (4 networks). For all four networks: Molecular network analysis of physical or functional interactions between 89 drusen genes/proteins using Ingenuity. The knowledge database generated four most likely functional networks from the given input (drusen proteins). The functionalities in the figures are generated based on a combination of available molecular and cellular experimental data in human, mouse, rat, and in vitro data. In each network the circles, squares and other symbols represent proteins from a homologue from either human, rat or mouse. The systematic name of the gene/protein is printed on each symbol. Double circles in a single symbol denotes a group or /family of entries with a specific function and are sometimes introduced by the knowledge database to make networks possible or to simplify them. Solid lines represent strong physical or functional interaction between the entries, taken from published peer reviewed literature and/or transcriptomics and proteomics databases. Dotted lines represent weaker, associated relationships between the genes/proteins based on published peer reviewed experimental data (for example co-upregulation of expression in an in vitro experiment). The lines represent thus functionalities found in either, both, or all experiments on human, rat or mice (tissues) and in vitro findings. For example, the functional relationship between molecules A, B, C, could possibly be defined as follows A-functional mouse finding-B-functional human



finding-C. The underlying hypothesis is that the functionalities in human, mouse and rat are very similar. One can also generate networks of human (or rat or mice) functional data separately, but they are frequently quite similar, but less extensive.

In the first network (Figure 2a), clearly three functional clusters of closely related entries can be recognized: The complement cluster, the collagen cluster and the crystallin cluster. The second network (Figure 2b) is much more complicated and heterogeneous and is a network of genes and proteins related to development and genetic or ophthalmic disorders. The common theme of the third network (Figure 2c) is the immune response. Finally, the fourth and last network (Figure 2d) presents functional and structural relationships between entries involved in cell-cell interactions and systemic involvement.

Figure 3. Schematic overview of various strategies used for dataset curation. This figure shows several ways to curate (pre-existing) transcriptomics or proteomics datasets to form an improved, thorough or more specific dataset. For example, in (A) several datasets are merged into a cumulative new one by simply combining the datasets. The possible overlap is counted only once in the new merged database. One dataset was deleted, because it did not adhere to quality standard or had a different signature as the other ones. Strategy (B) has been published before (Booij et al., 2010b). In this case the original enriched RPE database contains 10% of the highest expressed genes in the cell. Some of the expressed genes in the RPE10% dataset overlap with the genes expressed in the adjacent tissues (photoreceptors and/or choroid). These “overlapping expressed genes” are therefore not specific of the RPE. Thus, to obtain a more specific (smaller) dataset, we discard of all the “overlapping expressed genes” in the RPE dataset, to obtain a highly enriched RPE dataset. Curation strategy C shows the breakdown of two datasets into desired subfamilies: The overlap between datasets X and Z is Y. Dataset Y can be used if overlap between X and Z is desired. Dataset X minus Y can be used to obtain unique entries from X (compared to set Z).

Figure 4. Scheme of the relationships between the respective transcriptomic and proteomic datasets used for quantitative studies. The curated drusen protein dataset represents 89 proteins known to be present in drusen/sub-RPE-BL space deposits (black box in the middle). These were compared with the entries present or produced

uniquely from the neural side of drusen (photoreceptor/RPE neural source), and with entries uniquely from the systemic side of drusen (blood /choroid basal source). The “neural source” and “systemic source” merged data-sets each consist of non-curated datasets and curated datasets. The non-curated (pure) dataset contain, by virtue of their nature or previous curation in the literature) only entries from, respectively, the neural (RPE-ST; RPE-IVS) and systemic side (BL-SP1; BL-SP2) of drusen. The curated datasets (cPROs; cPR-ET and cChor-ET)) contained, before curation, a number of entries expressed/present in both the neural and systemic side (see PROs; PR-ET and Chor-ET). Thus, we removed all overlapping expressed genes between the PROs; PR-ET and Chor-ET datasets, to obtain unique datasets from both sides of drusen.

Figure 5. Potential contribution of neural and systemically expressed/present proteins to drusen formation. Venn diagram showing overlap between (A) neural RPE and photoreceptor-derived proteins, (B) systemically derived choroid and blood proteins and (C) drusen-associated proteins.

Figure 6. Hydroxyapatite spherules can retain proteins originating from blood in the sub-RPE-BL space. (A) Immunocytochemical labelling of histidine-rich glycoprotein (HRG) using a specific anti-HRG primary antibody (green) on the surface of a HAP spherule labelled by LiCor680 (magenta); scale bar: 10  $\mu$ m. (B) Binding of purified human HRG to HAP-coated magnetic beads. Binding assays were performed using 0.3 mg beads per sample. HAP-beads were washed with 50 mM Tris, 140 mM NaCl, pH 7.4 and incubated with 400  $\mu$ l of 0-1 $\mu$ M human HRG for an hour at room temperature. The protein-bound beads were washed with the same buffer twice followed by blocking with 1% BSA for an hour. Rabbit anti-human HRG antibody (1:1000 dilution) and HRP-conjugated anti-rabbit antibody (1:10000 dilution) were respectively used as primary and secondary antibodies. Detection was done at 492 nm using o-phenylenediamine dihydrochloride (OPD, Sigma Aldrich) substrate.

Figure 7. A model for drusen formation. Top row (A-E) is adopted from the schematic diagram proposed for sub-RPE-BL space deposit formation by Thompson and colleagues (Thompson et al., 2015). (A) Healthy eyes show no sub-RPE-BL space deposit formation. (B) At Stage 1 lipid droplets are retained in the sub-RPE-BL space (black dot). (C) At

Stage 2 mineralization occurs surrounding the lipid droplets (magenta ring). (D) At Stage 3 proteins bind to the HAP surfaces (blue ring). (E) At Stage 4 proteins and lipids start accumulating around the “seed” (yellow material). The bottom row (A’-E’) shows morphological evidence for the prediction in the top row. (A’) Retinal pigment epithelium forms a monolayer along the inner collagenous layer of the Bruch’s membrane in healthy eyes (scanning electron microscopic image); scale bar: 10  $\mu$ m. (B’) Transmission electron micrograph of lipid droplets that accumulate in the sub-RPE-BL space; reproduced with permission from Curcio and Millican (Curcio and Millican, 1999); scale bar: 2  $\mu$ m. (C’) Scanning electron microscopic identification of a single spherule located between the RPE basement membrane and the inner collagenous layer of Bruch’s membrane; scale bar: 2  $\mu$ m. (D’) Immunofluorescent labelling of HRG (green) on the surface of a HAP spherule (magenta); scale bar: 2  $\mu$ m. (E’) An immunofluorescent labelling of complement factor H on a spherule surrounded by the autofluorescence of drusen (green) and RPE cells (yellow) (blue is DAPI staining the cell nuclei); scale bar: 10  $\mu$ m.

Figure 8. Schematic showing factors that are identified to contribute to mineralization of soft tissues and may contribute to HAP deposition in the sub-RPE-BL space.

Abbreviations: ABCC6, ATP binding cassette subfamily C member 6; ANKH, ankylosis protein homolog; ATP, adenosine triphosphate; BrMP2, bone morphogenetic protein-2; BrMP2R, bone morphogenetic protein-2 receptor; BSP, bone sialoprotein; Ca, calcium; Cbfa-1, core-binding factor alpha-1; ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase; Glu- and Gla-MGP, uncarboxylated- and carboxylated-matrix Gla protein; OPG, osteoprotegerin; OPN, osteopontin; Pi, inorganic phosphate; Pit-1, phosphate transporter-1; PPi, pyrophosphate; RANKL, receptor activator of nuclear factor kappa-B ligand; TNAP, tissue non-specific alkaline phosphatase. Figure adapted from (Ronchetti et al., 2013).

Figure 9. Proteins present in atherosclerotic plaques and drusen. A. Venn diagram showing 64 out of 89 drusen proteins overlap with the atherosclerotic plaque proteome, while 25 entries are unique to drusen in this comparison. B. Venn diagram showing 50 out of 60 proteins (from the 89 drusen proteins) that come from blood (as unique source or shared with the PR/RPE) are actually present in atherosclerotic plaques. C.

Venn diagram displaying the uniqueness and overlap of proteins between drusen (C.A), Alzheimer plaque proteins (C.B.) and atherosclerotic plaque proteins (C.C). The corresponding STable 11 and STable 11a present the corresponding entries in detail.

#### **Table Legends:**

Table 1. List of proteins present in the curated drusen dataset. We assembled a list of 89 drusen proteins, mostly derived from the macular area, from the literature. For each entry the Gene symbol, Entrez gene name, location and type, human immunohistochemistry source and literature references are provided based on information found via the Ingenuity knowledge database (Qiagen, all rights reserved), relevant literature (PubMed searches) and other public databases, such as Genecard ([www.genecard.org](http://www.genecard.org)) and DAVID (<https://david.ncifcrf.gov/>) Crabb 2002 (Crabb et al., 2002); Wang 2002 (Wang et al., 2010); Entries with \*: although assigned to drusen by proteomics, IHC studies suggest a more likely protein location around or directly external from drusen. Further detailed investigation is warranted for these entries. \*\*First detected in cynomolgus monkeys, afterwards in human drusen.

Table 2. Summary of Ingenuity knowledge database core analysis of 89 proteins present in the curated drusen protein dataset. Summary of enriched motifs present in the dataset presented as top disease and biological functions, canonical pathways and discrete molecular networks. Note that these functional annotations types relate to either cellular (LRX/RXR/FXR activation; macrophages) or systemic (acute phase, atherosclerosis) entities. In the top disease and biological functions, we see that the dataset is enriched for hereditary disorders, ophthalmic disease, injury, metabolic diseases and developmental disorders. Finally, in the top functional or structural molecular networks, we find combinations of very basic functions (cancer and cellular) to more specific pathobiological ones (ophthalmic and neurological disease etc.

Table 3. Summary of datasets used in this study and their respective functional clusters. Table displaying various datasets used in this study, along with their characteristics. In the first column, the result of the Ingenuity network analysis of drusen proteins is given in 4 significant molecular networks (N=1-4) corresponding to the networks shown in

Figure 2a-2d. Within these networks, six functional molecule clusters can be observed. For example, Network 1 (N1) contains 3 functional clusters: the complement (Network 1. cluster 1), the collagen (1.2) and the crystallines (heatshock) (1.3). Network 2 consist of 1 large cluster (2.4) being genetic and developmental ophthalmic disorders. Network 3 can be viewed as a cluster (# 5) of injury and inflammatory response and dermatological disease. Network 4 (N4) contains a cluster (4.6) of cell-to cell-signaling and systemic involvement. Column B gives the actual gene/protein names in these clusters. Column C states the overall functional annotation of these clusters. The first row of the Table from column D onward states the compartment of the datasets to be compared with drusen proteins in the functional clusters (within brackets, the number of entire in each dataset are given). In row 2 (acronym) from column D onward, the short and systematic acronym of each dataset is given. Row 3 (reference) contains from column D onward, the reference where the dataset can be found. Row 4 (methodology), from column D onward, contains the method by which the data were generated (transcriptomics, proteomics). Row five (source), from column D onward, contains the primary author who submitted the data or who can be contacted to obtain further information. The remaining boxes contains information which entries of the functional cluster are present both in drusen as well as in the transcriptomics or proteomics dataset(s). Combined analysis of the clusters in different datasets gives a qualitative idea from which cell type(s) drusen protein are derived.

Table 4. Summary of Ingenuity knowledge database core analysis of the curated photoreceptor gene expression (cPR-ET) dataset. Functional annotation of the curated and highly enriched photoreceptor cPR-ET database using the ingenuity knowledge database. The data driven top canonical pathways are highly relevant for photoreceptor function: Phototransduction pathway, glutamate receptor signaling, cholesterol biosynthesis and Wnt/Ca<sup>2+</sup> signaling. The only surprise in our data-driven analysis could be the Huntington disease signaling pathway. However, it has recently become clear that in Huntington's disease (HD), an inherited neurodegenerative disorder resulting in motor disturbances, cognitive and behavioral changes, deficits in retinal and visual processing function are significantly present (Coppen et al., 2018). Although we curated the PR database quite extensively, and thus selected for specific photoreceptor molecular signature and function, it is interesting to see that these motifs occur also in a

number of other (top) diseases and functions, such as cancer, organismal injury, gastrointestinal disease, Hepatic disease and reproductive system disease. This may reflect the accumulating evidence that a substantial number of genetic or metabolic disease are also affect photoreceptor function. Similar to the canonical pathways and the biological motifs, the functional annotation of the photoreceptor selected molecular machinery apparently reflects a broad spectrum of biological and disease processes.

Table 5. Summary of Ingenuity knowledge database core analysis of the curated choroid, cChor-ET datasets. In this Table, we present the summary of the functional annotation of the choroid. Of course, the choroid is not a single tissue, but contains multiple cell types (endothelial cells, fibroblasts, macrophages, etc.) and the sample is inevitably contaminated with the blood. Within these limitations, data driven analysis of this specifically curated data set yielded a number of interesting enriched motifs, which indeed can be contributed to the choroid or blood: The canonical pathways indicate enriched immunological themes, such as the complement system, acute phase response signaling, and antigen-presenting cells, which is confirmed by several biological motifs (inflammatory disease and response, injury). Further, the canonical pathways generated, suggest an overlap between the molecular machinery of the choroid and atherosclerosis signaling. Indeed, in this manuscript, we devoted a whole section (8) to the pathobiological and molecular similarities between drusen and atherosclerotic plaques, and their –in time-associated diseases: AMD and atherosclerosis. Finally, a homology between hepatic function and choroid was observed. Indeed, there are a number of reports in the literature of cross-talk between liver and choroidal function, but that potential relationship remains to be elucidated. The final biological motifs are cancer and connective tissue disorders. Cancer, is of course very broad and frequently relates to blood vessel metabolism or (abnormal) cell division, while the connective tissue motif may relate to the action of local fibroblasts. The choroidal networks, show, again a very broad spectrum of molecular interactions, but this spectrum is quite distinct from the functional annotation of the photoreceptor networks presented in Table 5.

Table 6. Drusen proteins expressed or present in the PR/RPE and their characteristics. Overview and characteristics of ten drusen proteins, which most likely originate from

the neural side of drusen (namely PR and Chor). In the first column (A), general used abbreviations (according Gen bank) for gene/protein names are given. In column B, C, D respectively systematic Entrez number, cellular location and protein type corresponding to these proteins are presented. Column E and F contain the amino acid (aa) size and Molecular weight (Mw) of the proteins. Further the isoelectric point (pI; column G), the number of negative and positive charged aa residues (column H), the protein instability Index number (column I); the Alipathic index for solubility (J), and the GRAVY (hydrophobicity and hydrophilicity index). These are all standard characteristic of proteins which can be found in the Ingenuity database (Qiagen all right reserved) and public databases such as DAVID, (<https://david.ncifcrf.gov>), SWISS-prot (<https://www.ebi.ac.uk/uniprot>), Genecards ([www.genecard.org](http://www.genecard.org)) and/or the data shows that these entries apparently do not have specific characteristics, except perhaps for their ability to interact with one another, that could explain why they would get stuck in BrM as a drusen protein. We conclude that, if it is not the proteins that explain this, it must be the structure of BrM.

#### **Supplementary Table Legends:**

Table S1. List of 276 proteins present in the RPE-IVS dataset. For each entry the gene symbol, Entrez gene name, location and type are provided based on information found in the Ingenuity knowledge database.

Table S2. List of 170 proteins present in the RPE-ST dataset. For each entry the gene symbol, Entrez gene name, location and type are provided based on information found in the Ingenuity knowledge database.

Table S3. List of 412 proteins present in the Pros-EP dataset. For each entry the gene symbol, Entrez gene name, location and type are provided based on information found in the Ingenuity knowledge database.

Table S4. List of 995 proteins present in the BLP-SP1 dataset. For each entry the gene symbol, Entrez gene name, location and type are provided based on information found in the Ingenuity knowledge database.

2659

2660 Table S5. List of 262 HAP binding proteins in the BL-PHP blood proteome dataset. For  
 2661 each entry the gene symbol, Entrez gene name, location and type are provided based on  
 2662 information found in the Ingenuity knowledge database.

2663

2664 Table S6. List of 754 expressed genes present in the cPR-ET dataset. For each entry the  
 2665 gene symbol, Entrez gene IDs for human and mouse are provided.

2666

2667 Table S7. List of 848 expressed genes present in the cChor-ET dataset. For each entry the  
 2668 gene symbol, Entrez gene IDs for human and mouse are provided.

2669

2670 Table S8. Annotation of 37 drusen proteins (out of 89) that may uniquely originate from  
 2671 the blood. For each entry, the gene symbol. Entrez gene IDs for human and mouse are  
 2672 presented.

2673

2674 Table S8a Functional annotation of 37 drusen proteins that may originate from the  
 2675 blood. Combinations of genes/proteins in this group makes up specific functional  
 2676 categories associated with biological function or disease.

2677

2678 Table S9. Annotation of 23 drusen proteins that may originate either from the neural or  
 2679 from the systemic side, using Ingenuity. For each entry its functional category, specific  
 2680 associated disease or function, p-value, gene names of associated proteins and number  
 2681 of proteins in each category are provided.

2682

2683 Table S9a Functional annotation of 23 drusen proteins that may originate from either  
 2684 the neural or the systemic side of drusen using Ingenuity. Combinations of  
 2685 genes/proteins in this group makes up specific functional categories associated with  
 2686 biological function or disease.

2687

2688 Table S10 Annotation of 19 drusen proteins of unclear origin. Entrez gene IDs for human  
 2689 and mouse are presented.

2690



2691 Table S10a Functional annotation of 19 drusen proteins of unclear origin using  
2692 Ingenuity. For each entry its functional category, specific associated disease or function,  
2693 p-value, gene names of associated proteins and number of proteins in each category are  
2694 provided.

2695

2696 Table S11 List of 64 proteins common to both drusen and atherosclerotic plaques. For  
2697 each entry, the gene symbol and Entrez Gene IDs for human and mouse and are  
2698 provided.

2699

2700 Table S11a Functional annotation of 64 proteins common to both drusen and  
2701 atherosclerotic plaques. For each entry its functional category, specific associated  
2702 disease or function, p-value, gene names of associated proteins and number of proteins  
2703 in each category are provided.

2704

2705

2706

2707

2708

2709

2710

2711

2712

2713

2714

2715

2716

2717

2718

2719

2720

2721

2722

2723 Next page : Table 1: 89 drusen proteins used in this study.

ID/Symbol	Entrez Gene Name	Location	Type(s)	Source	Human IHC ref
ACTB	Actin beta	Cytoplasm	other	(Crabb et al., 2002)	
ACTN1	Actinin alpha 1	Cytoplasm	transcription regulator	(Crabb et al., 2002)	
ALB	Albumin	Extracellular Space	transporter	(Crabb et al., 2002)	(Hollyfield et al., 2003)
ALDH1A1	Aldehyde dehydrogenase 1 family, A1	Cytoplasm	enzyme	(Crabb et al., 2002)	
AMBP	Alpha-1-microglobulin/bikunin precursor	Extracellular Space	transporter	(Crabb et al., 2002)	
ANXA1	Annexin A1	Plasma Membrane	enzyme	(Crabb et al., 2002)	(Rayborn et al., 2006)
ANXA2	Annexin A2*	Plasma Membrane	other	(Crabb et al., 2002)	(Crabb et al., 2002)*
ANXA5	Annexin A5	Plasma Membrane	transporter	(Crabb et al., 2002)	
ANXA6	Annexin A6	Plasma Membrane	ion channel	(Crabb et al., 2002)	(Crabb et al., 2002); (Rayborn et al., 2006)
APCS	Amyloid P component, serum	Extracellular Space	other	(Crabb et al., 2002)	(Mullins et al., 2000)
APOA1	Apolipoprotein A1	Extracellular Space	transporter	(Crabb et al., 2002)	(Mullins et al., 2000)
APOA4	Apolipoprotein A4	Extracellular Space	transporter	(Crabb et al., 2002)	
APOE	Apolipoprotein E	Extracellular Space	transporter	(Crabb et al., 2002)	(Mullins et al., 2000)
ATP5A1	ATP synth., H+ transp., mitochondr. F1 compl., alpha sub. 1, cardiac muscle	Cytoplasm	transporter	(Crabb et al., 2002)	
ATP5B	ATP synth., H+ transp., mitochondr. F1 compl., beta pp	Cytoplasm	transporter	(Wang et al., 2010)	
BFSP1	Beaded filament structural protein 1	Cytoplasm	enzyme	(Crabb et al., 2002)	
BFSP2	Beaded filament structural protein 2	Cytoplasm	other	(Crabb et al., 2002)	
BGN	Biglycan	Extracellular Space	other	(Crabb et al., 2002)	

C7	Complement C7	Extracellular Space	other	(Crabb et al., 2002)	
C8A	Complement C8 alpha chain	Extracellular Space	other	(Crabb et al., 2002)	(Wang et al., 2010)
C8B	Complement C8 beta chain	Extracellular Space	other	(Crabb et al., 2002)	(Wang et al., 2010)
C8G	Complement C8 gamma chain	Extracellular Space	transporter	(Crabb et al., 2002)	(Wang et al., 2010)
CFH	Complement factor H	Extracellular Space	other	(Wang et al., 2010)	(Arya et al., 2018)
CKB	Creatine kinase B	Cytoplasm	kinase	(Crabb et al., 2002)	
CLU	Clusterin	Cytoplasm	other	(Crabb et al., 2002)	(Sakaguchi et al., 2002)
COL1A2	Collagen type I alpha 2 chain	Extracellular Space	other	(Crabb et al., 2002)	(Newsome et al., 1987)
COL6A1	Collagen type VI alpha 1 chain	Extracellular Space	other	(Crabb et al., 2002)	
COL6A2	Collagen type VI alpha 2 chain	Extracellular Space	other	(Crabb et al., 2002)	
COL8A1	Collagen type VIII alpha 1 chain	Extracellular Space	other	(Crabb et al., 2002)	
CRYAB	Crystallin alpha B*	Nucleus	other	(Crabb et al., 2002)	(De et al., 2007)*
CRYBA1	Crystallin beta A1	Other	other	(Crabb et al., 2002)	
CRYBA4	Crystallin beta A4	Other	other	(Crabb et al., 2002)	
CRYBB1	Crystallin beta B1	Other	other	(Crabb et al., 2002)	
CRYBB2	Crystallin beta B2	Other	other	(Crabb et al., 2002)	
CRYGB	Crystallin gamma B	Nucleus	other	(Crabb et al., 2002)	
CRYGC	Crystallin gamma C	Cytoplasm	other	(Crabb et al., 2002)	
CRYGD	Crystallin gamma D	Cytoplasm	other	(Crabb et al., 2002)	
CRYGS	Crystallin gamma S	Other	other	(Crabb et al., 2002)	
CTSD	Cathepsin D*	Cytoplasm	peptidase	(Crabb et al., 2002)	(Rakoczy et al., 1999)*

DIP2C	Disco interacting protein 2 homolog C	Other	other	(Crabb et al., 2002)	
EFEMP1	EGF containing fibulin like ECM protein 1	Extracellular Space	enzyme	(Crabb et al., 2002)	
ELN	Elastin*	Extracellular Space	other	(Crabb et al., 2002)*	
ENO2	Enolase 2	Cytoplasm	enzyme	(Wang et al., 2010)	
FBLN5	Fibulin 5	Extracellular Space	other	(Crabb et al., 2002)	(Mullins et al., 2000)
FGG	Fbrinogen gamma chain	Extracellular Space	other	(Crabb et al., 2002)	(Mullins et al., 2000)
FHAD1	Forkhead ass.phosphopept.bind. dom. 1	Other	other	(Wang et al., 2010)	
FN1	Fibronectin 1	Extracellular Space	enzyme	(Crabb et al., 2002)	(Newsome et al., 1987)
FRZB	Frizzled-related protein	Extracellular Space	other	(Crabb et al., 2002)	
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase	Cytoplasm	enzyme	(Crabb et al., 2002)	
GPNMB	Glycoprotein nmb	Plasma Membrane	enzyme	(Crabb et al., 2002)	
HIST1H1E	Histone cluster 1 H1 family member e	Nucleus	other	(Crabb et al., 2002)	
HIST1H2BJ	Histone cluster 1 H2B family member j	Nucleus	other	(Crabb et al., 2002)	
HIST1H2BL	Histone cluster 1 H2B family member l	Nucleus	other	(Crabb et al., 2002)	
HIST2H2BE	Histone cluster 2 H2B family member e	Nucleus	other	(Crabb et al., 2002)	
HLA-DRA	Major histocompatibility complex, class II, DR alpha	Plasma Membrane	transmembrane receptor	(Wang et al., 2010)	
HRG	Histidine rich glycoprotein	Extracellular Space	other	(Kobayashi et al., 2014)**	Figure 6 and 7 (this study)
LAMB2	Laminin subunit beta 2	Extracellular Space	enzyme	(Crabb et al., 2002)	(Newsome et al., 1987)

LTF	Lactotransferrin	Extracellular Space				
LUM	Lumican	Extracellular Space	other	(Crabb et al., 2002)		
MFAP4	Microfibril associated protein 4	Extracellular Space	other	(Crabb et al., 2002)		
MYH9	Myosin heavy chain 9	Cytoplasm	enzyme	(Crabb et al., 2002)		
OGN	Osteoglycin	Extracellular Space	growth factor	(Crabb et al., 2002)		
ORM1	Orosomucoid 1	Extracellular Space	other	(Crabb et al., 2002)		
PLG	Plasminogen	Extracellular Space	peptidase	(Crabb et al., 2002)		
PRDX1	peroxiredoxin 1	Cytoplasm	enzyme	(Crabb et al., 2002)		
PRELP	Pro, Arg rich end Leu rich repeat protein	Extracellular Space	other	(Crabb et al., 2002)		
PSMB5	Proteasome subunit beta 5	Cytoplasm	peptidase	(Crabb et al., 2002)		
RBP3	Retinol binding protein 3	Extracellular Space	transporter	(Crabb et al., 2002)		
RDH5	Retinol dehydrogenase 5	Cytoplasm	enzyme	(Wang et al., 2010)		
RGR	Retinal G protein coupled receptor	Plasma Membrane	G-protein coupled recept.	(Crabb et al., 2002)		
RNASE4	Ribonuclease A family member 4	Extracellular Space	enzyme	(Crabb et al., 2002)		
S100A7	S100 calcium binding proteA7	Cytoplasm	other	(Crabb et al., 2002)	(Crabb et al., 2002)	
S100A8	S100 calcium binding protein A8	Cytoplasm	other	(Crabb et al., 2002)	(Crabb et al., 2002)	
S100A9	S100 calcium binding protein A9	Cytoplasm	other	(Crabb et al., 2002)	(Crabb et al., 2002)	
SAA1	Serum amyloid A1	Extracellular Space	transporter	(Crabb et al., 2002)		
SCARB2	Scavenger receptor class B member 2	Plasma Membrane	other	(Wang et al., 2010)		

SEMA3B	Semaphorin 3B	Extracellular Space	other	(Crabb et al., 2002)	
SERPINA1	Serp family A member 1	Extracellular Space	other	(Crabb et al., 2002)	
SERPINA3	Serp family A member 3	Extracellular Space	other	(Crabb et al., 2002)	
SERPINF1	Serp family F member 1	Extracellular Space	other	(Crabb et al., 2002)	
SPP2	Secreted phosphoprotein 2	Extracellular Space	other	(Crabb et al., 2002)	
SPTAN1	Spectrin alpha, non-erythrocytic 1	Plasma Membrane	other	(Crabb et al., 2002)	
THBS4	Thrombospondin 4	Extracellular Space	other	(Crabb et al., 2002)	
TIMP3	TIMP metalloproteinase inhibitor 3*	Extracellular Space	other	(Crabb et al., 2002)	(Kamei and Hollyfield, 1999)*
TNC	Tenascin C	Extracellular Space	other	(Crabb et al., 2002)	
TUBA1C	Tubulin alpha 1c	Cytoplasm	other	(Crabb et al., 2002)	
TUBB3	Tubulin beta 3 class III	Cytoplasm	other	(Crabb et al., 2002)	
TYRP1	Tyrosinase related protein 1	Cytoplasm	enzyme	(Crabb et al., 2002)	
VIM	Vimentin*	Cytoplasm	other	(Crabb et al., 2002)	(Johnson et al., 2003)*






Figure 1








Figure 2A




Figure 2B

© Qiagen, 2000-2018, all rights reserved






Figure 2C



Database curation examples

Figure 3









Figure 5



**A****B**







Figure 7






Figure 9A




Figure 9B




Figure 9C

# Ingenuity Pathway Analysis (IPA). Table 2.

Analysis Name: Table 2 Functional annotation 89 drusen proteins  
Bergen et al.09:05 AM Analysis Creation Date: 2018-05-02  
Build version: 470319M  
Content version: 43605602 (Release Date: 2018-03-28)

## Top Canonical Pathways

Name	p-value	Overlap
Acute Phase Response Signaling	7,51E-15	8,2 % 14/170
LXR/RXR Activation	2,29E-12	9,1 % 11/121
FXR/RXR Activation	9,39E-11	7,9 % 10/126
Atherosclerosis Signaling	2,35E-09	7,1 % 9/127
IL-12 Signaling and Production in Macrophages	1,42E-07	5,5 % 8/146

## Top Diseases and Bio Functions

### Diseases and Disorders

Name	p-value	#Molecules
Hereditary Disorder	1,04E-04 - 3,14E-19	51
Ophthalmic Disease	1,04E-04 - 3,14E-19	37
Organismal Injury and Abnormalities	1,19E-04 - 3,14E-19	88
Metabolic Disease	9,39E-05 - 4,75E-14	47
Developmental Disorder	1,04E-04 - 9,87E-14	34

### Molecular and Cellular Functions

Name	p-value	#Molecules
Cellular Movement	1,18E-04 - 2,86E-16	44

Cell-To-Cell Signaling and Interaction	1,18E-04 - 1,74E-12	43
Lipid Metabolism	9,71E-05 - 1,02E-10	27
Molecular Transport	1,09E-04 - 1,02E-10	33
Small Molecule Biochemistry	9,71E-05 - 1,02E-10	27

Physiological System Development and Function

Name	p-value	#Molecules
Embryonic Development	1,04E-04 - 3,33E-17	30
Nervous System Development and Function	1,04E-04 - 3,33E-17	31
Organ Development	1,04E-04 - 3,33E-17	25
Organismal Development	1,04E-04 - 3,33E-17	53
Tissue Development	1,08E-04 - 3,33E-17	52

Top Networks

ID Associated Network Functions	Score
1.Cancer, Connective Tissue Disorders, Organismal Injury and Abnormalities	44
2.Developmental Disorder, Ophthalmic Disease, Organismal Injury and Abnormalities	30
3.Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Lipid Metabolism	27
4.Cell-To-Cell Signaling and Interaction, Cellular Assembly and Organization, Neurological Disease	25
5. Neurological Disease, Infectious Diseases, Respiratory Disease	22

# Ingenuity Pathway Analysis (IPA). Table 4.

Analysis Name: Table 4 Summary photoreceptor core annotation analysis (745); Bergen et al.

2018-05-07 10:07 PM Analysis Creation Date: 2018-05-07

Build version: 470319M

Content version: 43605602 (Release Date: 2018-03-28)

## Top Canonical Pathways

Name	p-value	Overlap
Phototransduction Pathway	7,98E-11	28,3 % 15/53
Huntington's Disease Signaling	2,04E-04	8,0 % 20/250
Glutamate Receptor Signaling	4,79E-04	14,0 % 8/57
Superpathway of Cholesterol Biosynthesis	1,87E-03	17,9 % 5/28
Wnt/Ca+ pathway	4,20E-03	11,1 % 7/63

## Top Diseases and Bio Functions

### Diseases and Disorders

Name	p-value	#Molecules
Cancer	1,31E-02 - 6,87E-28	680
Organismal Injury and Abnormalities	1,33E-02 - 6,87E-28	685
Gastrointestinal Disease	1,21E-02 - 4,26E-22	629
Hepatic System Disease	2,47E-03 - 8,92E-15	474
Reproductive System Disease	1,27E-02 - 3,21E-08	420

### Molecular and Cellular Functions

Name	p-value	#Molecules
Cellular Assembly and Organization	1,28E-02 - 1,06E-08	165

Cellular Function and Maintenance	1,31E-02 - 1,06E-08	185
Cell Death and Survival	1,32E-02 - 3,71E-06	240
Cell Morphology	1,31E-02 - 5,38E-06	149
Cell-To-Cell Signaling and Interaction	1,16E-02 - 8,21E-06	61

Physiological System Development and Function

Name	p-value	#Molecules
Organ Development	1,25E-02 - 3,12E-06	88
Tissue Development	1,28E-02 - 3,12E-06	129
Visual System Development and Function	1,16E-02 - 3,12E-06	30
Nervous System Development and Function	1,28E-02 - 8,07E-06	161
Tissue Morphology	1,28E-02 - 9,43E-06	92

Top Networks

ID	Associated Network Functions	Score
1.	Cellular Assembly and Organization, Cellular Function and Maintenance, Molecular Transport	50
2.	Molecular Transport, RNA Trafficking, Behavior	47
3.	Developmental Disorder, Neurological Disease, Cellular Assembly and Organization	47
4.	Molecular Transport, RNA Trafficking, Connective Tissue Development and Function	42
5.	Developmental Disorder, Hereditary Disorder, Organismal Injury and Abnormalities	42

# Ingenuity Pathway Analysis (IPA). Table 5.

Analysis Name: Table 5 Summary Functional Annotation Choroid- Bergen et al  
Analysis Creation Date: 2018-05-07  
Build version: 470319M  
Content version: 43605602 (Release Date: 2018-03-28)

## Top Canonical Pathways

Name	p-value	Overlap
Antigen Presentation Pathway	7,58E-12	36,8 % 14/38
Atherosclerosis Signaling	3,26E-11	18,0 % 23/128
Hepatic Fibrosis / Hepatic Stellate Cell Activation	3,88E-11	14,7 % 28/191
Acute Phase Response Signaling	5,19E-10	14,5 % 25/172
Complement System	1,90E-09	31,6 % 12/38

## Top Diseases and Bio Functions

### Diseases and Disorders

Name	p-value	#Molecules
Cancer	1,44E-06 - 4,74E-32	730
Organismal Injury and Abnormalities	1,48E-06 - 4,74E-32	746
Inflammatory Response	1,09E-06 - 1,87E-21	263
Connective Tissue Disorders	1,48E-06 - 1,46E-17	192
Inflammatory Disease	4,57E-08 - 1,46E-17	174

### Molecular and Cellular Functions

Name	p-value	#Molecules
Cellular Movement	1,26E-06 - 1,81E-32	257



Cell Death and Survival	1,47E-06 - 4,17E-21	323
Cell-To-Cell Signaling and Interaction	1,50E-06 - 9,12E-15	218
Cellular Development	1,49E-06 - 1,14E-14	326
Cellular Function and Maintenance	8,75E-07 - 3,23E-12	274

Physiological System Development and Function

Name	p-value	#Molecules
Cardiovascular System Development and Function	9,30E-07 - 1,46E-28	192
Organismal Development	1,47E-06 - 1,38E-24	325
Immune Cell Trafficking	1,29E-06 - 1,10E-23	158
Hematological System Development and Function	1,29E-06 - 3,90E-23	236
Organismal Survival	5,54E-08 - 1,79E-22	244

Top Networks

ID	Associated Network Functions	Score
1.	Organ Morphology, Organismal Injury and Abnormalities, Renal Atrophy	49
2.	Organismal Injury and Abnormalities, Skeletal and Muscular Disorders, Developmental Disorder	41
3.	Molecular Transport, Nucleic Acid Metabolism, Small Molecule Biochemistry	38
4.	Tissue Development, Cellular Movement, Hair and Skin Development and Function	37
5.	Cell Cycle, Gene Expression, Cellular Growth and Proliferation	36

**Authors' statement**

All authors have seen and approved the final version of the manuscript being submitted. They warrant that the article is the authors' original work, hasn't received prior publication and isn't under consideration for publication elsewhere.

None of the authors has a financial or personal conflicts of interest defined as a set of conditions in which professional judgment concerning a primary interest, such as the validity of research, may be influenced by a secondary interest, such as financial gain.

The work on this manuscript is approximately divided as follows:

AAB 28 %, SA 5 %, CK 5 %, MP 5 %, DW 4 %, PvdS 4 %, SMH 4 %, CJFB 4 %, EE 5 %, AJS 18 %, IL 18 %